

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A non-randomised control trial, implementation evaluation, and economic evaluation of an integrated child and family health hub (FDCC) for migrant and refugee women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061002
Article Type:	Protocol
Date Submitted by the Author:	12-Jan-2022
Complete List of Authors:	Hodgins, Michael; UNSW, Ostojsic, Katarina; University of New South Wales Hu, Nan; UNSW, Lawson, K; Western Sydney University Samir, Nora; University of New South Wales - Randwick Campus, School of Women's and Children's Health Webster, Amanda; South Eastern Sydney Local Health District Rogers, Helen; South Eastern Sydney Local Health District, Henry, Amanda ; University of New South Wales Faculty of Medicine, Women's and Children's Health Murphy, Elisabeth; University of New South Wales; New South Wales Ministry of Health Lingam, Raghu; University of New South Wales Raman, Shanti; University of New South Wales School of Women's and Children's Health, ; South Western Sydney Local Health District, Community Paediatrics Mendoza Diaz , Antonio; University of New South Wales, Discipline of Psychiatry Dadich, Ann; Western Sydney University, School of Business Eapen, Valsamma; South Western Sydney Local Health District, ICAMHS; University of New South Wales, School of Psychiatry Rimes, Tania; South Eastern Sydney Local Health District, Child Youth and Family Services Woolfenden, Susan ; University of New South Wales; Sydney Local Health District
Keywords:	Community child health < PAEDIATRICS, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PAEDIATRICS, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3 **TITLE:** A non-randomised control trial, implementation evaluation, and economic
4 evaluation of an integrated child and family health hub (FDCC) for migrant and
5 refugee women
6
7
8

9
10
11 **AUTHORS:** Michael Hodgins¹, Katarina Ostojic¹, Nan Hu¹, Kenny Lawson², Nora Samir¹,
12 Amanda Webster³, Helen Rogers³, Amanda Henry¹, Elisabeth Murphy⁴, Raghu
13 Lingam^{1,5}, Shanti Raman⁶, Antonio Mendoza Diaz¹, Ann Dadich⁷, Valsamma
14 Eapen^{1,6}, Tania Rimes^{3*}, Sue Woolfenden^{1,8*}

15 On behalf of the FDCC Collaborative Group
16
17

18 **AFFILIATIONS**

19
20 ¹ University of New South Wales, NSW 2751

21
22 ² University of Sydney, NSW 2006

23
24 ³ South Eastern Sydney Local Health District, NSW 2229

25
26 ⁴ North Sydney Local Health District, NSW 2065

27
28 ⁵ Sydney Children's Hospitals Network, Sydney, NSW, 2031

29
30 ⁶ South Western Sydney Local Health District, NSW 2170

31
32 ⁷ Western Sydney University, NSW 2150

33
34 ⁸ Sydney Local Health District, NSW 2050

35 **CORRESPONDING AUTHORS***

36
37 Dr Michael Hodgins

38
39 School of Women's & Children's Health

40
41 UNSW

42
43 Email: michael.hodgins1@unsw.edu.au

44
45
46
47
48 **KEYWORDS** Integrated care, community child health, maternal health, organisation of health
49 services, paediatrics, public health
50
51

52
53
54 1
55
56
57
58
59
60

WORD COUNTS

Abstract: 299 words

Main text: 3,976 words (excluding title page, tables, and references)

Protocol version: version 1.0 (10.01.2022)

For peer review only

ABSTRACT

Introduction: Continuity of child and family healthcare is vital for optimal child health and development for developmentally vulnerable children. Migrant and refugee communities are often at-risk of poor health outcomes, facing barriers to health service attendance including cultural, language, limited health literacy, discrimination, and unmet psychosocial needs. ‘Integrated health-social care hubs’ are physical hubs where health and social services are co-located, with shared referral pathways and care navigation. Our study will evaluate the impact, implementation, and cost-benefit of the First 2000 Days Care Connect (FDCC) integrated hub model for pregnant migrant and refugee women and their infants.

Methods and analysis: This study has three components. Component 1 is a non-randomised controlled trial to compare the FDCC model of care with usual care. This trial will allocate eligible women to intervention and control groups based on their geographical proximity to the Hub sites. Impact measures include: the proportion of children attending child and family health (CFH) nurse services and completing their CFH checks to 12 months of age; improved surveillance of growth and development in children up to 12 months, post-partum; improved breastfeeding rates; reduced emergency department presentations; and improve maternal wellbeing. Component 2 will involve a mixed-method implementation evaluation to clarify how and why FDCC was implemented within the sites to inform future roll-out Guided by the Consolidated Framework for Implementation Research and Proctor and colleague’s implementation outcomes taxonomy. Component 3 is a within-trial economic evaluation to assess the cost-effectiveness of the Hubs relative to usual care and the implementation costs if Hubs were scaled and replicated.

Ethics and dissemination: Ethical approval was granted by the South Eastern Sydney Local Health District Human Research Ethics Committee in July 2021 (Project ID: 020/ETH03295). Results will be submitted for publication in peer-reviewed journals and presented at relevant conferences.

Trial registration: ACTRN12621001088831

ARTICLE SUMMARY

Strength and limitations

- First Australian multi-site non-randomised controlled trial to test the effectiveness of integrated health-social care hubs.
- The model could be an exemplar for scaling up nationally and adapting to other populations who have barriers to accessing child and family health services.
- The non-randomised design of the trial has some limitations, particularly the inability to guarantee the comparability of the intervention and control groups.
- The model, tested in the New South Wales healthcare system, would potentially need further adaptation to be delivered in other health care settings.

BACKGROUND AND RATIONALE

In New South Wales (NSW), Australia, 25% of children from migrant and refugee families are 'developmentally vulnerable'.¹ Developmental vulnerability is associated with undetected maternal postnatal depression, the early cessation of breastfeeding², and parental unmet psychosocial needs (e.g., housing, domestic violence).^{3 4} Children who are developmentally vulnerable are twice as likely to struggle at school, experience adverse childhood events and have poorer long-term health outcomes and higher healthcare costs.^{1 5-12} These adverse childhood events can continue into adulthood, contributing up to 44% of adult morbidity.^{13 14}

Continuity of care with regular child and family health (CFH) checks by local health district (LHD) employed child and family health nurses (CFHN) are the foundation for optimal child health and development. This is particularly the case for priority populations, including newly arrived migrant and refugee women, children, and their families.⁵ However, these populations also experience significant barriers to services including cultural, language, limited health literacy, discrimination, and unmet psychosocial needs.¹⁵⁻³¹ Families with greater disadvantage are at greater risk of developmental vulnerability and poorer maternal mental health. These families are less likely to engage with health services, particularly health promotion programs, like CFH checks.^{2-4 15 32-35}

Australian policymakers identified service areas that need improvement to optimise outcomes in the

1
2
3 first 2,000 days of a child's life.^{5 36} These include the transition from maternity to CFH services;
4 increasing uptake and length of time families stay connected with CFH services; and supporting
5 priority populations. Unfortunately, in NSW, two-thirds of children stop attending CFH services by
6
7 12 months of age,^{15 18-20} further fragmenting care.
8
9

10 **Benefits of integrated health-social care hubs**

11
12 To address the fragmented CFH services for priority populations, integrated health-social care hubs
13 were established in multiple jurisdictions across Australia. These are physical hubs where health and
14 social services are co-located, supported by care navigators and shared referral pathways.^{37 38} Co-
15 location and navigation support aims to remove barriers that hinder engagement between families and
16 CFH services. However, the evidence-base for their effectiveness is limited. Our recent systematic
17 review demonstrated the dearth of experimental trial evidence in Australia regarding physical CFH
18 Hubs. Yet, individual studies have found Hub models increase access to CFH services and the
19 identification of developmental vulnerability.³⁹ Additionally, a recent scoping review of models of
20 care across the continuum of pregnancy, birth, and the postpartum period for women from migrant and
21 refugee backgrounds in high-income countries highlighted an evidence gap for models that improved
22 maternal and child infant health outcomes.⁸
23
24

25 Research led by some of the researchers^{8 40 41} extended this evidence-base by showing the feasibility
26 and efficacy of integrated CFH hubs and cross-cultural workers (CCW) models in South Eastern
27 Sydney. These models support women and families to navigate maternity, CFH, and community-based
28 services, providing continuity of care across the continuum of pregnancy and transition to CFH. The
29 pilot interventions demonstrated that, for women and families from migrant and refugee populations:
30 CFH services embedded in integrated hubs increased the completion rate of CFH checks from 30% to
31 60% at 12-months and facilitated linkage with co-located non-government organisations.^{40 41} Cross-
32 cultural worker support in pregnancy was also highly rated by staff and pregnant women regarding
33 support for pregnancy and linkage with services.^{42 43}
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Current study: First 2000 Days Care Connect**

49
50 *First 2000 Days Care Connect* (FDCC) is an integrated health-social care hub model that builds on
51 these feasible and acceptable pilot interventions. The FDCC model involves co-located CFH services
52
53

54 5

and non-government organisations (NGO), including psychosocial support services (e.g., playgroups, domestic violence support, mental health support, early childhood education, family support). These services operate from a physical location to facilitate service collaboration, integration, and a community-led approach to local needs. This Hub is supported by care navigation, increasing continuity from maternity to CFH services.

Objectives

The overall aim of the FDCC study is to evaluate: the impact of FDCC (an integrated CFH Hub) on attendance at CFHN services and completion of CFH checks, support of child growth and development, breastfeeding and maternal wellbeing, and meeting family psychosocial needs (Component 1); the process of implementing FDCC (Component 2); and the cost-effectiveness of FDCC (Component 3).

METHODS AND ANALYSIS

Study Setting

FDCC is a multisite study, conducted across three metropolitan LHDs in Greater Sydney, NSW – namely, SESLHD, SWSLHD, and NSLHD. Participants will be recruited from public and universally available antenatal services at participating public hospitals within the LHDs and receive services from CFHN services within each LHD.

Recruitment and Consent

The study will recruit 240 women between November 2021 and April 2022. Eighty participants will be enrolled within SESLHD, NSLHD, and SWSLHD, with 40 allocated to the intervention arm (FDCC Hub) and 40 to the control arm (routine care). Potential participants are women attending antenatal clinics at the participating public hospitals within each study site and fulfilling the eligibility criteria (Table 1).

Table 1: Inclusion and Exclusion Criteria

Inclusion criteria	Exclusion criteria
Eligible women will be expectant mothers who are:	<ul style="list-style-type: none"> Does not comprehend the recruitment invitation (not proficient in English and/or

6

<ul style="list-style-type: none"> • Attending antenatal clinics linked to the three study sites • Residing in geographical catchment for the respective antenatal clinic • Expectant mother > 20 weeks gestation • 16 years of age or older at enrolment • Newly arrived migrant (< 10 years in Australia) or self-identified refugee (< 10 years in Australia), from a non-English speaking background • Provide a signed and dated informed consent form 	<ul style="list-style-type: none"> • declines the offer of an interpreter in their home language) • Have no mechanism for contact (telephone or email) • Already an active client in other targeted support services • Less than 16 years of age at enrolment • Migrant > 5 years in Australia or self-identified refugee > 10 years in Australia, • From an English speaking background • Not residing in geographical area of study
--	--

Using three processes, midwives and CCWs (where available) will identify eligible women attending antenatal services at the intervention sites during regular consultations. The processes include: midwives and CCW introduce the project to women attending a group model of antenatal care; midwives will promote the study during individual hospital antenatal visits and provide potential participants a flyer; and midwives will identify potential participants who meet the eligibility criteria and provide study details during regular antenatal visits. If potential participants provide verbal consent, they will be introduced to the project officer. The project officer will explain the study and provide a participant information sheet and consent form (PISCF) using translated documents and/or interpreter services, if required. They will confirm eligibility at face-to-face clinic visits or via telephone consultation. If the woman is not interested in the study, there will be no further contact regarding the study.

Participants will provide informed consent via completing paper-based consent forms, via email or verbally via phone or via online electronic signature option using the RedCap database. Participants consenting to the study can opt out of the data linkage component.

For component 2, once the FDCC trial is underway, the project implementation scientist will contact participating CFHNs, NGO staff, and Hub administrative staff via telephone and/or email to invite them to an interview or focus group. Prior to the interviews and focus groups, the implementation researcher will describe the study to participants and its rationale, providing a PISCF, and obtain informed consent. Hub staff and service leaders, including LHD partners and policymakers, will be invited to complete a 32-item online survey at the completion of *Component 1*. The online survey will include a detailed description of the study, rationale, and an opportunity to indicate informed consent

7

1
2
3 before survey completion. Hub staff and managers who do not complete the survey will receive a
4 reminder thrice via email.
5

6 **Study Procedures**

7
8
9 This protocol has used the SPIRIT reporting guidelines.⁴⁴ Following the identification of potential
10 participants, project officers will confirm participant eligibility as part of the consent process. This is
11 a non-randomised study whereby eligible participants will be allocated to a study arm (FDCC
12 intervention or control group) based on their residential postcode at the time of enrolment (see below).
13 Participation will be 12 months, including: intervention allocation; intervention delivery (12 months);
14 and data collection (baseline, 6 months post-partum, 12 month post-partum). In addition to English,
15 the study materials will be translated in the six most common community languages (Arabic, Bengali,
16 Simplified Chinese, Korean, Hindi, and Vietnamese).
17
18
19
20
21
22

23 *Allocation, Concealment, and Implementation*

24
25
26 Women attending antenatal services from the participating hospitals who live in a defined geographic
27 area (postcode) served by an established CFH Hub in their LHD will be allocated to the FDCC
28 intervention group. Women attending antenatal services from the participating hospitals but do not live
29 in the defined geographic area above will be in the control group.
30
31
32

33 *Blinding*

34
35
36 Given the nature of the study, blinding to group allocation is impractical. However, as the intervention
37 is dependent on participant postcode of residence, there is expected to be minimal treatment
38 contamination between the intervention and control groups. To assess for intervention contamination,
39 women in all groups will be asked at the 12 months postpartum assessment regarding the use of any
40 Hub and CFHN service. While the site project officers collecting survey data at each site will not be
41 blinded to allocation, the researcher analysing data will be blinded to group allocation.
42
43
44
45

46 *Intervention*

47
48
49 After recruitment, the Hub navigator will contact participants to introduce Hub services and support
50 engagement with identified services, if needed. This will be followed by another contact between birth
51 and 8 weeks postpartum. Following mothers' and infants' discharge from birthing services, women
52
53
54

55
56
57
58
59
60
8

1
2
3 will access CFH services via the Hub, as well as psychosocial support services suited to maternal needs
4 and preferences. Per routine care, all women and their babies will be offered an appointment
5 (approximately 1 hour) with a CFHN at 1 to 4 weeks postpartum, 6 to 8 weeks postpartum, 6 months
6 postpartum, and 12 months postpartum.
7
8
9

10 Hub services will be face-to-face, online, and one-to-one. Some services, such as playgroup or
11 mothers' groups, might be in a group setting. Mothers and their babies will have access to the Hub for
12 12 months. Further contacts with the Hub navigator or keyworker as participants require.
13
14
15

16 The integrated FDCC Hubs are a physical building and a way of working, facilitating service
17 collaboration, integration, and a community-led approach to local needs. Hubs most commonly operate
18 from a host building from which partner community-based or public services are delivered. In our Hub
19 model, CFH services are co-located with NGOs. Families are linked with psychosocial support
20 services, including playgroups, early childhood learning opportunities, and family support. Within
21 the Hub services, existing CFH and NGO services support families to navigate systems and engage
22 with other health services. These include general practitioners, early childhood, education, and
23 psychosocial support to address their needs.
24
25
26
27
28
29

30 *Control Arm: Routine Care*

31
32 Pregnant women attending the participating hospitals who meet eligibility criteria but do not live in
33 the geographic area will be allocated to a control cohort and receive routine care (e.g., receive
34 information on CFHN services at discharge and follow-up as per current pathways).
35
36
37

38 **Implementation Evaluation**

39
40 Our mixed-methods implementation evaluation will assess the barriers and facilitators to implementing
41 the FDCC Hubs at the three sites, as guided by the consolidated framework for implementation
42 research (CFIR).⁴⁵ The CFIR is a comprehensive framework designed to 'offer an overarching
43 typology to promote implementation theory development and verification about what works where
44 and why across multiple contexts'.⁴⁵ The CFIR is widely used in diverse healthcare contexts, including
45 primary care.⁴⁶ The CFIR identifies five major domains and guides the consideration and assessment
46 of factors that can impact intervention implementation and effectiveness. Additionally, the researchers
47 will evaluate specific implementation outcomes of acceptability, appropriateness, fidelity to the
48
49
50
51
52
53
54
55
56
57
58
59
60

implementation strategy, coverage, sustainability, and cost (Table 2) as guided by the taxonomy proposed by Proctor and colleagues.⁴⁷

Table 2: Proctor and colleagues (2011) implementation outcomes mapped to FDCC evaluation

	Questions addressed by each implementation factor
Acceptability	Do Hub staff and families view the Hub model as acceptable?
Adoption	Do Hub staff intend to apply the Hub model as described in the study protocol?
Appropriateness	Do Hub staff perceive the Hub model as relevant & useful for their services?
Fidelity	Is the Hub model applied as intended?
Coverage	How many eligible families are reached through the Hub model and keyworker?
Cost	How much does it cost to implement Hubs?
Sustainability	What are the factors that will allow the Hubs to be sustained/scaled-up further?

Logic Model

We developed a logic model to inform the FDCC implementation evaluation (**Error! Reference source not found.**). We used a modified version of existing logic model frameworks^{48 49} to include the inner context (i.e., individual factors, organisational settings) and the outer context of each site (i.e., area demographics, policy climate, relevant geographically adjacent clinical services). These contextual factors were incorporated within the logic modelling to enable implementation researchers to better describe the determinants of successful implementation in clinical practice.⁵⁰

[INSERT FIGURE 1]

Additionally, we included a detailed description of the intervention to identify feasibility elements to measure during the study. These include features of the physical location of services, how services are integrated, the availability of culturally sensitive support materials and services, and the navigator or keyworker. To supplement the practical elements of the intervention, we described the underlying theoretical principles of the model. These include the collective impact framework⁵¹ and the elements of the behaviour change wheel that we perceived the model to adhere.⁵² Collective impact is designed to inform change on complex social issues, and draws on five conditions: common agenda; continuous communication; mutually reinforcing activities; backbone support; and shared measurement.⁵³ Collective impact and the behavioural change wheel mechanisms of change within the logic model will inform the qualitative interview schedule. Finally, we drew connections from these underlying theories of change to the specific intermediate and long-term outcomes that we hypothesised the model will produce. Principally, we hypothesise that the intervention components will work on the core

10

principles of environmental restructure, enablement, modelling, and training within the Hub sites, underpinned by the collective impact principles to support migrant and refugee parents to engage with health and social support services. This engagement will provide better outcomes for children and families. It will also create opportunities for shared knowledge between health and non-health services, as part of an acceptable and cost-effective model delivery. Table 3 provides an overview of the planned outcomes and measurement for the implementation evaluation.

Table 3: Overview of the Implementation Evaluation Outcomes

Implementation Evaluation Outcomes			
Outcome measure	Data Source	Methods	Data Collection
Description of local context and Hub	SEIFA data, search of grey literature, informal contact with Hub service leaders	SEIFA data, search of grey literature, informal contact with Hub service leaders	Trial commencement
Fidelity of Hub Model	Hub intervention log	A bespoke log completed by site project officers	Ongoing during the trial
Acceptability of intervention measure (AIM), intervention appropriateness measure (IAM), and feasibility of intervention measure (FIM) ⁵⁴	Research survey administered by project officer	AIM, IAM, and FIM measures completed by Hub staff, service leaders, participants in the intervention group	Trial end (included in the 12-month postpartum parent survey for parents and separate staff survey)
Barriers and facilitators to running the FDCC Hubs	Interviews with Hub staff, service leaders, participants in the intervention group	Qualitative interviews and focus groups, guided by the CFIR	Pre-trial (with Hub staff and service leaders). Ongoing during and end of the trial for all participants

The NoMAD tool ⁵⁵ to assess Hub staff buy in to the model	Research survey administered by project officer	NoMAD tool completed by Hub staff	Trial end
--	---	-----------------------------------	-----------

Economic Evaluation

The economic evaluation will explore the costs of Hub implementation, including: the establishment and operation of Hubs; and the flow-on cost from service use from Hub referrals. Hubs are likely to be implemented in different ways relative to local context and, as such, costs might differ. Two bespoke costing templates will be shared with Hub managers upon trial commencement to be completed at 6 and 12 months, with researcher support to ensure accuracy. The templates will allow for standardisation and between-site comparison.

Establishment and Operational Costs

A micro-costing approach will be adopted to account for funded and in-kind expenditures.^{56 57} A simple template will have major generic expenditure categories, including upfront capital costs (e.g., vehicles, buildings), governance arrangements to manage the Hubs (e.g., staff meeting time), material costs (e.g., brochures), and in-kind support from staff, including partner agencies. There might be expenditures against these categories. At this stage, there is no plan for capital expenditures. This is included for completeness. Operational costs pertain to daily Hub operation, including new staff hired (e.g., salary, on-costs), in-kind costs (e.g., time costs from non-salaried staff), venue costs (e.g., utilities, even if in-kind), and material costs (e.g., brochures).

Referral Costs

Prior to Hub commencement, Hub personnel will be asked for a list of service partners to create a template where clients will be asked the services accessed and frequency. Table 2 in Appendix 11.5 provides the list collated for SWSLHD; clients will be surveyed using this. Other sites will follow suit. Full client recall is not anticipated. However, it is important that the study clarifies the impact on referral services, if possible. A top-down costing estimate will then be made.^{56 57} Each partner service will then be contacted to generate an estimate of the average client service cost. Providers typically

adopt an activity-based costing approach in accounting and funding proposals. No specific client data will be accessed. Rather, the researchers will guide service providers to generate average costs, which typically only involves dividing total funding for service(s) by total occasions of service. Researchers will only be privy to the overall average costs. Where costs are unavailable, an approximation will be made if public and research data are available. Otherwise, a list of service counts only will be made and remain un-costed. Table 4 provides an overview of the planned outcomes and measurement for the implementation evaluation.

Table 4: Overview of the Economic Evaluation Outcomes

Economic Evaluation Outcomes			
Outcome measure	Data Source	Methods	Data Collection
Mother quality of life (EQ-5D quality of life)	Research survey administered by project officer	Research survey administered by project officer. EQ-5D quality of life questionnaire.	Baseline (antenatal time of enrolment) 6 months post-partum 12 months post-partum
Cost of implementing Hubs	Bespoke surveys	Bespoke surveys completed by Hub Staff and Participants in the intervention group	6 and 12 months 6 and 12 months

Primary and Secondary Outcome Measures

Outcomes will be measured from enrolment (baseline) until and including 12 months post-partum (Table 5). Outcomes will be gathered via: the extraction of routinely collected clinical data from electronic medical records at each site or LHD; surveys administered by a researcher to mothers; and data linkage of participants with administrative datasets (NSW perinatal data collection, NSW emergency department data collection). The primary outcome measure is the proportion of mothers and their respective infant who attend CFH services for early childhood health checks at 1 to 4 weeks postpartum, 6-8 weeks postpartum, 6 months postpartum, and 12 months postpartum. For primary and secondary variables, see Table 5.

Table 5: Overview of the FDCC Study Outcome Variables

FDCC trial			
Outcome measure	Data Source	Methods	Data Collection
Proportion of mothers and their respective infant who attend CFH services for early childhood health checks (<i>Primary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD.	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Infant identified as at developmental risk by CFHN using the Learnt the Signs Act Early (LtSAE) and Ages and Stages Questionnaire Screening tools	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD. <ul style="list-style-type: none"> • LtSAE screening completed, and the concerns/no concerns identified on LtSAE screening domains. • Ages and Stages Questionnaire (ASQ & ASQ-SE) given to families by CFHN. 	<ul style="list-style-type: none"> • 6-8 weeks post-partum (LtSAE) • 6 months post-partum (LtSAE and ASQ) • 12 months post-partum (LtSAE and ASQ and ASQ-SE)
Proportion of children monitored for growth parameters and their growth parameters (weight, height, head circumference)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical. <ul style="list-style-type: none"> • height (cm) • weight (kg) • head circumference (cm) 	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Mother identified as at-risk of experiencing depression (Edinburgh Postnatal Depression Scale (EPDS)) ⁵⁸	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical. <ul style="list-style-type: none"> • Edinburgh Depression Scale (EPDS) total score • Response to item 10 of EDS 	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum

<p>Mother identified as experiencing psychosocial vulnerability/risk factors (Safe Start Psychosocial assessment including Domestic Violence screen)⁵⁹</p>	<p>Electronic medical record at LHD.</p>	<p>Extraction of routine clinical data from electronic medical.</p> <ul style="list-style-type: none"> • Presence/absence of psychosocial risk factors on Safe Start Psychosocial assessment including the Domestic Violence screen. 	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum
<p>Mother experiencing unmet social need/s (THRIVE We Care questionnaire)⁶⁰</p>	<p>Research survey administered by project officer</p>	<p>Research survey administered by project officer. THRIVE We Care questionnaire.</p>	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 6 months post-partum • 12 months post-partum
<p>Mother exclusively breastfeeding /partially breastfeeding/ artificially feeding</p>	<p>Electronic medical record at LHD. Data linkage with NSW Perinatal Data Collection.</p>	<p>Extraction of routine clinical data from electronic medical.</p> <ul style="list-style-type: none"> • Exclusively breastfed • Predominately breastfed • Partial breastfed • Artificial feeding 	<p>Electronic medical record at LHD:</p> <ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum <p>Data linkage with NSW Perinatal Data Collection</p> <ul style="list-style-type: none"> • Breast feeding initiated at discharge postnatally.
<p>Mother and infant attendance at emergency departments from recruitment to 12 months post-partum.</p>	<p>Data linkage with NSW-wide Emergency Department Data Collection (EDDC)</p>	<p>NSW-wide EDDC data Linkage</p>	<p>Between baseline and 12 months post-partum</p>

Data Analysis Plan

Sample Size Estimation

Based on pilot data, we anticipate the percentage of children to have their CFH check done by a CFHN will be 60% in the intervention group and 30% in the control group. Therefore, 72 children will be needed for each arm to provide 80% of power to detect the magnitude of such an increase with a p value <0.05 . Allowing for a 40% attrition rate (i.e., loss-to-follow-up) as this is a vulnerable community¹⁵, we aim to recruit 120 children in each arm or 240 children in total across the three sites.

Statistical Analysis

Statistical analysis will include descriptive analysis of participating mother and child outcomes at each assessment. We will compare outcomes between the intervention and control groups using the Fisher's test for binary outcomes, Chi-square method for categorical outcomes, non-parametric method (e.g., Wilcoxon rank-sum test) and parametric methods (e.g., t -test) for continuous and ordinal variables. As outcomes will be measured repeatedly, multilevel regression analysis will be undertaken to examine intervention impact on outcomes, controlling for the plausible confounders at the individual (e.g., mother's sociodemographic characteristics, geographic area of residence) and community levels at baseline (e.g., neighbourhood socioeconomic factors). Generalised estimating equations method will be used in the regression analysis, considering the potential clustering effect by site. Only deidentified data will be analysed. No data safety monitoring committee is needed for this study due to the known minimal risks. No interim analyses or stopping rules will be applied.

Implementation Evaluation Analysis

Implementation effectiveness will be evaluated using the validated scoring system of -2 to $+2$ with score descriptions as follows: -2 indicates the construct has negatively influenced the practice and examples of negative manifestations are indicated; -1 indicates the construct has negatively influenced the practice and general statements of negative manifestations are made; 0 indicates the construct neutrally influenced the practice; $+1$ indicates the construct positively influenced the practice and general statements of positive manifestations are made; and $+2$ indicates the construct positively

1
2
3 influenced the practice and explicit examples of positive manifestations are described.⁶¹ Using these
4 scores, construct scores can range from a low of -80 to a high of +80, demonstrating the key barriers
5 and facilitators to uptake and sustain the FDCC hubs. This method of quantifying implementation
6 effectiveness will be supplemented with an inductive analysis of qualitative data to ensure openness
7 to emerging themes not readily captured by the CFIR and Proctor and colleague's outcome measures.⁴⁷
8
9

10 11 12 *Economic Analysis*

13
14 We will first assess comparative costs and outcomes between the Hubs. Second, we will estimate the
15 overall cost of Hubs and likely costs and affordability, if Hubs was scaled-up across NSW. The latter
16 will involve estimating the potential Hubs would be made and an average cost (of the three Hubs)
17 applied, with high and low estimates in a sensitivity analysis.
18
19

20 21 22 **Data Management**

23
24 All participants will be allocated a randomly generated unique identifier code to be used throughout
25 the study. Project officers will have identified information of the participants enrolled at their site,
26 stored in password protected files. The project officer within each LHD will work with data managers
27 to extract routinely collected clinical data from electronic medical records for all participants, per Table
28 3. Data will be stored within a protected site-based server. Only deidentified data will be transferred
29 from each LHD to the researchers (SW, KO, NH) for data analysis, using encrypted transfer.
30
31

32
33 Project officers with support from CCWs and/or interpreters will collect surveys at baseline, 6 months
34 postpartum, and 12 months postpartum. The survey can be completed in hardcopy (face-to-face or
35 telephone) or online by participants using a secure link to REDCap®. Subsequently, project officers
36 who can access the identifying information within each LHD will enter survey data into the REDCap®
37 database. REDCap® is hosted on the University of NSW (UNSW) infrastructure. Permissions granted
38 to each user within each REDCap® project is controlled by and is the responsibility of the project
39 team. Hardcopy materials will be stored in locked cabinets for the required period, either indefinitely
40 if the participant consents to providing their data for data pooling or for 15 years after the completion
41 of the study. After these periods, hardcopy materials will be destroyed and password-protected
42 electronic archives will be deleted.
43
44

45
46 The identifying information collected within each LHD will be compiled into a single password-
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 protected file and sent to The Centre for Health Record Linkage (CHeReL) for data linkage. The
4 minimum identifying information for mothers and infants will be used to extract participant records
5 from the administrative data. Upon completion of data extraction, CHeReL will transfer to UNSW
6 administrative data of the participants who consented to data linkage. The administrative records will
7 be deidentified by CHeReL, which will create the person project number (PPN) for each participant.
8 The PPN will be linked to the participant's unique project identification number to link the
9 administrative records with the electronic medical record (eMR) and survey records that belong to the
10 same participant.
11
12
13
14
15
16
17

18 ETHICS AND DISSEMINATION

19
20 Ethical approval was granted by the South Eastern Sydney LHD (SESLHD) (2020/ETH03295). This
21 trial was registered with the Australian New Zealand Clinical Trials (ACTRN12621001088831).
22
23

24 **Confidentiality**

25
26 The researchers acknowledge that ensuring confidentiality is essential. The researchers will exercise
27 due diligence to anonymise participants' responses for reporting, publication, and presentation
28 purposes. Only deidentified data will be transferred from each LHD to the UNSW researchers for data
29 analysis. The deidentified data from each LHD to the UNSW team will be securely transferred through
30 a NSW Health-approved e-health platform.
31
32
33
34

35 **Managing Potential Harms**

36
37 If issues are disclosed outside of the study parameters, mandatory NSW Health policy directives will
38 apply (e.g., family and domestic violence, child protection matters). These will be managed as per
39 current policies and practices within LHDs. The child protection and domestic violence counselling
40 teams are readily accessible to provide advice and support if issues are identified. As the researchers
41 are all mandatory reporters, they will inform participants that they are not able to maintain
42 confidentiality when it relates to the safety of the participant, the child/ren, the family, and the wider
43 community. These obligations are detailed in the PISCF.
44
45
46
47
48
49

50 **Patient and Public Involvement**

51
52 The research questions were developed based on qualitative research undertaken with Hub participants
53
54
55
56
57
58
59
60

1
2
3 and community members and service providers in the pilot study.^{40 62} The FDCC team have a consumer
4 representative and consultation was undertaken with local Hub partner services. The researchers also
5 consulted multicultural health services, including cultural support workers, to ensure research
6 materials are culturally nuanced. Patients or participants have not directly been involved in the current
7 study design.
8
9
10
11

12 **Dissemination**

13
14 Data obtained for the study will be published in reports, peer reviewed journals and presented at
15 appropriate conferences. The de-identified data will be available to all investigators. Access by
16 individuals' other than the named investigators will only be permitted after consideration and
17 agreement by all the remaining investigators. An essential element of knowledge translation are the
18 study partners and advisors who will share findings and consider if and how to progress to trialling or
19 implementing the program at scale. We intend to produce at least two papers (e.g. protocol, main
20 findings) for peer-review publication, written by core research and implementation team.
21
22
23
24
25
26

27 **Study governance**

28
29 The FDCC Team will support planning, implementation and governance of the project and ensure that
30 WH&S requirements and policies are considered and actioned. There are currently no procedures for
31 auditing trial conduct. All protocol modifications will be discussed within all levels of governance and
32 communicated to the SESLHD HREC. Figure 2 outlines our governance structure.
33
34
35

36
37 [INSERT FIGURE 2]
38
39

40 **Author contributions**

41
42 The original trial design was conceived by SW and TR. All authors contributed to refinement of, and
43 approved, the final manuscript.
44
45

46 **Funding statement**

47
48 The study is funded through a 3-year NSW Health Translational Research Grants Scheme.
49
50
51
52
53

Competing interests

The views expressed are those of the author(s) and not necessarily those of the funding partners. NSW Health has no direct role in study design; data collection, analysis, and interpretation, or writing of final reports, presentations, or publications.

Acknowledgements

This protocol has been authored on behalf of the FDCC Collaborative Group. The authors would like to acknowledge the members of the group not listed as authors: Melissa Green, John Eastwood, Karen Sorensen, Kim Lyle, Catherine Jones, Vicki Blight, Amit Arora, Michelle de Vroome, Andrew Hayen, Nick Hopwood, Virginia Schmied, Rebekah Grace, Jane Kohlhoff, Fiona Brooks, Cathy Kaplun, Kathleen Baird, Myna Hua, Lisa Woodland, Ben Harris-Roxas, Brendan Goodger, Tracey Szanto, Karen Zwi, and Grainne O'Loughlin.

REFERENCES

1. AEDC. Australian Early Development Census. <https://www.aedc.gov.au/data/data-explorer?id=135216>. 2020
2. COAG. COAG Health Council 2019 The Australian National Breastfeeding Strategy: 2019 and Beyond was prepared under the auspices of the COAG Health Council. 2019
3. Moore T, Arefadib N, Deery A, et al. The first thousand days: an evidence paper. *Melbourne: Murdoch Children's Research Institute* 2017
4. Goldfeld S, D'Abaco E, Bryson H, et al. Surveying social adversity in pregnancy: The antenatal risk burden experienced by Australian women. *Journal of paediatrics and child health* 2018;54(7):754-60.
5. NSW Health. The First 2000 Days Framework. 2019
6. Goldfeld S, O'Connor M, Chong S, et al. The impact of multidimensional disadvantage over childhood on developmental outcomes in Australia. *International Journal of Epidemiology* doi:<https://doi.org/10.1093/ije/dyy087>
7. Woolfenden S, Asher I, Bauert P, et al. Summary of position statement on inequities in child health. 2018;54(8):832-33.
8. Rogers HJ, Hogan L, Coates D, et al. Responding to the health needs of women from migrant and refugee backgrounds—Models of maternity and postpartum care in high-income countries: A systematic scoping review. *Health & Social Care in the Community* 2020
9. Hiscock H, Danchin MH, Efron D, et al. Trends in paediatric practice in Australia: 2008 and 2013 national audits from the Australian Paediatric Research Network. *Journal of paediatrics and child health* 2017;53(1):55-61.
10. Palfrey JS, Tonniges TF, Green M, et al. Introduction: addressing the millennial morbidity—the context of community pediatrics. *Pediatrics* 2005;115(Supplement 3):1121-23.

20

11. Woolfenden S, Galea C, Smithers-Sheedy H, et al. Impact of social disadvantage on cerebral palsy severity. *Developmental Medicine & Child Neurology* 2019;61(5):586-92.
12. Brinkman S, Gregory T, Harris J, et al. Associations between the early development instrument at age 5, and reading and numeracy skills at ages 8, 10 and 12: a prospective linked data study. *Child Indicators Research* 2013;6(4):695-708.
13. Merrick MT, Ford DC, Ports KA, et al. Vital signs: Estimated proportion of adult health problems attributable to adverse childhood experiences and implications for prevention—25 States, 2015–2017. *Morbidity and Mortality Weekly Report* 2019;68(44):999.
14. Kezelman C, Hossack N, Stavropoulos P, et al. The cost of unresolved childhood trauma and abuse in adults in Australia, Adults Surviving Child Abuse and Pegasus Economics, Sydney. 2015
15. Woolfenden S, Eapen V, Jalaludin B, et al. Prevalence and factors associated with parental concerns about development detected by the Parents' Evaluation of Developmental Status (PEDS) at 6-month, 12-month and 18-month well-child checks in a birth cohort. *BMJ open* 2016;6(9):e012144.
16. Ayer C, Eapen V, Overs B, et al. Risk factors for non-participation in a universal developmental surveillance program in a population in Australia. *Australian Health Review*
17. Eapen V, Walter A, Guan J, et al. Maternal help-seeking for child developmental concerns: Associations with socio-demographic factors. *J Paediatr Child Health* 2017;53(10):963-69. doi: 10.1111/jpc.13607 [published Online First: 2017/07/01]
18. Zwi K, Rungan S, Woolfenden S, et al. Refugee children and their health, development and well-being over the first year of settlement: A longitudinal study. *Journal of paediatrics and child health* 2017;53(9):841-49.
19. NSW Health. NSW Child Health Survey 2009-2010 Summary report. 2010
20. McLean K, Goldfeld S, Molloy C, et al. Screening and surveillance in early childhood health: rapid review of evidence for effectiveness and efficiency of models. *Ultimo, NSW, Australia: The Sax Institute* 2014
21. Garg P, Ha MT, Eastwood J, et al. Explaining culturally and linguistically diverse (CALD) parents' access of healthcare services for developmental surveillance and anticipatory guidance: qualitative findings from the 'Watch Me Grow' study. *BMC health services research* 2017;17(1):228.
22. Almeida LM, Caldas J, Ayres-de-Campos D, et al. Maternal healthcare in migrants: a systematic review. *Matern Child Health J* 2013;17(8):1346-54. doi: <https://dx.doi.org/10.1007/s10995-012-1149-x> [published Online First: 2013/01/22]
23. Fellmeth G, Fazel M, Plugge E. Migration and perinatal mental health in women from low- and middle-income countries: a systematic review and meta-analysis. *BJOG* 2017;124(5):742-52. doi: <https://doi.org/10.1111/1471-0528.14184> [published Online First: 2016/06/21]
24. World Health Organization (WHO). Promoting the health of refugees and migrants: Framework of priorities and guiding principles to promote the health of refugees and migrants. Geneva: WHO Secretariat, 2017:1-4.
25. Higginbottom G, Morgan M, Alexandre M, et al. Immigrant women's experiences of maternity-care services in Canada: a systematic review using a narrative synthesis. *Syst Rev* 2015;4(13):13. doi: <https://doi.org/10.1186/2046-4053-4-13> [published Online First: 2015/07/19]
26. Correa-Velez I, Ryan J. Developing a best practice model of refugee maternity care. *Women Birth*

21

- 2012;25(1):13-22. doi: <https://dx.doi.org/10.1016/j.wombi.2011.01.002> [published Online First: 2011/02/15]
27. Henderson S, Kendall E. Culturally and linguistically diverse peoples' knowledge of accessibility and utilisation of health services: exploring the need for improvement in health service delivery. *Aust J Prim Health* 2011;17(2):195-201. doi: <https://doi.org/10.1071/PY10065> [published Online First: 2011/06/08]
28. Heslehurst N, Brown H, Pemu A, et al. Perinatal health outcomes and care among asylum seekers and refugees: a systematic review of systematic reviews. *BMC Medicine* 2018;16(1) doi: <https://doi.org/10.1186/s12916-018-1064-0> [published Online First: 2018/06/13]
29. Boyle JA, Willey S, Abbasova G. Supporting better outcomes for migrant and refugee women. *O&G Magazine* 2018; 20(1). <https://www.ogmagazine.org.au/20/1-20/better-outcomes-migrant-refugee-women/>.
30. Small R, Roth C, Raval M, et al. Immigrant and non-immigrant women's experiences of maternity care: a systematic and comparative review of studies in five countries. *BMC Pregnancy Childbirth* 2014;14(152):1-17. doi: 10.1186/1471-2393-14-152 [published Online First: 2014/04/30]
31. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expectations* 2015;18(6):3286-301. doi: 10.1111/hex.12318
32. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expect* doi: 101111/hex12318 2014
33. Woolfenden S, Eapen V, Williams K, et al. A systematic review of the prevalence of parental concerns measured by the Parents' Evaluation of Developmental Status (PEDS) indicating developmental risk. *BMC Pediatr* 2014;14
34. Woolfenden S, Galea C, Badland H, et al. Use of health services by preschool-aged children who are developmentally vulnerable and socioeconomically disadvantaged: testing the inverse care law. *J Epidemiol Community Health* 2020;74(6):495-501.
35. Chando S, Craig JC, Burgess L, et al. Developmental risk among Aboriginal children living in urban areas in Australia: the Study of Environment on Aboriginal Resilience and Child Health (SEARCH). *BMC pediatrics* 2020;20(1):1-13.
36. Henry R. Review of health services for children, young people and families within the NSW Health system, 2019.
37. National Academies of Sciences E, Medicine. Integrating Social Care Into the Delivery of Health Care: Moving Upstream to Improve the Nation's Health: Washington, DC: National Academies Press, 2019.
38. Moore T. Using place-based approaches to strengthen child wellbeing. *Developing Practice: The Child, Youth and Family Work Journal* 2014(40):40.
39. Glover J, Samir N, Kaplun C, et al. The effectiveness of place-based interventions in improving development, health and wellbeing outcomes in children aged 0–6 years living in disadvantaged neighbourhoods in high-income countries – A systematic review. *Wellbeing, Space and Society* 2021;2:100064. doi: <https://doi.org/10.1016/j.wss.2021.100064>
40. Edwards K, Rimes T, Smith R, et al. Improving Access to Early Childhood Developmental


22

- 1
2
3 Surveillance for Children from Culturally and Linguistically Diverse (CALD) Background. .
4 *International Journal of Integrated Care* 2020;Apr;20(2)
5
6 41. Edwards K, Fernandez R, Rimes T, et al. "Happy, Healthy, Ready – working with early childhood
7 non-government organisations for developmental surveillance for vulnerable children". .
8 *Australian Journal of Advanced Nursing* 2020; 37(4)
9
10 42. Rogers HJ, Hogan L, Coates D, et al. Cross Cultural Workers for women and families from migrant
11 and refugee backgrounds: a mixed-methods study of service providers perceptions. *BMC*
12 *Women's Health* 2021;21(1):222. doi: 10.1186/s12905-021-01368-4
13
14 43. Rogers HJ, Hogan L, Coates D, et al.
15 A Bridge to Health: The Cross Cultural Workers in Maternity and Child and Family Health Service
16 for women and families from migrant and refugee backgrounds: A mixed-methods study of
17 service providers perceptions in Sydney, Australia (Manuscript not yet published). 2020
18
19 44. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
20 for protocols of clinical trials. *Bmj* 2013;346
21
22 45. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research
23 findings into practice: a consolidated framework for advancing implementation science.
24 *Implement Science* 2009;4(1):50.
25
26 46. Kirk MA, Kelley C, Yankey N, et al. A systematic review of the use of the consolidated framework
27 for implementation research. *Implementation Science* 2016;11(72):1-13.
28
29 47. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
30 distinctions, measurement challenges, and research agenda. *Administration and Policy in*
31 *Mental Health and Mental Health Services Research* 2011;38(2):65-76.
32
33 48. Lawton B, Brandon PR, Cicchinelli L, et al. Logic Models: A Tool for Designing and Monitoring
34 Program Evaluations. REL 2014-007. *Regional Educational Laboratory Pacific* 2014
35
36 49. U.S. Department of Health and Human Services Centres for Disease Control and Prevention.
37 Introduction to program evaluation for public health programs: A self-study guide. Atlanta,
38 GA: Centers for Disease Control and Prevention, 2011.
39
40 50. Li S-A, Jeffs L, Barwick M, et al. Organizational contextual features that influence the
41 implementation of evidence-based practices across healthcare settings: a systematic integrative
42 review. *Systematic Reviews* 2018;7(1):72. doi: 10.1186/s13643-018-0734-5
43
44 51. Kania J, Kramer M. Collective impact: Leland Stanford Jr. University 2011.
45
46 52. Michie S, Atkins L, West R. The behaviour change wheel. *A guide to designing interventions 1st*
47 *ed Great Britain: Silverback Publishing* 2014:1003-10.
48
49 53. Smart JR. Collective impact: Evidence and implications for practice: Australian Institute of Family
50 Studies Melbourne 2017.
51
52 54. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed
53 implementation outcome measures. *Implementation Science* 2017;12(1):108.
54
55 55. Finch TL, Rapley T, Girling M, et al. Improving the normalization of complex interventions:
56 measure development based on normalization process theory (NoMAD): study protocol.
57 *Implementation Science* 2013;8(1):43. doi: 10.1186/1748-5908-8-43
58
59 56. Chapko MK, Liu CF, Perkins M, et al. Equivalence of two healthcare costing methods: bottom-up
60 and top-down. *Health economics* 2009;18(10):1188-201.
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

23

programmes: Oxford university press 2015.


58. Cox JL, Holden JM, Sagovsky R. Detection of Postnatal Depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 1987;150(6):782-86. doi: 10.1192/bjp.150.6.782 [published Online First: 2018/01/02]
59. NSW Department of Health. NSW Health/Families NSW Supporting Families Early Package – SAFE START Strategic Policy, 2009.
60. Garg A, Toy S, Tripodis Y, et al. Addressing Social Determinants of Health at Well Child Care Visits: A Cluster RCT. *Pediatrics* 2015;135(2):e296-e304. doi: 10.1542/peds.2014-2888
61. Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research (CFIR). *Implementation Science* 2013;8(51):1-32.
62. Edwards B, Mullan K, Katz I, et al. The Stronger Families in Australia (SFIA) Study: Phase 2 The Stronger Families in Australia (SFIA) Study: Phase 2. 2014



FDCC implementation evaluation logic model

861x484mm (118 x 118 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



FDCC governance structure

626x342mm (38 x 38 DPI)

APPENDICES

Appendix 1: Participant Information Sheet and Consent Form

Primary and Community Health Directorate

PARTICIPANT INFORMATION SHEET AND CONSENT FORM Participant

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

Invitation

You are invited to take part in the Family Care Connect project. Family Care Connect involves child and family Hubs, where health and other agencies work together and you are supported to navigate these services. Our research is seeing whether these Hubs support the health and development of children, mothers and families from migrant and refugee communities.

Who is doing the research?

Tania Rimes

Children and Communities Program Coordinator

Primary and Community Health Directorate | South Eastern Sydney Local Health District (SESLHD).

Associate Professor Sue Woolfenden (Research lead)

NHMRC Senior Research Fellow, Population Child Health Group | The University of New South Wales (UNSW). Senior Staff Specialist, Community Child Health | Sydney Children's Hospitals Network.

Before you decide if you want to take part in this research, we would like to explain what we are doing and why we are doing it. . Please take the time to read the following information carefully. You can talk about it with a relative or a friend if you wish before deciding.

What is the purpose of this research?

We want to see if child and family Hubs help women and families from migrant and refugee communities move from pregnancy to Child and Family Health services. Also, we want to see if these Hubs support children's health and development in the first 12 months of life.

We will also look at how easy and cost-effective the Hub is for you and other women and families.

Why have I been invited to participate in this research?

You are eligible to participate in this research because you:

- are having your baby or recently given birth to your baby at [INSERT HOSPITAL SITES]
- live in the postcode of [INSERT POSTCODE/S]

- are at least 20 weeks pregnant, OR have recently given birth to your baby and have not been discharged home from postnatal ward
- are a newly arrived migrant (within the last 10 years) from a non-English speaking background; or a refugee (living in Australia for less than 10 years) from a non-English speaking background
- are 16 years of age or older.

If I say yes, what will it involve?

If you decide to take part in the research and live in [INSERT SITE AREA] you will be in the **'FDCC Group'**. You will receive information about the child and family services in your area you can access after the birth of your baby. This information is given to all women, regardless of whether or not they participate in the study.

If you take part in the **"FDCC Group"**, you will also be contacted by a worker from the local child and family Hub who will give you more information on the services offered and assist you with accessing these services if you choose.

If you agree to take part, we will ask you to sign the Participant Information and Consent form below; OR sign the online consent found here [INSERT ONLINE CONSENT URL]; OR provide verbal consent over the telephone to the contact person for the research.

After you provide consent to take part in this research, we will ask you to:

- Complete a survey about you, your family, your support needs, and your wellbeing. This will take about 30 minutes. You can choose to do it online, by paper, over the phone, or in-person. **We can provide an interpreter to assist.**
- Complete another survey when your baby is 6 months and 12 months old. This will ask questions about you, what your needs are, and what services you have used. **We can provide an interpreter to assist.**
- We will also collect data from your local and state-wide hospital/s about you and your baby. This reduces the number of questions we need to ask you.

The data we collect from local hospitals includes:

- Information about you and your child such as country of birth, date of birth, gender, language spoken at home
- Information from routine questions asked to all women when they come to hospital about their health and wellbeing and their child's
- Information about the services you or your child has seen, for example the child and family health nurse.

The data we collect from state-wide hospitals includes:

- Information that is collected on all new mothers and babies in NSW
- Emergency Department presentations for you and your baby

If you don't want us to collect data about you and your baby from state-wide hospitals, then we won't. Please let us know by checking the box.

I DO NOT want my state-wide hospital data included as part of this research

1
2
3
4 **If you only provide verbal consent, we will not collect data about you and your baby**
5 **from state-wide hospitals.**

6 As part of this research, we may also invite you to be interviewed. We will contact you at
7 another time to discuss this process before the research is complete.
8
9

10 Any information we collect that can identify you or your child will remain confidential.
11

12 The total time you are involved with this project will be for 12 to 18 months, but you can
13 choose to withdraw at any time.
14

15
16 **What if I don't want to take part in this research, or if I want to withdraw later?**

17 It is completely up to you whether or not you decide to take part. Saying yes or no will not
18 affect your relationship with the care you receive, the services you access, or your visa
19 status now or in the future.
20

21 If you wish to leave the research once it has started, you can do so verbally or in writing at
22 any time without giving a reason. However, it may not be possible to withdraw your data
23 from the research results once we have collected it and removed your identifying details.
24 This is due to be done from March 2023.
25

26
27 **How is this research being paid for?**

28 The research is being paid for by NSW Health as part of the Translational Research Grant
29 Scheme. More information about this scheme can be found here:

30 <https://www.medicalresearch.nsw.gov.au/translational-research-grants-scheme/>
31
32

33 **Are there risks to me in taking part in this research?**

34 There is very little risk to you, however if you become upset or distressed because of taking
35 part in the research, the research team will arrange for counselling or other help. Any
36 counselling or help will be provided by qualified staff who are not members of the research
37 team. This will be provided free of charge.
38

39 Another risk in taking part in this research is the risk to your privacy as part of collecting
40 data about you, your child, and your family. While this is a risk, we will take all the steps to
41 ensure your information remains private and confidential. We do not collect you or your
42 baby's name, or anything else that could identify you or your family. Instead, your name will
43 be replaced with a number. Only people involved with this research will be able to tell that
44 the information is about you.
45
46

47
48 **What happens if I suffer injury or complications as a result of the research?**

49 It is very unlikely that you will suffer any injury as we are only asking you to complete
50 questionnaires. However, if you require treatment or suffer loss as a result of the
51 wrongdoing of any of the parties involved in the research, you can seek compensation. The
52 cost of your treatment must be paid by the compensation you receive.
53
54

55 **Will I benefit from the research?**

56 This research aims to determine how best to provide child health services for families and
57 to improve how parents in the future access child and family health services, however it
58 may or may not directly benefit you or your baby.
59
60

Will taking part in this research cost me anything, and will I be paid?

Taking part in this research will not cost you anything, nor will you be paid.

How will my confidentiality be protected?

Any information that is collected about you as part of this research will remain private and confidential and will be discussed only with your permission, except as required by law. This means the research team are Mandatory Reporters and may need to speak with NSW Department of Communities and Justice if they are told or are concerned that a child is being hurt or is at risk of being hurt e.g. if there is abuse or violence in the home.

If such a situation happens, we would discuss this with you in private and arrange for you to speak with another professional if required.

Only the researchers named above will have access to your details. All information will be stored on a secure drive within [INSERT LHD SITES] and UNSW. We will keep the information for 5 years after the research ends. After this time, it will be destroyed.

In line with Australian, New South Wales, and other relevant laws, you have the right to access and correct the information we collect and store about you. Please contact us if you would like to access the information.

What happens with the results?

If you give us your permission by providing your consent in written form, online, or verbally, we plan to publish the results in a report and in peer reviewed journals. We may also present results at professional forums and conferences to inform better ways of working and providing services.

We will also give a report on the research to the South Eastern Sydney Local Health District Human Research Ethics Committee.

In any report, publication, or presentation, information will be provided in such a way that you or your family cannot be identified.

What should I do if I want to discuss this research further before I decide?

When you have read this information, the researcher interviewer/project officer will discuss it with you and answer any queries you may have. If you would like to know more at any stage, please do not hesitate to contact Tania Rimes, Principal Investigator on (02) 9382 8696 or email her at tania.rimes@health.nsw.gov.au. If you need an interpreter, you can contact Tania through the Translating and Interpreting Service (TIS) on 131 450.

Who should I contact if I have concerns about the conduct of this research?

This research has been approved by the South Eastern Sydney Local Health District Human Research Ethics Committee. Any person with concerns or complaints about the conduct of this research should contact the Research Support Office which is nominated to receive complaints from research participants. You should contact them on 02 9382 3587, or email SESLHD-RSO@health.nsw.gov.au and quote HREC reference number: 2020/ETH03295.

The conduct of this research is at the [INSERT SITE NAMES]. Any person with concerns or complaints about the conduct of this research may also contact the [*details of the Research Governance Officer of the health district will be provided following SSA application*]

1
2
3
4 **Thank you for taking the time to consider this research.**
5 **If you wish to take part in it, please sign the attached consent form.**
6 **This information sheet is for you to keep.**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Primary and Community Health Directorate

CONSENT FORM

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

1. I,.....
of.....
agree to take part in the research described in the participant information statement set out above and to have my data linked as outlined in the information sheet.
2. I have read the participant information statement, which explains why I have been asked to take part, the aims of the research and the possible risks of the research, and the statement has been explained to me to my satisfaction.
3. Before signing this consent form, I have been able to ask any questions relating to any possible physical and mental harm I might suffer as a result of taking part and I have received satisfactory answers.
4. I understand that I can withdraw from the research at any time without affecting my relationship with South Eastern Sydney Local Health District or service at the child and family hub.
5. I agree that research information collected from the results of the research may be published and presented, provided that I cannot be identified.
6. I understand that if I have any questions relating to my participation in this research, I may contact Tania Rimes on telephone (02) 9382 8696, who will be happy to answer them. I can call 131450 (TIS) for language support.
7. I have been given a copy of this Consent Form and the Participant Information Statement.

Complaints may be directed to the Research Support Office, South Eastern Sydney Local Health District, Prince of Wales Hospital, Randwick NSW 2031 Australia (phone 02-9382 3587, fax 02-9382 2813, email SESLHD-RSO@health.nsw.gov.au).

Signature of participant

Please PRINT name

Date

Signature of witness

Please PRINT name

Date

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Signature of investigator	Please PRINT name	Date
_____	_____	_____

Investigator/officer taking consent to complete:

Check box if participant DOES NOT want their state-wide hospital data included as part of this research

For peer review only

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a Trial identifier and registry name. If not yet	17

1		registered, name of intended registry	
2			
3			
4	Trial registration:	#2b All items from the World Health Organization Trial	
5			
6	data set	Registration Data Set	
7			
8			
9	Protocol version	#3 Date and version identifier	2
10			
11			
12	Funding	#4 Sources and types of financial, material, and other	19
13			
14		support	
15			
16			
17	Roles and	#5a Names, affiliations, and roles of protocol	19
18			
19	responsibilities:	contributors	
20			
21	contributorship		
22			
23			
24			
25	Roles and	#5b Name and contact information for the trial sponsor	19
26			
27	responsibilities:		
28			
29	sponsor contact		
30			
31	information		
32			
33			
34			
35	Roles and	#5c Role of study sponsor and funders, if any, in study	19
36			
37	responsibilities:	design; collection, management, analysis, and	
38			
39	sponsor and funder	interpretation of data; writing of the report; and the	
40			
41		decision to submit the report for publication,	
42			
43		including whether they will have ultimate authority	
44			
45		over any of these activities	
46			
47			
48			
49	Roles and	#5d Composition, roles, and responsibilities of the	19
50			
51	responsibilities:	coordinating centre, steering committee, endpoint	
52			
53	committees	adjudication committee, data management team,	
54			
55		and other individuals or groups overseeing the	
56			
57			
58			
59			
60			

trial, if applicable (see Item 21a for data
monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4
Objectives	#7	Specific objectives or hypotheses	5-6
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	7
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries	6

1		where data will be collected. Reference to where	
2			
3		list of study sites can be obtained	
4			
5			
6	Eligibility criteria	#10 Inclusion and exclusion criteria for participants. If	6
7			
8		applicable, eligibility criteria for study centres and	
9			
10		individuals who will perform the interventions (eg,	
11			
12		surgeons, psychotherapists)	
13			
14			
15			
16	Interventions:	#11a Interventions for each group with sufficient detail	5,8
17			
18	description	to allow replication, including how and when they	
19			
20		will be administered	
21			
22			
23	Interventions:	#11b Criteria for discontinuing or modifying allocated	n/a
24			
25	modifications	interventions for a given trial participant (eg, drug	
26			There are no plans
27			to discontinue or
28		dose change in response to harms, participant	modify the
29			interventions.
30		request, or improving / worsening disease)	
31			
32			
33			
34			
35			
36	Interventions:	#11c Strategies to improve adherence to intervention	7
37			
38	adherence	protocols, and any procedures for monitoring	
39			
40		adherence (eg, drug tablet return; laboratory	
41			
42		tests)	
43			
44			
45			
46	Interventions:	#11d Relevant concomitant care and interventions that	n/a
47			
48	concomitant care	are permitted or prohibited during the trial	
49			
50			
51	Outcomes	#12 Primary, secondary, and other outcomes,	12-15
52			
53		including the specific measurement variable (eg,	
54			
55		systolic blood pressure), analysis metric (eg,	
56			
57			
58			
59			
60			

change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce	7
---------------------------------	----------------------	---	---

1		predictability of a random sequence, details of any	
2		planned restriction (eg, blocking) should be	
3		provided in a separate document that is	
4		unavailable to those who enrol participants or	
5		assign interventions	
6			
7			
8			
9			
10			
11			
12			
13	Allocation	#16b Mechanism of implementing the allocation	7
14			
15	concealment	sequence (eg, central telephone; sequentially	
16		numbered, opaque, sealed envelopes), describing	
17	mechanism	any steps to conceal the sequence until	
18		interventions are assigned	
19			
20			
21			
22			
23			
24			
25	Allocation:	#16c Who will generate the allocation sequence, who	7
26			
27	implementation	will enrol participants, and who will assign	
28		participants to interventions	
29			
30			
31			
32	Blinding (masking)	#17a Who will be blinded after assignment to	8
33		interventions (eg, trial participants, care providers,	
34		outcome assessors, data analysts), and how	
35			
36			
37			
38			
39			
40	Blinding (masking):	#17b If blinded, circumstances under which unblinding	8
41			
42	emergency	is permissible, and procedure for revealing a	
43		participant's allocated intervention during the trial	
44	unblinding		
45			
46			
47			
48	Methods: Data		
49			
50	collection,		
51			
52	management, and		
53			
54	analysis		
55			
56			
57			
58	Data collection plan	#18a Plans for assessment and collection of outcome,	12-15
59			
60			

1 baseline, and other trial data, including any
 2 related processes to promote data quality (eg,
 3 duplicate measurements, training of assessors)
 4 and a description of study instruments (eg,
 5 questionnaires, laboratory tests) along with their
 6 reliability and validity, if known. Reference to
 7 where data collection forms can be found, if not in
 8 the protocol
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18

19	Data collection plan: #18b	Plans to promote participant retention and	14
20	retention	complete follow-up, including list of any outcome	
21		data to be collected for participants who	
22		discontinue or deviate from intervention protocols	
23			
24			
25			
26			
27			
28			
29	Data management #19	Plans for data entry, coding, security, and storage,	15-16
30		including any related processes to promote data	
31		quality (eg, double data entry; range checks for	
32		data values). Reference to where details of data	
33		management procedures can be found, if not in	
34		the protocol	
35			
36			
37			
38			
39			
40			
41			
42			
43	Statistics: outcomes #20a	Statistical methods for analysing primary and	16
44		secondary outcomes. Reference to where other	
45		details of the statistical analysis plan can be	
46		found, if not in the protocol	
47			
48			
49			
50			
51			
52			
53	Statistics: additional #20b	Methods for any additional analyses (eg,	16
54	analyses	subgroup and adjusted analyses)	
55			
56			
57			
58			
59			
60			

1	Statistics: analysis	#20c	Definition of analysis population relating to	16
2				
3	population and		protocol non-adherence (eg, as randomised	
4				
5	missing data		analysis), and any statistical methods to handle	
6				
7			missing data (eg, multiple imputation)	
8				
9				
10				
11	Methods: Monitoring			
12				
13				
14	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	16
15				
16	formal committee		summary of its role and reporting structure;	
17				
18			statement of whether it is independent from the	
19				
20			sponsor and competing interests; and reference to	
21				
22			where further details about its charter can be	
23				
24			found, if not in the protocol. Alternatively, an	
25				
26			explanation of why a DMC is not needed	
27				
28				
29				
30				
31	Data monitoring:	#21b	Description of any interim analyses and stopping	16
32				
33	interim analysis		guidelines, including who will have access to	
34				
35			these interim results and make the final decision	
36				
37			to terminate the trial	
38				
39				
40				
41	Harms	#22	Plans for collecting, assessing, reporting, and	16-17
42				
43			managing solicited and spontaneously reported	
44				
45			adverse events and other unintended effects of	
46				
47			trial interventions or trial conduct	
48				
49				
50				
51	Auditing	#23	Frequency and procedures for auditing trial	19
52				
53			conduct, if any, and whether the process will be	
54				
55			independent from investigators and the sponsor	
56				
57				
58				
59				
60				

1 **Ethics and**

2
3 **dissemination**

4			
5			
6			
7	Research ethics	#24	Plans for seeking research ethics committee /
8			
9	approval		institutional review board (REC / IRB) approval
10			
11			
12	Protocol	#25	Plans for communicating important protocol
13			
14	amendments		modifications (eg, changes to eligibility criteria,
15			outcomes, analyses) to relevant parties (eg,
16			investigators, REC / IRBs, trial participants, trial
17			registries, journals, regulators)
18			
19			
20			
21			
22			
23			
24	Consent or assent	#26a	Who will obtain informed consent or assent from
25			
26			potential trial participants or authorised
27			surrogates, and how (see Item 32)
28			
29			
30			
31			
32	Consent or assent:	#26b	Additional consent provisions for collection and
33			
34	ancillary studies		use of participant data and biological specimens
35			
36			in ancillary studies, if applicable
37			
38			
39			
40			
41			
42			
43	Confidentiality	#27	How personal information about potential and
44			
45			enrolled participants will be collected, shared, and
46			
47			maintained in order to protect confidentiality
48			
49			before, during, and after the trial
50			
51			
52	Declaration of	#28	Financial and other competing interests for
53			
54	interests		principal investigators for the overall trial and each
55			
56			study site
57			
58			
59			
60			

1	Data access	#29	Statement of who will have access to the final trial	16
2				
3			dataset, and disclosure of contractual agreements	
4				
5			that limit such access for investigators	
6				
7				
8				
9	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	n/a
10				
11	trial care		and for compensation to those who suffer harm	This is a low-risk
12				
13			from trial participation	trial with minimal
14				
15				foreseen harms to
16				
17				participants.
18				
19				
20				
21				
22	Dissemination	#31a	Plans for investigators and sponsor to	17
23				
24	policy: trial results		communicate trial results to participants,	
25				
26			healthcare professionals, the public, and other	
27				
28			relevant groups (eg, via publication, reporting in	
29				
30			results databases, or other data sharing	
31				
32			arrangements), including any publication	
33				
34			restrictions	
35				
36				
37				
38	Dissemination	#31b	Authorship eligibility guidelines and any intended	17
39				
40	policy: authorship		use of professional writers	
41				
42				
43				
44	Dissemination	#31c	Plans, if any, for granting public access to the full	17
45				
46	policy: reproducible		protocol, participant-level dataset, and statistical	
47				
48	research		code	
49				
50				
51	Appendices			
52				
53				
54	Informed consent	#32	Model consent form and other related	Supp. file
55				
56	materials		documentation given to participants and	
57				
58				
59				
60				

1 authorised surrogates

2
3
4 Biological [#33](#) Plans for collection, laboratory evaluation, and n/a
5
6 specimens storage of biological specimens for genetic or
7 No biological
8 molecular analysis in the current trial and for
9 specimens will be
10 future use in ancillary studies, if applicable
11 collected as part of
12
13 this trial.
14
15

16
17 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
18 Commons Attribution License CC-BY-NC. This checklist can be completed online using
19 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
20
21 [Penelope.ai](#)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Study protocol for a real-world evaluation of an integrated child and family health hub for migrant and refugee women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061002.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Jul-2022
Complete List of Authors:	Hodgins, Michael; UNSW, Ostojic, Katarina; University of New South Wales Hu, Nan; UNSW, Lawson, K; Western Sydney University Samir, Nora; University of New South Wales - Randwick Campus, School of Women's and Children's Health Webster, Amanda; South Eastern Sydney Local Health District Rogers, Helen; South Eastern Sydney Local Health District, Henry, Amanda ; University of New South Wales Faculty of Medicine, Women's and Children's Health Murphy, Elisabeth; University of New South Wales; New South Wales Ministry of Health Lingam, Raghu; University of New South Wales Raman, Shanti; University of New South Wales School of Women's and Children's Health, ; South Western Sydney Local Health District, Community Paediatrics Mendoza Diaz , Antonio; University of New South Wales, Discipline of Psychiatry Dadich, Ann; Western Sydney University, School of Business Eapen, Valsamma; South Western Sydney Local Health District, ICAMHS; University of New South Wales, School of Psychiatry Rimes, Tania; South Eastern Sydney Local Health District, Child Youth and Family Services Woolfenden, Susan ; University of New South Wales; Sydney Local Health District
Primary Subject Heading:	Public health
Secondary Subject Heading:	Paediatrics, Health services research, Research methods
Keywords:	Community child health < PAEDIATRICS, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PAEDIATRICS, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5 **TITLE:** Study protocol for a real-world evaluation of an integrated child and family
6 health hub for migrant and refugee women
7
8
9

10
11 **AUTHORS:** Michael Hodgins¹, Katarina Ostojic¹, Nan Hu¹, Kenny Lawson², Nora Samir¹,
12 Amanda Webster³, Helen Rogers³, Amanda Henry¹, Elisabeth Murphy⁴,
13 Raghu Lingam^{1,5}, Shanti Raman⁶, Antonio Mendoza Diaz¹, Ann Dadich²,
14 Valsamma Eapen^{1,6}, Tania Rimes^{3*}, Sue Woolfenden^{1,7*}
15

16 On behalf of the FDCC Collaborative Group
17

18 **AFFILIATIONS**

19
20 ¹ University of New South Wales, NSW 2751
21

22 ² Western Sydney University, NSW 2150
23

24 ³ South Eastern Sydney Local Health District, NSW 2229
25

26 ⁴ North Sydney Local Health District, NSW 2065
27

28 ⁵ Sydney Children's Hospitals Network, Sydney, NSW, 2031
29

30 ⁶ South Western Sydney Local Health District, NSW 2170
31

32 ⁷ Sydney, Institute for Women, Children and their Families, Sydney Local Health District, NSW
33 2050
34

35 **CORRESPONDING AUTHORS***

36 Dr Michael Hodgins
37

38 School of Women's & Children's Health
39

40 UNSW
41

42 Email: michael.hodgins1@unsw.edu.au
43
44
45
46
47
48

49 **KEYWORDS** Integrated care, community child health, maternal health, organisation of health
50 services, paediatrics, public health
51
52
53

54 1
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

WORD COUNTS

Abstract: 299 words

Main text: 3,976 words (excluding title page, tables, and references)

Protocol version: version 1.0 (10.01.2022)

For peer review only

ABSTRACT

Introduction: Continuity of child and family healthcare is vital for optimal child health and development for developmentally vulnerable children. Migrant and refugee communities are often at-risk of poor health outcomes, facing barriers to health service attendance including cultural, language, limited health literacy, discrimination, and unmet psychosocial needs. ‘Integrated health-social care hubs’ are physical hubs where health and social services are co-located, with shared referral pathways and care navigation.

Aim: Our study will evaluate the impact, implementation, and cost-benefit of the First 2000 Days Care Connect (FDCC) integrated hub model for pregnant migrant and refugee women and their infants.

Materials and methods: This study has three components. Component 1 is a non-randomised controlled trial to compare the FDCC model of care with usual care. This trial will allocate eligible women to intervention and control groups based on their proximity to the Hub sites. Outcome measures include: the proportion of children attending child and family health (CFH) nurse services and completing their CFH checks to 12 months of age; improved surveillance of growth and development in children up to 12 months, post-partum; improved breastfeeding rates; reduced emergency department presentations; and improve maternal wellbeing. These will be measured using linked medical record data and surveys. Component 2 will involve a mixed-method implementation evaluation to clarify how and why FDCC was implemented within the sites to inform future roll-out. Component 3 is a within-trial economic evaluation from a healthcare perspective to assess the cost-effectiveness of the Hubs relative to usual care and the implementation costs if Hubs were scaled and replicated.

Ethics and dissemination: Ethical approval was granted by the South Eastern Sydney Local Health District Human Research Ethics Committee in July 2021 (Project ID: 020/ETH03295). Results will be submitted for publication in peer-reviewed journals and presented at relevant conferences.

Trial registration: ACTRN12621001088831

ARTICLE SUMMARY

Strength and limitations

- First Australian multi-site non-randomised controlled trial to test the effectiveness of integrated health-social care hubs.
- The study is novel as it has an embedded implementation evaluation and economic evaluation in addition to the non-randomised trial component of the study.
- The non-randomised design of the trial has some limitations, particularly the inability to guarantee the comparability of the intervention and control groups.

BACKGROUND AND RATIONALE

In New South Wales (NSW), Australia, 25% of children from migrant and refugee families are 'developmentally vulnerable'.¹ Developmental vulnerability is measured by the Australian Early Development Census across five domains including physical health and wellbeing, social competence, emotional maturity, language and cognitive skills, and communication skills and general knowledge. Children who are in the lowest 10 per cent of the national population are classified as developmentally 'vulnerable'.¹ Developmental vulnerability is associated with undetected maternal postnatal depression, the early cessation of breastfeeding², and parental unmet psychosocial needs (e.g., housing, domestic violence).^{3 4} Children who are developmentally vulnerable are twice as likely to struggle at school, experience adverse childhood events and have poorer long-term health outcomes and higher healthcare costs.^{1 5-12} These adverse childhood events can continue into adulthood, contributing up to 44% of adult morbidity.^{13 14}

Continuity of care with regular child and family health (CFH) checks by local health district (LHD) employed child and family health nurses (CFHN) are the foundation for optimal child health and development. This is particularly the case for priority populations, including newly arrived migrant and refugee women, children, and their families.⁵ However, these populations also experience significant barriers to services including cultural, language, limited health literacy, discrimination, and unmet psychosocial needs.¹⁵⁻³¹ Families with greater disadvantage are at greater risk of developmental vulnerability and poorer maternal mental health and other health problems. These families are less likely to engage with health services, particularly health promotion programs, like

4

1
2
3 CFH checks.^{2-4 15 32-36}

4
5 Australian policymakers identified service areas that need improvement to optimise outcomes in the
6 first 2,000 days of a child's life.^{5 37} These include the transition from maternity to CFH services;
7 increasing uptake and length of time families stay connected with CFH services; and supporting
8 priority populations. Unfortunately, in NSW, two-thirds of children stop attending CFH services by
9 12 months of age,^{15 18-20} further fragmenting care.

14 **Benefits of integrated health-social care hubs**

15
16 To address the fragmented CFH services for priority populations, integrated health-social care hubs
17 were established in multiple jurisdictions across Australia. These are physical hubs where health and
18 social services are co-located, supported by care navigators and shared referral pathways.^{38 39} Co-
19 location and navigation support aims to remove barriers that hinder engagement between families
20 and CFH services. However, the evidence-base for their effectiveness is limited. Our recent
21 systematic review demonstrated the dearth of experimental trial evidence in Australia regarding
22 physical CFH Hubs.⁴⁰ Yet, individual studies have found Hub models increase access to CFH
23 services and the identification of developmental vulnerability.⁴⁰ Additionally, a recent scoping
24 review of models of care across the continuum of pregnancy, birth, and the postpartum period for
25 women from migrant and refugee backgrounds in high-income countries highlighted an evidence gap
26 for models that improved maternal and child infant health outcomes.⁸

27
28 We have extended this evidence-base by showing the feasibility and efficacy of integrated CFH
29 hubs and cross-cultural workers (CCW) models in South Eastern Sydney.^{8 41-43} These models support
30 women and families to navigate maternity, CFH, and community-based services, providing
31 continuity of care across the continuum of pregnancy and transition to CFH. The pilot interventions
32 demonstrated that, for women and families from migrant and refugee populations: CFHN services
33 embedded in integrated hubs increased the completion rate of CFH checks from 30% to 60% at 12-
34 months and facilitated linkage with co-located non-government organisations.^{41 42} Cross-cultural
35 worker support in pregnancy was also highly rated by staff and pregnant women regarding support
36 for pregnancy and linkage with services.^{44 45}

52 **Current study: First 2000 Days Care Connect**

53
54 5

1
2
3 *First 2000 Days Care Connect* (FDCC) is an integrated health-social care hub model that builds on
4 these feasible and acceptable pilot interventions. The FDCC model involves co-located CFH services
5 and non-government organisations (NGO), including psychosocial support services (e.g., playgroups,
6 domestic violence support, mental health support, early childhood education, family support). These
7 services operate from a physical location to facilitate service collaboration, integration, and a
8 community-led approach to local needs. This Hub is supported by care navigation, increasing
9 continuity from maternity to CFH services.
10
11
12
13
14

15 **Objectives**

16
17
18 The overall aim of the FDCC study is to evaluate: the impact of FDCC (an integrated CFH Hub) on
19 attendance at CFHN services and completion of CFH checks, support of child growth and
20 development, breastfeeding and maternal wellbeing, and meeting family psychosocial needs
21 (Component 1); the process of implementing FDCC (Component 2); and the cost-effectiveness of
22 FDCC (Component 3).
23
24
25
26

27 **METHODS AND ANALYSIS**

28 **Study Setting**

29
30
31
32 FDCC is a multisite study, conducted across three metropolitan LHDs in Greater Sydney, NSW –
33 namely, SESLHD, SWSLHD, and NSLHD. Participants will be recruited from public and
34 universally available antenatal services at participating public hospitals within the LHDs and receive
35 services from CFHN services within each LHD.
36
37
38

39 **Recruitment and Consent**

40
41
42 The study will recruit 240 women between November 2021 and April 2022. Eighty participants will
43 be enrolled within SESLHD, NSLHD, and SWSLHD, with 40 allocated to the intervention arm
44 (FDCC Hub) and 40 to the control arm (routine care). Potential participants are women attending
45 antenatal clinics at the participating public hospitals within each study site and fulfilling the
46 eligibility criteria (Table 1).
47
48
49

50
51 *Table 1: Inclusion and Exclusion Criteria*
52
53

54 6
55
56
57
58
59
60

Inclusion criteria	Exclusion criteria
<p>Eligible women will be expectant mothers who are:</p> <ul style="list-style-type: none"> • Attending antenatal clinics linked to the three study sites • Residing in geographical catchment for the respective antenatal clinic • Expectant mother > 20 weeks gestation • 16 years of age or older at enrolment • Newly arrived migrant (< 10 years in Australia) or self-identified refugee (< 10 years in Australia), from a non-English speaking background • Provide a signed and dated informed consent form 	<ul style="list-style-type: none"> • Does not comprehend the recruitment invitation (not proficient in English and/or declines the offer of an interpreter in their home language) • Have no mechanism for contact (telephone or email) • Already an active client in other targeted support services • Less than 16 years of age at enrolment • Migrant > 10 years in Australia or self-identified refugee > 10 years in Australia, • From an English speaking background • Not residing in geographical area of study

Using three processes, midwives and CCWs (where available) will identify eligible women attending antenatal services at the intervention sites during regular consultations. The processes include: midwives and CCW introduce the project to women attending a group model of antenatal care; midwives will promote the study during individual hospital antenatal visits and provide potential participants a flyer; and midwives will identify potential participants who meet the eligibility criteria and provide study details during regular antenatal visits. If potential participants provide verbal consent, they will be introduced to the project officer. The project officer will explain the study and provide a participant information sheet and consent form (PISCF) using translated documents and/or interpreter services, if required. They will confirm eligibility at face-to-face clinic visits or via telephone consultation. If the woman is not interested in the study, there will be no further contact regarding the study.

Participants will provide informed consent via completing paper-based consent forms, via email or verbally via phone or via online electronic signature option using the RedCap database. Participants consenting to the study can opt out of the data linkage component.

For component 2, once the FDCC trial is underway, the project implementation scientist will contact participating CFHNs, NGO staff, and Hub administrative staff via telephone and/or email to invite them to an interview or focus group. Prior to the interviews and focus groups, the implementation researcher will describe the study to participants and its rationale, providing a PISCF, and obtain informed consent. Hub staff and service leaders, including LHD partners and policymakers, will be

7

1
2
3 invited to complete a 32-item online survey at the completion of *Component 1*. The online survey
4 will include a detailed description of the study, rationale, and an opportunity to indicate informed
5 consent before survey completion. Hub staff and managers who do not complete the survey will
6 receive a reminder thrice via email.
7
8
9

10 **Study Procedures**

11
12 This protocol has used the SPIRIT reporting guidelines.⁴⁶ Following the identification of potential
13 participants, project officers will confirm participant eligibility as part of the consent process. This is
14 a non-randomised study whereby eligible participants will be allocated to a study arm (FDCC
15 intervention or control group) based on their residential postcode at the time of enrolment (see
16 below). Participation will be 12 months, including: intervention allocation; intervention delivery (12
17 months); and data collection (baseline, 6 months post-partum, 12 month post-partum). In addition to
18 English, the study materials will be translated in the six most common community languages
19 (Arabic, Bengali, Simplified Chinese, Korean, Hindi, and Vietnamese).
20
21
22
23
24
25
26

27 *Allocation, Concealment, and Implementation*

28
29 Women attending antenatal services from the participating hospitals who live in a defined
30 geographic area (postcode) served by an established CFH Hub in their LHD will be allocated to the
31 FDCC intervention group. Women attending antenatal services from the participating hospitals but
32 do not live in the defined geographic area above will be in the control group.
33
34
35
36

37 *Blinding*

38
39 Given the nature of the study, blinding to group allocation is impractical. However, as the
40 intervention is dependent on participant postcode of residence, there is expected to be minimal
41 treatment contamination between the intervention and control groups. To assess for intervention
42 contamination, women in all groups will be asked at the 12 months postpartum assessment regarding
43 the use of any Hub and CFHN service. While the site project officers collecting survey data at each
44 site will not be blinded to allocation, the researcher analysing data will be blinded to group
45 allocation.
46
47
48
49
50

51 *Intervention*

52
53
54 8
55
56
57
58
59
60

1
2
3 After recruitment, the Hub navigator or key worker (i.e. an individual based at the hub responsible
4 for linking participants with services, usually the CFHN) will contact participants to introduce Hub
5 services and support engagement with identified services, if needed. This will be followed by another
6 contact between birth and 8 weeks postpartum. Following mothers' and infants' discharge from
7 birthing services, women will access CFH services via the Hub, as well as psychosocial support
8 services suited to maternal needs and preferences. Per routine care, all women and their babies will
9 be offered an appointment (approximately 1 hour) with a CFHN at 1 to 4 weeks postpartum, 6 to 8
10 weeks postpartum, 6 months postpartum, and 12 months postpartum.

11
12
13
14
15
16
17 Hub services will be face-to-face, online, and one-to-one. Some services, such as playgroup or
18 mothers' groups, might be in a group setting. Mothers and their babies will have access to the Hub
19 for 12 months. Further contacts with the Hub navigator or keyworker as participants require.

20
21
22
23 The integrated FDCC Hubs are a physical building and a way of working, facilitating service
24 collaboration, integration, and a community-led approach to local needs. Hubs most commonly
25 operate from a host building from which partner community-based or public services are delivered.
26 In our Hub model, CFH services are co-located with NGOs. Families are linked with psychosocial
27 support services, including playgroups, early childhood learning opportunities, and family support.
28 Within the Hub services, existing CFH and NGO services support families to navigate systems and
29 engage with other health services. These include general practitioners, early childhood, education,
30 and psychosocial support to address their needs.

31 32 33 34 35 36 37 *Control Arm: Routine Care*

38
39
40 Pregnant women attending the participating hospitals who meet eligibility criteria but do not live in
41 the geographic area will be allocated to a control cohort and receive routine care (e.g., receive
42 information on CFHN services at discharge and follow-up as per current pathways).

43 44 45 **Implementation Evaluation**

46
47 Our mixed-methods implementation evaluation will assess the barriers and facilitators to
48 implementing the FDCC Hubs at the three sites, as guided by the consolidated framework for
49 implementation research (CFIR).⁴⁷ The CFIR is a comprehensive framework designed to 'offer an
50 overarching typology to promote implementation theory development and verification about what
51
52
53
54
55
56
57
58
59
60

works where and why across multiple contexts'.⁴⁷ The CFIR is widely used in diverse healthcare contexts, including primary care.⁴⁸ The CFIR identifies five major domains and guides the consideration and assessment of factors that can impact intervention implementation and effectiveness. Additionally, the researchers will evaluate specific implementation outcomes of acceptability, appropriateness, fidelity to the implementation strategy, coverage, sustainability, and cost (Table 2) as guided by the taxonomy proposed by Proctor and colleagues.⁴⁹

Table 2: Proctor and colleagues (2011) implementation outcomes mapped to FDCC evaluation

	Questions addressed by each implementation factor
Acceptability	Do Hub staff and families view the Hub model as acceptable?
Adoption	Do Hub staff intend to apply the Hub model as described in the study protocol?
Appropriateness	Do Hub staff perceive the Hub model as relevant & useful for their services?
Fidelity	Is the Hub model applied as intended?
Coverage	How many eligible families are reached through the Hub model and keyworker?
Cost	How much does it cost to implement Hubs?
Sustainability	What are the factors that will allow the Hubs to be sustained/scaled-up further?

Logic Model

We developed a logic model to inform the FDCC implementation evaluation (**Error! Reference source not found.**). We used a modified version of existing logic model frameworks^{50 51} to include the inner context (i.e., individual factors, organisational settings) and the outer context of each site (i.e., area demographics, policy climate, relevant geographically adjacent clinical services). These contextual factors were incorporated within the logic modelling to enable implementation researchers to better describe the determinants of successful implementation in clinical practice.⁵²

[INSERT FIGURE 1]

Additionally, we included a detailed description of the intervention to identify feasibility elements to measure during the study. These include features of the physical location of services, how services are integrated, the availability of culturally sensitive support materials and services, and the navigator or keyworker. To supplement the practical elements of the intervention, we described the underlying theoretical principles of the model. These include the collective impact framework⁵³ and the elements of the behaviour change wheel that we perceived the model to adhere.⁵⁴ Collective impact is designed to inform change on complex social issues, and draws on five conditions: common agenda; continuous communication; mutually reinforcing activities; backbone support; and

10

shared measurement.⁵⁵ Collective impact and the behavioural change wheel mechanisms of change within the logic model will inform the qualitative interview schedule. Finally, we drew connections from these underlying theories of change to the specific intermediate and long-term outcomes that we hypothesised the model will produce. Principally, we hypothesise that the intervention components will work on the core principles of environmental restructure, enablement, modelling, and training within the Hub sites, underpinned by the collective impact principles to support migrant and refugee parents to engage with health and social support services. This engagement will provide better outcomes for children and families. It will also create opportunities for shared knowledge between health and non-health services, as part of an acceptable and cost-effective model delivery. Table 3 provides an overview of the planned outcomes and measurement for the implementation evaluation.

Table 3: Overview of the Implementation Evaluation Outcomes

Implementation Evaluation Outcomes			
Outcome measure	Data Source	Methods	Data Collection
Description of local context and Hub	SEIFA data, search of grey literature, informal contact with Hub service leaders	SEIFA data, search of grey literature, informal contact with Hub service leaders	Trial commencement
Fidelity of Hub Model	Hub intervention log	A bespoke log completed by site project officers	Ongoing during the trial
Acceptability of intervention measure (AIM), intervention appropriateness measure (IAM), and feasibility of intervention measure (FIM) ⁵⁶	Research survey administered by project officer	AIM, IAM, and FIM measures completed by Hub staff, service leaders, participants in the intervention group	Trial end (included in the 12-month postpartum parent survey for parents and separate staff survey)

Barriers and facilitators to running the FDCC Hubs	Interviews with Hub staff, service leaders, participants in the intervention group	Qualitative interviews and focus groups, guided by the CFIR	Pre-trial (with Hub staff and service leaders). Ongoing during and end of the trial for all participants
The NoMAD tool ⁵⁷ to assess Hub staff buy in to the model	Research survey administered by project officer	NoMAD tool completed by Hub staff	Trial end

Economic Evaluation

The economic evaluation will adopt a healthcare perspective beginning with a cost consequence analysis to describe the costs and all main study outcome measures (tables 4 and 5) and then generate a cost-utility analysis. The costs of Hub implementation will include: the establishment and operation of Hubs; and the flow-on cost from service use from Hub referrals. Hubs are likely to be implemented in different ways relative to local context and, as such, costs might differ. Two bespoke costing templates will be shared with Hub managers upon trial commencement to be completed at 6 and 12 months, with researcher support to ensure accuracy. The templates will allow for standardisation and between-site comparison.

Establishment and Operational Costs

A micro-costing approach will be adopted to account for funded and in-kind expenditures.^{58 59} A simple template will have major generic expenditure categories, including upfront capital costs (e.g., vehicles, buildings), governance arrangements to manage the Hubs (e.g., staff meeting time), material costs (e.g., brochures), and in-kind support from staff, including partner agencies. There might be expenditures against these categories. At this stage, there is no plan for capital expenditures. This is included for completeness. Operational costs pertain to daily Hub operation, including new staff hired (e.g., salary, on-costs), in-kind costs (e.g., time costs from non-salaried staff), venue costs (e.g., utilities, even if in-kind), and material costs (e.g., brochures).

Referral Costs

Prior to Hub commencement, Hub personnel will be asked for a list of service partners to create a template where clients will be asked the services accessed and frequency; clients will be surveyed using this. Other sites will follow suit. Full client recall is not anticipated. However, it is important that the study clarifies the impact on referral services, if possible. A top-down costing estimate will then be made.^{58 59} Each partner service will then be contacted to generate an estimate of the average client service cost. Providers typically adopt an activity-based costing approach in accounting and funding proposals. No specific client data will be accessed. Rather, the researchers will guide service providers to generate average costs, which typically only involves dividing total funding for service(s) by total occasions of service. Researchers will only be privy to the overall average costs. Where costs are unavailable, an approximation will be made if public and research data are available. Otherwise, a list of service counts only will be made and remain un-costed. Table 4 provides an overview of the planned outcomes and measurement for the implementation evaluation.

Table 4: Overview of the Economic Evaluation Outcomes

Economic Evaluation Outcomes			
Outcome measure	Data Source	Methods	Data Collection
Mother quality of life (EQ-5D quality of life)	Research survey administered by project officer	Research survey administered by project officer. EQ-5D quality of life questionnaire.	Baseline (antenatal time of enrolment) 6 months post-partum 12 months post-partum
Cost of implementing Hubs and referral services	Bespoke surveys	Bespoke surveys completed by Hub Staff and Participants in the intervention group	6 and 12 months 6 and 12 months

Primary and Secondary Outcome Measures

Outcomes will be measured from enrolment (baseline) until and including 12 months post-partum (Table 5). Outcomes will be gathered via: the extraction of routinely collected clinical data from electronic medical records at each site or LHD; surveys administered by a researcher to mothers; and data linkage of participants with administrative datasets (NSW perinatal data collection, NSW

emergency department data collection). The primary outcome measure is the proportion of mothers and their respective infant who attend CFHN services for early childhood health checks at 1 to 4 weeks postpartum, 6-8 weeks postpartum, 6 months postpartum, and 12 months postpartum. For primary and secondary variables, see Table 5.

Table 5: Overview of the FDCC Study Outcome Variables

FDCC trial			
Outcome measure	Data Source	Methods	Data Collection
Proportion of mothers, children and families who attend CFHN at FDCC Hub for checks (<i>Primary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD.	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Proportion of mothers, children and families who are up to date with age appropriate health checks, either via CFHN services or GP (<i>Secondary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD.	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Proportion of women identified as at risk of experiencing depression on the Edinburgh Depression Scale (EPDS) ⁶⁰ (<i>Secondary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical. <ul style="list-style-type: none"> • Edinburgh Depression Scale (EPDS) total score Response to item 10 of EDS	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum
Proportion of women identified as having more than one unmet social need on the We Care questionnaire ⁶¹ (<i>Secondary Outcome</i>)	Research survey administered by project officer	Research survey administered by project officer. We Care questionnaire.	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 6 months post-partum • 12 months post-partum

14

<p>Proportion of women identified as experiencing psychosocial vulnerability on NSW Health psychosocial screening tools (Safe Start Psychosocial assessment including Domestic Violence screen)⁶² <i>(Secondary Outcome)</i></p>	<p>Electronic medical record at LHD.</p>	<p>Extraction of routine clinical data from electronic medical. Presence/absence of psychosocial risk factors on Safe Start Psychosocial assessment including the Domestic Violence screen.</p>	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum
<p>Proportion of children monitored for growth parameters and their growth parameters (weight, height, head circumference) <i>(Secondary Outcome)</i></p>	<p>Electronic medical record at LHD</p>	<p>Extraction of routine clinical data from electronic medical.</p> <ul style="list-style-type: none"> • height (cm) • weight (kg) • head circumference (cm) 	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
<p>Proportion of women exclusively breastfeeding /predominately breastfeeding/partially breastfeeding/ artificially feeding <i>(Secondary Outcome)</i></p>	<p>Electronic medical record at LHD. Data linkage with NSW Perinatal Data Collection.</p>	<p>Extraction of routine clinical data from electronic medical.</p> <ul style="list-style-type: none"> • Exclusively breastfed • Predominately breastfed • Partial breastfed • Artificial feeding 	<p>Electronic medical record at LHD:</p> <ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum <p>Data linkage with NSW Perinatal Data Collection</p> <ul style="list-style-type: none"> • Breast feeding initiated at discharge postnatally.

<p>Proportion of children identified by CFHN as at developmental risk on the Learn the Signs Act Early (LtSAE) and Ages and Stages Questionnaire Screening tools (<i>Secondary Outcome</i>)</p>	<p>Electronic medical record at LHD</p>	<p>Extraction of routine clinical data from electronic medical record at LHD.</p> <ul style="list-style-type: none"> LtSAE screening completed, and the concerns/no concerns identified on LtSAE screening domains. <p>Ages and Stages Questionnaire (ASQ & ASQ-SE) secondary screener given to families by CFHN as clinically required .</p>	<ul style="list-style-type: none"> 6-8 weeks post-partum (LtSAE) 6 months post-partum (LtSAE and ASQ) <p>12 months post-partum (LtSAE and ASQ and ASQ-SE)</p>
<p>Mother and infant attendance at emergency departments from recruitment at 6-month postpartum and 12-month postpartum. (<i>Secondary Outcome</i>)</p>	<p>Data linkage with NSW-wide Emergency Department Data Collection (EDDC)</p>	<p>NSW-wide EDDC data Linkage</p>	<p>At 6-month postpartum and 12-month postpartum.</p>

Data Analysis Plan

Sample Size Estimation

Based on pilot data, we anticipate the percentage of children to have their CFH check done by a CFHN will be 60% in the intervention group and 30% in the control group. Therefore, 72 children will be needed for each arm to provide 80% of power to detect the magnitude of such an increase with a p value <0.05 . Allowing for a 40% attrition rate (i.e., loss-to-follow-up) as this is a vulnerable community¹⁵, we aim to recruit 120 children in each arm or 240 children in total across the three sites.

Statistical Analysis

Statistical analysis will include descriptive analysis of participating mother and child outcomes at

1
2
3 each assessment. We will compare outcomes between the intervention and control groups using the
4 Fisher's test for binary outcomes, Chi-square method for categorical outcomes, non-parametric
5 method (e.g., Wilcoxon rank-sum test) and parametric methods (e.g., *t*-test) for continuous and
6 ordinal variables. As outcomes will be measured repeatedly, multilevel regression analysis will be
7 undertaken to examine intervention impact on outcomes, controlling for the plausible confounders at
8 the individual (e.g., mother's sociodemographic characteristics, geographic area of residence) and
9 community levels at baseline (e.g., neighbourhood socioeconomic factors). Generalised estimating
10 equations method will be used in the regression analysis, considering the potential clustering effect
11 by site. Only deidentified data will be analysed. No data safety monitoring committee is needed for
12 this study due to the known minimal risks. No interim analyses or stopping rules will be applied.
13
14
15
16
17
18
19

20 21 *Implementation Evaluation Analysis*

22
23 Implementation effectiveness will be evaluated using the validated scoring system of -2 to +2 with
24 score descriptions as follows: -2 indicates the construct has negatively influenced the practice and
25 examples of negative manifestations are indicated; -1 indicates the construct has negatively
26 influenced the practice and general statements of negative manifestations are made; 0 indicates the
27 construct neutrally influenced the practice; +1 indicates the construct positively influenced the
28 practice and general statements of positive manifestations are made; and +2 indicates the construct
29 positively influenced the practice and explicit examples of positive manifestations are described.⁶³
30 Using these scores, construct scores can range from a low of -80 to a high of +80, demonstrating the
31 key barriers and facilitators to uptake and sustain the FDCC hubs. This method of quantifying
32 implementation effectiveness will be supplemented with an inductive analysis of qualitative data to
33 ensure openness to emerging themes not readily captured by the CFIR and Proctor and colleague's
34 outcome measures.⁴⁹
35
36
37
38
39
40
41
42
43

44 *Economic Analysis*

45
46 First, a cost consequence analysis will collate and list the main costs and outcomes from the trial
47 (table 4 and 5) to provide transparency regarding the overall impacts of Hubs. Second, a cost-utility
48 will then report the incremental (net) cost per change in health utility (derived from the EQ5D)
49 simulated using a decision tree, and where the threshold willingness to pay is varied between
50
51
52
53

1
2
3 \$42,000-\$67,000.⁶⁴ Third, a probability sensitivity analysis (PSA) and value of information analysis
4 (VOI) will assess statistical uncertainty and value for further research, including for example the
5 value of longer follow-up to assess medium-to-long term impacts.⁶⁵ Finally, a budget impact analysis
6 (BIA) will estimate the overall financial cost if Hubs were scaled-up across NSW to inform policy
7 affordability considerations. The latter will involve estimating the potential Hubs would be made and
8 an average cost (of the three Hubs) applied, with high and low estimates in a sensitivity analysis.
9

14 **Data Management**

15
16 All participants will be allocated a randomly generated unique identifier code to be used throughout
17 the study. Project officers will have identified information of the participants enrolled at their site,
18 stored in password protected files. The project officer within each LHD will work with data
19 managers to extract routinely collected clinical data from electronic medical records for all
20 participants, per Table 3. Data will be stored within a protected site-based server. Only deidentified
21 data will be transferred from each LHD to the researchers (SW, KO, NH) for data analysis, using
22 encrypted transfer.
23
24

25
26 Project officers with support from CCWs and/or interpreters will collect surveys at baseline, 6
27 months postpartum, and 12 months postpartum. The survey can be completed in hardcopy (face-to-
28 face or telephone) or online by participants using a secure link to REDCap®. Subsequently, project
29 officers who can access the identifying information within each LHD will enter survey data into the
30 REDCap® database. REDCap® is hosted on the University of NSW (UNSW) infrastructure.
31 Permissions granted to each user within each REDCap® project is controlled by and is the
32 responsibility of the project team. Hardcopy materials will be stored in locked cabinets for the
33 required period, either indefinitely if the participant consents to providing their data for data pooling
34 or for 15 years after the completion of the study. After these periods, hardcopy materials will be
35 destroyed and password-protected electronic archives will be deleted.
36
37

38
39 The identifying information collected within each LHD will be compiled into a single password-
40 protected file and sent to The Centre for Health Record Linkage (CHeReL) for data linkage. The
41 minimum identifying information for mothers and infants will be used to extract participant records
42 from the administrative data. Upon completion of data extraction, CHeReL will transfer to UNSW
43
44
45

46
47
48
49
50
51
52
53
54 18
55
56
57
58
59
60

1
2
3 administrative data of the participants who consented to data linkage. The administrative records will
4 be deidentified by CHeReL, which will create the person project number (PPN) for each participant.
5 The PPN will be linked to the participant's unique project identification number to link the
6 administrative records with the electronic medical record (eMR) and survey records that belong to
7 the same participant.
8
9
10
11

12 **Patient and Public Involvement**

13
14 The research questions were developed based on qualitative research undertaken with Hub
15 participants and community members and service providers in the pilot study.^{41 66} The FDCC team
16 have a consumer representative and consultation was undertaken with local Hub partner services.
17 The researchers also consulted multicultural health services, including cultural support workers, to
18 ensure research materials are culturally nuanced. Patients or participants have not directly been
19 involved in the current study design.
20
21
22
23
24
25

26 **ETHICS AND DISSEMINATION**

27
28 Ethical approval was granted by the South Eastern Sydney LHD (SESLHD) (2020/ETH03295). This
29 trial was registered with the Australian New Zealand Clinical Trials (ACTRN12621001088831).
30
31

32 **Confidentiality**

33
34 The researchers acknowledge that ensuring confidentiality is essential. The researchers will exercise
35 due diligence to anonymise participants' responses for reporting, publication, and presentation
36 purposes. Only deidentified data will be transferred from each LHD to the UNSW researchers for
37 data analysis. The deidentified data from each LHD to the UNSW team will be securely transferred
38 through a NSW Health-approved e-health platform.
39
40
41
42

43 **Managing Potential Harms**

44
45 If issues are disclosed outside of the study parameters, mandatory NSW Health policy directives will
46 apply (e.g., family and domestic violence, child protection matters). These will be managed as per
47 current policies and practices within LHDs. The child protection and domestic violence counselling
48 teams are readily accessible to provide advice and support if issues are identified. As the researchers
49 are all mandatory reporters, they will inform participants that they are not able to maintain
50
51
52
53
54

19

1
2
3 confidentiality when it relates to the safety of the participant, the child/ren, the family, and the wider
4 community. These obligations are detailed in the PISCF (appendix 1).
5
6

7 **Dissemination**

8
9 Data obtained for the study will be published in reports, peer reviewed journals and presented at
10 appropriate conferences. The de-identified data will be available to all investigators. Access by
11 individuals' other than the named investigators will only be permitted after consideration and
12 agreement by all the remaining investigators. An essential element of knowledge translation are the
13 study partners and advisors who will share findings and consider if and how to progress to trialling
14 or implementing the program at scale. We intend to produce at least two papers (e.g. protocol, main
15 findings) for peer-review publication, written by core research and implementation team.
16
17
18
19
20
21

22 **Study governance**

23
24 The FDCC Team will support planning, implementation and governance of the project and ensure
25 that WH&S requirements and policies are considered and actioned. There are currently no
26 procedures for auditing trial conduct. All protocol modifications will be discussed within all levels of
27 governance and communicated to the SESLHD HREC. Figure 2 outlines our governance structure.
28
29
30

31 [INSERT FIGURE 2]
32
33

34 **Author contributions**

35
36 The original trial design was conceived by SW, TR, AW, RL, VE and HR. The implementation
37 evaluation design was conceived by MH and RL. The economic evaluation design was conceived by
38 KL. The statistical analysis methods were initially designed by NH. MH developed the initial draft of
39 the protocol, which was refined by SW, TR, AW, RL, VE, HR, KO, NH, KL, NS, AH, EM, SR,
40 AMD, and AD. All authors approved, the final manuscript.
41
42
43
44
45

46 **Funding statement**

47
48 This project was funded by the NSW Health Translational Research Grants Scheme. The views
49 expressed are those of the authors and not necessarily those of the partner organisations. Sue
50 Woolfenden is funded through the National Health and Medical Research Council. Raghu Lingam is
51
52
53

54 20
55
56
57
58
59
60

1
2
3 funded through the Financial Markets Foundation for Children. The project is supported in-kind by
4 the Early Life Determinants of Health Clinical Academic Group, Maridulu Budyari Gumal
5 (SPHERE).
6
7

8 9 **Competing interests**

10
11 The views expressed are those of the author(s) and not necessarily those of the funding partners.
12
13 NSW Health has no direct role in study design; data collection, analysis, and interpretation, or
14
15 writing of final reports, presentations, or publications.
16
17

18 **Acknowledgements**

19
20 This protocol has been authored on behalf of the FDCC Collaborative Group. The authors would like
21
22 to acknowledge the members of the group not listed as authors: Melissa Green, John Eastwood,
23
24 Karen Sorensen, Kim Lyle, Catherine Jones, Vicki Blight, Amit Arora, Michelle de Vroome,
25
26 Andrew Hayen, Nick Hopwood, Virginia Schmied, Rebekah Grace, Jane Kohlhoff, Fiona Brooks,
27
28 Cathy Kaplun, Kathleen Baird, Myna Hua, Lisa Woodland, Ben Harris-Roxas, Brendan Goodger,
29
30 Tracey Szanto, Karen Zwi, and Grainne O’Loughlin.

31 **REFERENCES**

- 32
33
34 1. AEDC. Australian Early Development Census. <https://www.aedc.gov.au/data/data-explorer?id=135216>. 2020
35
36 2. COAG. COAG Health Council 2019 The Australian National Breastfeeding Strategy: 2019 and
37
38 Beyond was prepared under the auspices of the COAG Health Council. 2019
39
40 3. Moore T, Arefadib N, Deery A, et al. The first thousand days: an evidence paper. *Melbourne:*
41
42 *Murdoch Children’s Research Institute* 2017
43
44 4. Goldfeld S, D’Abaco E, Bryson H, et al. Surveying social adversity in pregnancy: The antenatal risk
45
46 burden experienced by Australian women. *Journal of paediatrics and child health*
47
48 2018;54(7):754-60.
49
50 5. NSW Ministry of Health. The First 2000 Days Framework. 2019
51
52 6. Goldfeld S, O’Connor M, Chong S, et al. The impact of multidimensional disadvantage over
53
54 childhood on developmental outcomes in Australia. *International Journal of Epidemiology*
55
56 doi:<https://doi.org/10.1093/ije/dyy087>
57
58 7. Woolfenden S, Asher I, Bauert P, et al. Summary of position statement on inequities in child health.
59
60 2018;54(8):832-33.
61
62 8. Rogers HJ, Hogan L, Coates D, et al. Responding to the health needs of women from migrant and
63
64 refugee backgrounds—Models of maternity and postpartum care in high-income countries: A
65
66

21

- systematic scoping review. *Health & Social Care in the Community* 2020
9. Hiscock H, Danchin MH, Efron D, et al. Trends in paediatric practice in Australia: 2008 and 2013 national audits from the Australian Paediatric Research Network. *Journal of paediatrics and child health* 2017;53(1):55-61.
 10. Palfrey JS, Tonniges TF, Green M, et al. Introduction: addressing the millennial morbidity—the context of community pediatrics. *Pediatrics* 2005;115(Supplement 3):1121-23.
 11. Woolfenden S, Galea C, Smithers-Sheedy H, et al. Impact of social disadvantage on cerebral palsy severity. *Developmental Medicine & Child Neurology* 2019;61(5):586-92.
 12. Brinkman S, Gregory T, Harris J, et al. Associations between the early development instrument at age 5, and reading and numeracy skills at ages 8, 10 and 12: a prospective linked data study. *Child Indicators Research* 2013;6(4):695-708.
 13. Merrick MT, Ford DC, Ports KA, et al. Vital signs: Estimated proportion of adult health problems attributable to adverse childhood experiences and implications for prevention—25 States, 2015–2017. *Morbidity and Mortality Weekly Report* 2019;68(44):999.
 14. Kezelman C, Hossack N, Stavropoulos P, et al. The cost of unresolved childhood trauma and abuse in adults in Australia. Adults Surviving Child Abuse and Pegasus Economics, Sydney. 2015
 15. Woolfenden S, Eapen V, Jalaludin B, et al. Prevalence and factors associated with parental concerns about development detected by the Parents' Evaluation of Developmental Status (PEDS) at 6-month, 12-month and 18-month well-child checks in a birth cohort. *BMJ open* 2016;6(9):e012144.
 16. Ayer C, Eapen V, Overs B, et al. Risk factors for non-participation in a universal developmental surveillance program in a population in Australia. *Australian Health Review*
 17. Eapen V, Walter A, Guan J, et al. Maternal help-seeking for child developmental concerns: Associations with socio-demographic factors. *J Paediatr Child Health* 2017;53(10):963-69. doi: 10.1111/jpc.13607 [published Online First: 2017/07/01]
 18. Zwi K, Rungan S, Woolfenden S, et al. Refugee children and their health, development and well-being over the first year of settlement: A longitudinal study. *Journal of paediatrics and child health* 2017;53(9):841-49.
 19. NSW Health. NSW Child Health Survey 2009-2010 Summary report. 2010
 20. McLean K, Goldfeld S, Molloy C, et al. Screening and surveillance in early childhood health: rapid review of evidence for effectiveness and efficiency of models. *Ultimo, NSW, Australia: The Sax Institute* 2014
 21. Garg P, Ha MT, Eastwood J, et al. Explaining culturally and linguistically diverse (CALD) parents' access of healthcare services for developmental surveillance and anticipatory guidance: qualitative findings from the 'Watch Me Grow' study. *BMC health services research* 2017;17(1):228.
 22. Almeida LM, Caldas J, Ayres-de-Campos D, et al. Maternal healthcare in migrants: a systematic review. *Matern Child Health J* 2013;17(8):1346-54. doi: <https://dx.doi.org/10.1007/s10995-012-1149-x> [published Online First: 2013/01/22]
 23. Fellmeth G, Fazel M, Plugge E. Migration and perinatal mental health in women from low- and middle-income countries: a systematic review and meta-analysis. *BJOG* 2017;124(5):742-52. doi: <https://doi.org/10.1111/1471-0528.14184> [published Online First: 2016/06/21]
 24. World Health Organization (WHO). Promoting the health of refugees and migrants: Framework of priorities and guiding principles to promote the health of refugees and migrants. Geneva:

22

- WHO Secretariat, 2017:1-4.
25. Higginbottom G, Morgan M, Alexandre M, et al. Immigrant women's experiences of maternity-care services in Canada: a systematic review using a narrative synthesis. *Syst Rev* 2015;4(13):13. doi: <https://doi.org/10.1186/2046-4053-4-13> [published Online First: 2015/07/19]
 26. Correa-Velez I, Ryan J. Developing a best practice model of refugee maternity care. *Women Birth* 2012;25(1):13-22. doi: <https://dx.doi.org/10.1016/j.wombi.2011.01.002> [published Online First: 2011/02/15]
 27. Henderson S, Kendall E. Culturally and linguistically diverse peoples' knowledge of accessibility and utilisation of health services: exploring the need for improvement in health service delivery. *Aust J Prim Health* 2011;17(2):195-201. doi: <https://doi.org/10.1071/PY10065> [published Online First: 2011/06/08]
 28. Heslehurst N, Brown H, Pemu A, et al. Perinatal health outcomes and care among asylum seekers and refugees: a systematic review of systematic reviews. *BMC Medicine* 2018;16(1) doi: <https://doi.org/10.1186/s12916-018-1064-0> [published Online First: 2018/06/13]
 29. Boyle JA, Willey S, Abbasova G. Supporting better outcomes for migrant and refugee women. *O&G Magazine* 2018; 20(1). <https://www.ogmagazine.org.au/20/1-20/better-outcomes-migrant-refugee-women/>.
 30. Small R, Roth C, Raval M, et al. Immigrant and non-immigrant women's experiences of maternity care: a systematic and comparative review of studies in five countries. *BMC Pregnancy Childbirth* 2014;14(152):1-17. doi: 10.1186/1471-2393-14-152 [published Online First: 2014/04/30]
 31. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expectations* 2015;18(6):3286-301. doi: 10.1111/hex.12318
 32. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expect* doi: 101111/hex12318 2014
 33. Woolfenden S, Eapen V, Williams K, et al. A systematic review of the prevalence of parental concerns measured by the Parents' Evaluation of Developmental Status (PEDS) indicating developmental risk. *BMC Pediatr* 2014;14
 34. Woolfenden S, Galea C, Badland H, et al. Use of health services by preschool-aged children who are developmentally vulnerable and socioeconomically disadvantaged: testing the inverse care law. *J Epidemiol Community Health* 2020;74(6):495-501.
 35. Chando S, Craig JC, Burgess L, et al. Developmental risk among Aboriginal children living in urban areas in Australia: the Study of Environment on Aboriginal Resilience and Child Health (SEARCH). *BMC pediatrics* 2020;20(1):1-13.
 36. Alrashdi M, Hameed A, Cervantes Mendez MJ, et al. Education intervention with respect to the oral health knowledge, attitude, and behaviors of refugee families: A randomized clinical trial of effectiveness. *Journal of Public Health Dentistry* 2021;81(2):90-99. doi: <https://doi.org/10.1111/jphd.12415>
 37. Henry R. Review of health services for children, young people and families within the NSW Health system, 2019.

- 1
2
3
4 38. National Academies of Sciences E, Medicine. Integrating Social Care Into the Delivery of Health
5 Care: Moving Upstream to Improve the Nation's Health: Washington, DC: National
6 Academies Press, 2019.
- 7 39. Moore T. Using place-based approaches to strengthen child wellbeing. *Developing Practice: The*
8 *Child, Youth and Family Work Journal* 2014(40):40.
- 9 40. Glover J, Samir N, Kaplun C, et al. The effectiveness of place-based interventions in improving
10 development, health and wellbeing outcomes in children aged 0–6 years living in
11 disadvantaged neighbourhoods in high-income countries – A systematic review. *Wellbeing,*
12 *Space and Society* 2021;2:100064. doi: <https://doi.org/10.1016/j.wss.2021.100064>
- 13 41. Edwards K, Rimes T, Smith R, et al. Improving Access to Early Childhood Developmental
14 Surveillance for Children from Culturally and Linguistically Diverse (CALD) Background. .
15 *Int J Integr Care* 2020;Apr;20(2)
- 16 42. Edwards K, Fernandez R, Rimes T, et al. “Happy, Healthy, Ready – working with early childhood
17 non-government organisations for developmental surveillance for vulnerable children”. .
18 *Australian Journal of Advanced Nursing* 2020; 37(4)
- 19 43. Alrashdi M, Cervantes Mendez MJ, Farokhi MR. A Randomized Clinical Trial Preventive
20 Outreach Targeting Dental Caries and Oral-Health-Related Quality of Life for Refugee
21 Children. *International Journal of Environmental Research and Public Health*
22 2021;18(4):1686.
- 23 44. Rogers HJ, Hogan L, Coates D, et al. Cross Cultural Workers for women and families from migrant
24 and refugee backgrounds: a mixed-methods study of service providers perceptions. *BMC*
25 *Women's Health* 2021;21(1):222. doi: 10.1186/s12905-021-01368-4
- 26 45. Rogers HJ, Hogan L, Coates D, et al.
- 27 A Bridge to Health: The Cross Cultural Workers in Maternity and Child and Family Health Service
28 for women and families from migrant and refugee backgrounds: A mixed-methods study of
29 service providers perceptions in Sydney, Australia (Manuscript not yet published). 2020
- 30 46. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
31 for protocols of clinical trials. *Bmj* 2013;346
- 32 47. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research
33 findings into practice: a consolidated framework for advancing implementation science.
34 *Implement Science* 2009;4(1):50.
- 35 48. Kirk MA, Kelley C, Yankey N, et al. A systematic review of the use of the consolidated framework
36 for implementation research. *Implementation Science* 2016;11(72):1-13.
- 37 49. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
38 distinctions, measurement challenges, and research agenda. *Administration and Policy in*
39 *Mental Health and Mental Health Services Research* 2011;38(2):65-76.
- 40 50. Lawton B, Brandon PR, Cicchinelli L, et al. Logic Models: A Tool for Designing and Monitoring
41 Program Evaluations. REL 2014-007. *Regional Educational Laboratory Pacific* 2014
- 42 51. U.S. Department of Health and Human Services Centres for Disease Control and Prevention.
43 Introduction to program evaluation for public health programs: A self-study guide. Atlanta,
44 GA: Centers for Disease Control and Prevention, 2011.
- 45 52. Li S-A, Jeffs L, Barwick M, et al. Organizational contextual features that influence the
46 implementation of evidence-based practices across healthcare settings: a systematic integrative
47
48
49
50
51
52
53

- review. *Systematic Reviews* 2018;7(1):72. doi: 10.1186/s13643-018-0734-5
53. Kania J, Kramer M. Collective impact: Leland Stanford Jr. University 2011.
 54. Michie S, Atkins L, West R. The behaviour change wheel. *A guide to designing interventions 1st ed Great Britain: Silverback Publishing* 2014:1003-10.
 55. Smart JR. Collective impact: Evidence and implications for practice: Australian Institute of Family Studies Melbourne 2017.
 56. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed implementation outcome measures. *Implementation Science* 2017;12(1):108.
 57. Finch TL, Rapley T, Girling M, et al. Improving the normalization of complex interventions: measure development based on normalization process theory (NoMAD): study protocol. *Implementation Science* 2013;8(1):43. doi: 10.1186/1748-5908-8-43
 58. Chapko MK, Liu CF, Perkins M, et al. Equivalence of two healthcare costing methods: bottom-up and top-down. *Health economics* 2009;18(10):1188-201.
 59. O'Brien B, Drummond MF, Sculpher MJ, et al. Methods for the economic evaluation of health care programmes: Oxford university press 2015.
 60. Cox JL, Holden JM, Sagovsky R. Detection of Postnatal Depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 1987;150(6):782-86. doi: 10.1192/bjp.150.6.782 [published Online First: 2018/01/02]
 61. Garg A, Toy S, Tripodis Y, et al. Addressing Social Determinants of Health at Well Child Care Visits: A Cluster RCT. *Pediatrics* 2015;135(2):e296-e304. doi: 10.1542/peds.2014-2888
 62. NSW Department of Health. NSW Health/Families NSW Supporting Families Early Package – SAFE START Strategic Policy, 2009.
 63. Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research (CFIR). *Implementation Science* 2013;8(51):1-32.
 64. Huang L, Frijters P, Dalziel K, et al. Life satisfaction, QALYs, and the monetary value of health. *Social Science & Medicine* 2018;211:131-36. doi: <https://doi.org/10.1016/j.socscimed.2018.06.009>
 65. Briggs AH, Weinstein MC, Fenwick EAL, et al. Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6. *Medical Decision Making* 2012;32(5):722-32. doi: 10.1177/0272989X12458348
 66. Edwards B, Mullan K, Katz I, et al. The Stronger Families in Australia (SFIA) Study: Phase 2 The Stronger Families in Australia (SFIA) Study: Phase 2. 2014

FIGURE 1: FDCC IMPLEMENTATION EVALUATION LOGIC MODEL

FIGURE 2: FDCC GOVERNANCE STRUCTURE

CONTEXT

INTERVENTIONS BMJ Open

THEORETICAL FRAMEWORK

INTERMEDIATE OUTCOMES

LONG-TERM OUTCOMES

OUTER CONTEXT

INNER CONTEXT

Local area factors/LHD

- Patient load
- Area socio-economic status
- Community health relationship with hospital
- Make up of community based agencies, public and private health services in area (Area mapping)

Policy and governance context

- Existing CAFH policy affecting practice
- First 2000 days
- NGO partners core business, funding bodies, governance board

NGO factors

- Partner buy in
- Diversity of partner services
- Alignment of partner services (Reciprocity between health & NGOs) Location
- Collaboration features (i.e. frequency of contact, regular meetings, services integrating in real time)
- Billing and funding

Early childhood health staff factors

- Organisational context Support of Hub intervention within practice
- Structure and delivery of hub model (times location, structure)
- Altered work flows
- Care navigation (dedicated role, clear pathways)
- Number of CFHN in Hub
- Involvement of allied health
- GP relationships (Bilingual, referrals, knowledge of CFH, Medicare eligible)

Physical location

- Services in the same building
- Soft entry through existing non-health, non-threatening service (i.e. playgroup)
- Accessible to migrant and refugee communities

Integration of services

- Referral pathways between services (supported/warm referral or proactive introduction)
- Communication between services
- Shared resources/training/measurement
- Common agenda

Cultural sensitivity

- Culturally sensitive practices
- Training and resources

Key worker/ Navigator

Point of contact between maternity and hub

Collective Impact

Collective impact is designed to create change on complex social issues, and draws on five conditions: common agenda, continuous communication, mutually reinforcing activities, backbone support and shared measurement.

MECHANISMS OF CHANGE

Behaviour change wheel constructs

- **Enablement** – Hub in a location that suits families, helping navigation to relevant services
- **Modelling** – Modelling health/NGO practices
- **Training** – Ensure staff have been trained in culturally sensitive practices. Shared language/ understanding of the model
- **Environment restructure** – Hub creating integrated care environment

Service and community

- Increased knowledge and capacity of local services to provide culturally sensitive care and address health and social needs.

Child and Family


- 60% of mothers/families attending CFH service at Hubs
- Increased Breastfeeding rates
- Early identification of psychosocial concerns
- Social needs met by improved service access
- Child at healthy weight

System

- Earlier intervention for health and social need, reduced hospital visits (ED presentations)
- Cost-effective model of care for NSW Health
- Evidence that access is feasible, appropriate and acceptable
- Replicable, acceptable, appropriate and sustainable models of care - First 2000 Days Framework.

Child and Family

- Mothers/families will have optimal mental health and children will be school ready



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

APPENDICES

Appendix 1: Participant Information Sheet and Consent Form

Primary and Community Health Directorate

PARTICIPANT INFORMATION SHEET AND CONSENT FORM Participant

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

Invitation

You are invited to take part in the Family Care Connect project. Family Care Connect involves child and family Hubs, where health and other agencies work together and you are supported to navigate these services. Our research is seeing whether these Hubs support the health and development of children, mothers and families from migrant and refugee communities.

Who is doing the research?

Tania Rimes

Children and Communities Program Coordinator

Primary and Community Health Directorate | South Eastern Sydney Local Health District (SESLHD).

Associate Professor Sue Woolfenden (Research lead)

NHMRC Senior Research Fellow, Population Child Health Group | The University of New South Wales (UNSW). Senior Staff Specialist, Community Child Health | Sydney Children's Hospitals Network.

Before you decide if you want to take part in this research, we would like to explain what we are doing and why we are doing it. . Please take the time to read the following information carefully. You can talk about it with a relative or a friend if you wish before deciding.

What is the purpose of this research?

We want to see if child and family Hubs help women and families from migrant and refugee communities move from pregnancy to Child and Family Health services. Also, we want to see if these Hubs support children's health and development in the first 12 months of life.

We will also look at how easy and cost-effective the Hub is for you and other women and families.

Why have I been invited to participate in this research?

You are eligible to participate in this research because you:

- are having your baby or recently given birth to your baby at [INSERT HOSPITAL SITES]
- live in the postcode of [INSERT POSTCODE/S]

- are at least 20 weeks pregnant, OR have recently given birth to your baby and have not been discharged home from postnatal ward
- are a newly arrived migrant (within the last 10 years) from a non-English speaking background; or a refugee (living in Australia for less than 10 years) from a non-English speaking background
- are 16 years of age or older.

If I say yes, what will it involve?

If you decide to take part in the research and live in [INSERT SITE AREA] you will be in the **'FDCC Group'**. You will receive information about the child and family services in your area you can access after the birth of your baby. This information is given to all women, regardless of whether or not they participate in the study.

If you take part in the **"FDCC Group"**, you will also be contacted by a worker from the local child and family Hub who will give you more information on the services offered and assist you with accessing these services if you choose.

If you agree to take part, we will ask you to sign the Participant Information and Consent form below; OR sign the online consent found here [INSERT ONLINE CONSENT URL]; OR provide verbal consent over the telephone to the contact person for the research.

After you provide consent to take part in this research, we will ask you to:

- Complete a survey about you, your family, your support needs, and your wellbeing. This will take about 30 minutes. You can choose to do it online, by paper, over the phone, or in-person. **We can provide an interpreter to assist.**
- Complete another survey when your baby is 6 months and 12 months old. This will ask questions about you, what your needs are, and what services you have used. **We can provide an interpreter to assist.**
- We will also collect data from your local and state-wide hospital/s about you and your baby. This reduces the number of questions we need to ask you.

The data we collect from local hospitals includes:

- Information about you and your child such as country of birth, date of birth, gender, language spoken at home
- Information from routine questions asked to all women when they come to hospital about their health and wellbeing and their child's
- Information about the services you or your child has seen, for example the child and family health nurse.

The data we collect from state-wide hospitals includes:

- Information that is collected on all new mothers and babies in NSW
- Emergency Department presentations for you and your baby

If you don't want us to collect data about you and your baby from state-wide hospitals, then we won't. Please let us know by checking the box.

I DO NOT want my state-wide hospital data included as part of this research

1
2
3
4 **If you only provide verbal consent, we will not collect data about you and your baby**
5 **from state-wide hospitals.**

6 As part of this research, we may also invite you to be interviewed. We will contact you at
7 another time to discuss this process before the research is complete.
8
9

10 Any information we collect that can identify you or your child will remain confidential.
11

12 The total time you are involved with this project will be for 12 to 18 months, but you can
13 choose to withdraw at any time.
14

15
16 **What if I don't want to take part in this research, or if I want to withdraw later?**

17 It is completely up to you whether or not you decide to take part. Saying yes or no will not
18 affect your relationship with the care you receive, the services you access, or your visa
19 status now or in the future.
20

21 If you wish to leave the research once it has started, you can do so verbally or in writing at
22 any time without giving a reason. However, it may not be possible to withdraw your data
23 from the research results once we have collected it and removed your identifying details.
24 This is due to be done from March 2023.
25
26

27 **How is this research being paid for?**

28 The research is being paid for by NSW Health as part of the Translational Research Grant
29 Scheme. More information about this scheme can be found here:

30 <https://www.medicalresearch.nsw.gov.au/translational-research-grants-scheme/>
31
32

33 **Are there risks to me in taking part in this research?**

34 There is very little risk to you, however if you become upset or distressed because of taking
35 part in the research, the research team will arrange for counselling or other help. Any
36 counselling or help will be provided by qualified staff who are not members of the research
37 team. This will be provided free of charge.
38
39

40 Another risk in taking part in this research is the risk to your privacy as part of collecting
41 data about you, your child, and your family. While this is a risk, we will take all the steps to
42 ensure your information remains private and confidential. We do not collect you or your
43 baby's name, or anything else that could identify you or your family. Instead, your name will
44 be replaced with a number. Only people involved with this research will be able to tell that
45 the information is about you.
46
47

48 **What happens if I suffer injury or complications as a result of the research?**

49 It is very unlikely that you will suffer any injury as we are only asking you to complete
50 questionnaires. However, if you require treatment or suffer loss as a result of the
51 wrongdoing of any of the parties involved in the research, you can seek compensation. The
52 cost of your treatment must be paid by the compensation you receive.
53
54

55 **Will I benefit from the research?**

56 This research aims to determine how best to provide child health services for families and
57 to improve how parents in the future access child and family health services, however it
58 may or may not directly benefit you or your baby.
59
60

Will taking part in this research cost me anything, and will I be paid?

Taking part in this research will not cost you anything, nor will you be paid.

How will my confidentiality be protected?

Any information that is collected about you as part of this research will remain private and confidential and will be discussed only with your permission, except as required by law. This means the research team are Mandatory Reporters and may need to speak with NSW Department of Communities and Justice if they are told or are concerned that a child is being hurt or is at risk of being hurt e.g. if there is abuse or violence in the home.

If such a situation happens, we would discuss this with you in private and arrange for you to speak with another professional if required.

Only the researchers named above will have access to your details. All information will be stored on a secure drive within [INSERT LHD SITES] and UNSW. We will keep the information for 5 years after the research ends. After this time, it will be destroyed.

In line with Australian, New South Wales, and other relevant laws, you have the right to access and correct the information we collect and store about you. Please contact us if you would like to access the information.

What happens with the results?

If you give us your permission by providing your consent in written form, online, or verbally, we plan to publish the results in a report and in peer reviewed journals. We may also present results at professional forums and conferences to inform better ways of working and providing services.

We will also give a report on the research to the South Eastern Sydney Local Health District Human Research Ethics Committee.

In any report, publication, or presentation, information will be provided in such a way that you or your family cannot be identified.

What should I do if I want to discuss this research further before I decide?

When you have read this information, the researcher interviewer/project officer will discuss it with you and answer any queries you may have. If you would like to know more at any stage, please do not hesitate to contact Tania Rimes, Principal Investigator on (02) 9382 8696 or email her at tania.rimes@health.nsw.gov.au. If you need an interpreter, you can contact Tania through the Translating and Interpreting Service (TIS) on 131 450.

Who should I contact if I have concerns about the conduct of this research?

This research has been approved by the South Eastern Sydney Local Health District Human Research Ethics Committee. Any person with concerns or complaints about the conduct of this research should contact the Research Support Office which is nominated to receive complaints from research participants. You should contact them on 02 9382 3587, or email SESLHD-RSO@health.nsw.gov.au and quote HREC reference number: 2020/ETH03295.

The conduct of this research is at the [INSERT SITE NAMES]. Any person with concerns or complaints about the conduct of this research may also contact the [*details of the Research Governance Officer of the health district will be provided following SSA application*]

1
2
3
4 **Thank you for taking the time to consider this research.**
5 **If you wish to take part in it, please sign the attached consent form.**
6 **This information sheet is for you to keep.**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Primary and Community Health Directorate

CONSENT FORM

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

1. I,.....
of.....
agree to take part in the research described in the participant information statement set out above and to have my data linked as outlined in the information sheet.
2. I have read the participant information statement, which explains why I have been asked to take part, the aims of the research and the possible risks of the research, and the statement has been explained to me to my satisfaction.
3. Before signing this consent form, I have been able to ask any questions relating to any possible physical and mental harm I might suffer as a result of taking part and I have received satisfactory answers.
4. I understand that I can withdraw from the research at any time without affecting my relationship with South Eastern Sydney Local Health District or service at the child and family hub.
5. I agree that research information collected from the results of the research may be published and presented, provided that I cannot be identified.
6. I understand that if I have any questions relating to my participation in this research, I may contact Tania Rimes on telephone (02) 9382 8696, who will be happy to answer them. I can call 131450 (TIS) for language support.
7. I have been given a copy of this Consent Form and the Participant Information Statement.

Complaints may be directed to the Research Support Office, South Eastern Sydney Local Health District, Prince of Wales Hospital, Randwick NSW 2031 Australia (phone 02-9382 3587, fax 02-9382 2813, email SESLHD-RSO@health.nsw.gov.au .

Signature of participant	Please PRINT name	Date
_____	_____	_____
Signature of witness	Please PRINT name	Date
_____	_____	_____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Signature of investigator	Please PRINT name	Date
_____	_____	_____

Investigator/officer taking consent to complete:

Check box if participant DOES NOT want their state-wide hospital data included as part of this research

For peer review only

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a Trial identifier and registry name. If not yet	17

1		registered, name of intended registry	
2			
3			
4	Trial registration:	#2b All items from the World Health Organization Trial	
5			
6	data set	Registration Data Set	
7			
8			
9	Protocol version	#3 Date and version identifier	2
10			
11			
12	Funding	#4 Sources and types of financial, material, and other	19
13			
14		support	
15			
16			
17	Roles and	#5a Names, affiliations, and roles of protocol	19
18			
19	responsibilities:	contributors	
20			
21	contributorship		
22			
23			
24			
25	Roles and	#5b Name and contact information for the trial sponsor	19
26			
27	responsibilities:		
28			
29	sponsor contact		
30			
31	information		
32			
33			
34			
35	Roles and	#5c Role of study sponsor and funders, if any, in study	19
36			
37	responsibilities:	design; collection, management, analysis, and	
38			
39	sponsor and funder	interpretation of data; writing of the report; and the	
40			
41		decision to submit the report for publication,	
42			
43		including whether they will have ultimate authority	
44			
45		over any of these activities	
46			
47			
48			
49	Roles and	#5d Composition, roles, and responsibilities of the	19
50			
51	responsibilities:	coordinating centre, steering committee, endpoint	
52			
53	committees	adjudication committee, data management team,	
54			
55		and other individuals or groups overseeing the	
56			
57			
58			
59			
60			

1 trial, if applicable (see Item 21a for data

2
3 monitoring committee)

4
5
6 **Introduction**

7
8
9 Background and [#6a](#) Description of research question and justification 4
10
11 rationale for undertaking the trial, including summary of
12 relevant studies (published and unpublished)

13
14
15
16 examining benefits and harms for each
17
18 intervention

19
20
21 Background and [#6b](#) Explanation for choice of comparators 4
22
23 rationale: choice of
24 comparators

25
26
27
28 Objectives [#7](#) Specific objectives or hypotheses 5-6

29
30
31
32 Trial design [#8](#) Description of trial design including type of trial 7
33
34 (eg, parallel group, crossover, factorial, single
35 group), allocation ratio, and framework (eg,
36 superiority, equivalence, non-inferiority,
37 exploratory)

38
39
40
41
42
43 **Methods:**

44
45
46 **Participants,**
47
48 **interventions, and**
49
50 **outcomes**

51
52
53
54 Study setting [#9](#) Description of study settings (eg, community 6
55
56 clinic, academic hospital) and list of countries

1		where data will be collected. Reference to where	
2			
3		list of study sites can be obtained	
4			
5			
6	Eligibility criteria	#10 Inclusion and exclusion criteria for participants. If	6
7			
8		applicable, eligibility criteria for study centres and	
9			
10		individuals who will perform the interventions (eg,	
11			
12		surgeons, psychotherapists)	
13			
14			
15			
16	Interventions:	#11a Interventions for each group with sufficient detail	5,8
17			
18	description	to allow replication, including how and when they	
19			
20		will be administered	
21			
22			
23	Interventions:	#11b Criteria for discontinuing or modifying allocated	n/a
24			
25	modifications	interventions for a given trial participant (eg, drug	
26			There are no plans
27			to discontinue or
28		dose change in response to harms, participant	modify the
29			interventions.
30		request, or improving / worsening disease)	
31			
32			
33			
34			
35			
36	Interventions:	#11c Strategies to improve adherence to intervention	7
37			
38	adherence	protocols, and any procedures for monitoring	
39			
40		adherence (eg, drug tablet return; laboratory	
41			
42		tests)	
43			
44			
45			
46	Interventions:	#11d Relevant concomitant care and interventions that	n/a
47			
48	concomitant care	are permitted or prohibited during the trial	
49			
50			
51	Outcomes	#12 Primary, secondary, and other outcomes,	12-15
52			
53		including the specific measurement variable (eg,	
54			
55		systolic blood pressure), analysis metric (eg,	
56			
57			
58			
59			
60			

change from baseline, final value, time to event),
 method of aggregation (eg, median, proportion),
 and time point for each outcome. Explanation of
 the clinical relevance of chosen efficacy and harm
 outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce	7
---------------------------------------	----------------------	---	---

1 predictability of a random sequence, details of any
 2
 3 planned restriction (eg, blocking) should be
 4
 5 provided in a separate document that is
 6
 7 unavailable to those who enrol participants or
 8
 9 assign interventions
 10

11
 12
 13 Allocation [#16b](#) Mechanism of implementing the allocation 7

14 concealment
 15 sequence (eg, central telephone; sequentially
 16
 17 mechanism numbered, opaque, sealed envelopes), describing
 18
 19 any steps to conceal the sequence until
 20
 21 interventions are assigned
 22
 23

24 Allocation: [#16c](#) Who will generate the allocation sequence, who 7

25 implementation
 26 will enrol participants, and who will assign
 27
 28 participants to interventions
 29
 30

31
 32 Blinding (masking) [#17a](#) Who will be blinded after assignment to 8

33 interventions (eg, trial participants, care providers,
 34
 35 outcome assessors, data analysts), and how
 36
 37

38
 39
 40 Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding 8

41 emergency
 42 is permissible, and procedure for revealing a
 43
 44 unblinding participant's allocated intervention during the trial
 45
 46

47 Methods: Data

48 collection,

49 management, and

50 analysis

51
 52
 53
 54
 55
 56
 57 Data collection plan [#18a](#) Plans for assessment and collection of outcome, 12-15

1 baseline, and other trial data, including any
 2 related processes to promote data quality (eg,
 3 duplicate measurements, training of assessors)
 4 and a description of study instruments (eg,
 5 questionnaires, laboratory tests) along with their
 6 reliability and validity, if known. Reference to
 7 where data collection forms can be found, if not in
 8 the protocol
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18

19	Data collection plan:	#18b	Plans to promote participant retention and	14
20	retention		complete follow-up, including list of any outcome	
21			data to be collected for participants who	
22			discontinue or deviate from intervention protocols	
23				
24				
25				
26				
27				
28				
29	Data management	#19	Plans for data entry, coding, security, and storage,	15-16
30			including any related processes to promote data	
31			quality (eg, double data entry; range checks for	
32			data values). Reference to where details of data	
33			management procedures can be found, if not in	
34			the protocol	
35				
36				
37				
38				
39				
40				
41				
42				
43				
44	Statistics: outcomes	#20a	Statistical methods for analysing primary and	16
45			secondary outcomes. Reference to where other	
46			details of the statistical analysis plan can be	
47			found, if not in the protocol	
48				
49				
50				
51				
52				
53				
54	Statistics: additional	#20b	Methods for any additional analyses (eg,	16
55	analyses		subgroup and adjusted analyses)	
56				
57				
58				
59				
60				

1	Statistics: analysis	#20c	Definition of analysis population relating to	16
2				
3	population and		protocol non-adherence (eg, as randomised	
4				
5	missing data		analysis), and any statistical methods to handle	
6				
7			missing data (eg, multiple imputation)	
8				
9				
10				
11	Methods: Monitoring			
12				
13				
14	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	16
15				
16	formal committee		summary of its role and reporting structure;	
17				
18			statement of whether it is independent from the	
19				
20			sponsor and competing interests; and reference to	
21				
22			where further details about its charter can be	
23				
24			found, if not in the protocol. Alternatively, an	
25				
26			explanation of why a DMC is not needed	
27				
28				
29				
30				
31	Data monitoring:	#21b	Description of any interim analyses and stopping	16
32				
33	interim analysis		guidelines, including who will have access to	
34				
35			these interim results and make the final decision	
36				
37			to terminate the trial	
38				
39				
40				
41	Harms	#22	Plans for collecting, assessing, reporting, and	16-17
42				
43			managing solicited and spontaneously reported	
44				
45			adverse events and other unintended effects of	
46				
47			trial interventions or trial conduct	
48				
49				
50				
51	Auditing	#23	Frequency and procedures for auditing trial	19
52				
53			conduct, if any, and whether the process will be	
54				
55			independent from investigators and the sponsor	
56				
57				
58				
59				
60				

1 **Ethics and**

2
3 **dissemination**

4			
5			
6			
7	Research ethics	#24	Plans for seeking research ethics committee /
8			
9	approval		institutional review board (REC / IRB) approval
10			
11			
12	Protocol	#25	Plans for communicating important protocol
13			
14	amendments		modifications (eg, changes to eligibility criteria,
15			outcomes, analyses) to relevant parties (eg,
16			investigators, REC / IRBs, trial participants, trial
17			registries, journals, regulators)
18			
19			
20			
21			
22			
23			
24	Consent or assent	#26a	Who will obtain informed consent or assent from
25			
26			potential trial participants or authorised
27			surrogates, and how (see Item 32)
28			
29			
30			
31			
32	Consent or assent:	#26b	Additional consent provisions for collection and
33			
34	ancillary studies		use of participant data and biological specimens
35			
36			in ancillary studies, if applicable
37			
38			
39			
40			
41			
42			
43	Confidentiality	#27	How personal information about potential and
44			
45			enrolled participants will be collected, shared, and
46			
47			maintained in order to protect confidentiality
48			
49			before, during, and after the trial
50			
51			
52	Declaration of	#28	Financial and other competing interests for
53			
54	interests		principal investigators for the overall trial and each
55			
56			study site
57			
58			
59			
60			

1	Data access	#29	Statement of who will have access to the final trial	16
2			dataset, and disclosure of contractual agreements	
3			that limit such access for investigators	
4				
5				
6				
7				
8				
9	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	n/a
10	trial care		and for compensation to those who suffer harm	
11			from trial participation	This is a low-risk
12				trial with minimal
13				foreseen harms to
14				participants.
15				
16				
17				
18				
19				
20				
21				
22	Dissemination	#31a	Plans for investigators and sponsor to	17
23	policy: trial results		communicate trial results to participants,	
24			healthcare professionals, the public, and other	
25			relevant groups (eg, via publication, reporting in	
26			results databases, or other data sharing	
27			arrangements), including any publication	
28			restrictions	
29				
30				
31				
32				
33				
34				
35				
36				
37				
38	Dissemination	#31b	Authorship eligibility guidelines and any intended	17
39	policy: authorship		use of professional writers	
40				
41				
42				
43				
44	Dissemination	#31c	Plans, if any, for granting public access to the full	17
45	policy: reproducible		protocol, participant-level dataset, and statistical	
46			code	
47				
48				
49				
50				
51	Appendices			
52				
53				
54	Informed consent	#32	Model consent form and other related	Supp. file
55	materials		documentation given to participants and	
56				
57				
58				
59				
60				

1 authorised surrogates

2
3
4 Biological [#33](#) Plans for collection, laboratory evaluation, and n/a
5
6 specimens storage of biological specimens for genetic or
7 No biological
8 molecular analysis in the current trial and for
9 specimens will be
10 future use in ancillary studies, if applicable
11 collected as part of
12
13 this trial.
14
15

16
17 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
18 Commons Attribution License CC-BY-NC. This checklist can be completed online using
19 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
20
21 [Penelope.ai](#)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Study protocol for a real-world evaluation of an integrated child and family health hub for migrant and refugee women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061002.R2
Article Type:	Protocol
Date Submitted by the Author:	11-Aug-2022
Complete List of Authors:	Hodgins, Michael; UNSW, Ostojic, Katarina; University of New South Wales Hu, Nan; UNSW, Lawson, K; Western Sydney University Samir, Nora; University of New South Wales - Randwick Campus, School of Women's and Children's Health Webster, Amanda; South Eastern Sydney Local Health District Rogers, Helen; South Eastern Sydney Local Health District, Henry, Amanda ; University of New South Wales Faculty of Medicine, Women's and Children's Health Murphy, Elisabeth; University of New South Wales; New South Wales Ministry of Health Lingam, Raghu; University of New South Wales Raman, Shanti; University of New South Wales School of Women's and Children's Health, ; South Western Sydney Local Health District, Community Paediatrics Mendoza Diaz , Antonio; University of New South Wales, Discipline of Psychiatry Dadich, Ann; Western Sydney University, School of Business Eapen, Valsamma; South Western Sydney Local Health District, ICAMHS; University of New South Wales, School of Psychiatry Rimes, Tania; South Eastern Sydney Local Health District, Child Youth and Family Services Woolfenden, Susan ; University of New South Wales; Sydney Local Health District
Primary Subject Heading:	Public health
Secondary Subject Heading:	Paediatrics, Health services research, Research methods
Keywords:	Community child health < PAEDIATRICS, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PAEDIATRICS, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5 **TITLE:** Study protocol for a real-world evaluation of an integrated child and family
6 health hub for migrant and refugee women
7
8
9

10
11 **AUTHORS:** Michael Hodgins¹, Katarina Ostojic¹, Nan Hu¹, Kenny Lawson², Nora Samir¹,
12 Amanda Webster³, Helen Rogers³, Amanda Henry¹, Elisabeth Murphy⁴,
13 Raghu Lingam^{1,5}, Shanti Raman⁶, Antonio Mendoza Diaz¹, Ann Dadich²,
14 Valsamma Eapen^{1,6}, Tania Rimes^{3*}, Sue Woolfenden^{1,7*}
15

16 On behalf of the FDCC Collaborative Group
17

18 **AFFILIATIONS**

19
20 ¹ University of New South Wales, NSW 2751

21
22 ² Western Sydney University, NSW 2150

23
24 ³ South Eastern Sydney Local Health District, NSW 2229

25
26 ⁴ North Sydney Local Health District, NSW 2065

27
28 ⁵ Sydney Children's Hospitals Network, Sydney, NSW, 2031

29
30 ⁶ South Western Sydney Local Health District, NSW 2170

31
32 ⁷ Sydney, Institute for Women, Children and their Families, Sydney Local Health District, NSW
33 2050
34

35 **CORRESPONDING AUTHORS***

36
37 Dr Michael Hodgins

38
39 School of Women's & Children's Health

40
41 UNSW

42
43 Email: michael.hodgins1@unsw.edu.au
44
45
46
47

48
49 **KEYWORDS** Integrated care, community child health, maternal health, organisation of health
50 services, paediatrics, public health
51
52
53

54
55
56
57
58
59
60
1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

WORD COUNTS

Abstract: 299 words

Main text: 3,976 words (excluding title page, tables, and references)

Protocol version: version 1.0 (10.01.2022)

For peer review only

ABSTRACT

Introduction: Continuity of child and family healthcare is vital for optimal child health and development for developmentally vulnerable children. Migrant and refugee communities are often at-risk of poor health outcomes, facing barriers to health service attendance including cultural, language, limited health literacy, discrimination, and unmet psychosocial needs. ‘Integrated health-social care hubs’ are physical hubs where health and social services are co-located, with shared referral pathways and care navigation.

Aim: Our study will evaluate the impact, implementation, and cost-benefit of the First 2000 Days Care Connect (FDCC) integrated hub model for pregnant migrant and refugee women and their infants.

Materials and methods: This study has three components. Component 1 is a non-randomised controlled trial to compare the FDCC model of care with usual care. This trial will allocate eligible women to intervention and control groups based on their proximity to the Hub sites. Outcome measures include: the proportion of children attending child and family health (CFH) nurse services and completing their CFH checks to 12 months of age; improved surveillance of growth and development in children up to 12 months, post-partum; improved breastfeeding rates; reduced emergency department presentations; and improve maternal wellbeing. These will be measured using linked medical record data and surveys. Component 2 will involve a mixed-method implementation evaluation to clarify how and why FDCC was implemented within the sites to inform future roll-out. Component 3 is a within-trial economic evaluation from a healthcare perspective to assess the cost-effectiveness of the Hubs relative to usual care and the implementation costs if Hubs were scaled and replicated.

Ethics and dissemination: Ethical approval was granted by the South Eastern Sydney Local Health District Human Research Ethics Committee in July 2021 (Project ID: 020/ETH03295). Results will be submitted for publication in peer-reviewed journals and presented at relevant conferences.

Trial registration: ACTRN12621001088831

ARTICLE SUMMARY

Strength and limitations

- The study has an embedded implementation evaluation and economic evaluation in addition to the non-randomised trial component of the study.
- A strength of the design of the study is the logic modelling process used to map the implementation context and intervention components to guide data collection methods.
- A strength of the design of the implementation evaluation is a mixed methods approach that will enable the triangulation of barriers and facilitators to implementing hubs with implementation success across the sites qualitatively and quantitatively.
- The non-randomised design of the trial has some limitations, particularly the inability to guarantee the comparability of the intervention and control groups.

BACKGROUND AND RATIONALE

In New South Wales (NSW), Australia, 25% of children from migrant and refugee families are 'developmentally vulnerable'.¹ Developmental vulnerability is measured by the Australian Early Development Census across five domains including physical health and wellbeing, social competence, emotional maturity, language and cognitive skills, and communication skills and general knowledge. Children who are in the lowest 10 per cent of the national population are classified as developmentally 'vulnerable'.¹ Developmental vulnerability is associated with undetected maternal postnatal depression, the early cessation of breastfeeding², and parental unmet psychosocial needs (e.g., housing, domestic violence).^{3,4} Children who are developmentally vulnerable are twice as likely to struggle at school, experience adverse childhood events and have poorer long-term health outcomes and higher healthcare costs.^{1, 5-12} These adverse childhood events can continue into adulthood, contributing up to 44% of adult morbidity.^{13,14}

Continuity of care with regular child and family health (CFH) checks by local health district (LHD) employed child and family health nurses (CFHN) are the foundation for optimal child health and development. This is particularly the case for priority populations, including newly arrived migrant and refugee women, children, and their families.⁵ However, these populations also experience

1
2
3 significant barriers to services including cultural, language, limited health literacy, discrimination,
4 and unmet psychosocial needs.¹⁵⁻³¹ Families with greater disadvantage are at greater risk of
5 developmental vulnerability and poorer maternal mental health and other health problems. These
6 families are less likely to engage with health services, particularly health promotion programs, like
7 CFH checks.^{2-4 15 32-36}

8
9
10
11
12 Australian policymakers identified service areas that need improvement to optimise outcomes in the
13 first 2,000 days of a child's life.^{5 37} These include the transition from maternity to CFH services;
14 increasing uptake and length of time families stay connected with CFH services; and supporting
15 priority populations. Unfortunately, in NSW, two-thirds of children stop attending CFH services by
16 12 months of age,^{15 18-20} further fragmenting care.

21 **Benefits of integrated health-social care hubs**

22
23
24 To address the fragmented CFH services for priority populations, integrated health-social care hubs
25 were established in multiple jurisdictions across Australia. These are physical hubs where health and
26 social services are co-located, supported by care navigators and shared referral pathways.^{38 39} Co-
27 location and navigation support aims to remove barriers that hinder engagement between families
28 and CFH services. However, the evidence-base for their effectiveness is limited. Our recent
29 systematic review demonstrated the dearth of experimental trial evidence in Australia regarding
30 physical CFH Hubs.⁴⁰ Yet, individual studies have found Hub models increase access to CFH
31 services and the identification of developmental vulnerability.⁴⁰ Additionally, a recent scoping
32 review of models of care across the continuum of pregnancy, birth, and the postpartum period for
33 women from migrant and refugee backgrounds in high-income countries highlighted an evidence gap
34 for models that improved maternal and child infant health outcomes.⁸

35
36
37
38
39
40
41
42
43 We have extended this evidence-base by showing the feasibility and efficacy of integrated CFH
44 hubs and cross-cultural workers (CCW) models in South Eastern Sydney.^{8 41-43} These models support
45 women and families to navigate maternity, CFH, and community-based services, providing
46 continuity of care across the continuum of pregnancy and transition to CFH. The pilot interventions
47 demonstrated that, for women and families from migrant and refugee populations: CFHN services
48 embedded in integrated hubs increased the completion rate of CFH checks from 30% to 60% at 12-

53
54 5

1
2
3 months and facilitated linkage with co-located non-government organisations.^{41 42} Cross-cultural
4 worker support in pregnancy was also highly rated by staff and pregnant women regarding support
5 for pregnancy and linkage with services.^{44 45}
6
7

8 9 **Current study: First 2000 Days Care Connect**

10
11 *First 2000 Days Care Connect* (FDCC) is an integrated health-social care hub model that builds on
12 these feasible and acceptable pilot interventions. The FDCC model involves co-located CFH services
13 and non-government organisations (NGO), including psychosocial support services (e.g., playgroups,
14 domestic violence support, mental health support, early childhood education, family support). These
15 services operate from a physical location to facilitate service collaboration, integration, and a
16 community-led approach to local needs. This Hub is supported by care navigation, increasing
17 continuity from maternity to CFH services.
18
19
20
21
22

23 24 **Objectives**

25
26 The overall aim of the FDCC study is to evaluate: the impact of FDCC (an integrated CFH Hub) on
27 attendance at CFHN services and completion of CFH checks, support of child growth and
28 development, breastfeeding and maternal wellbeing, and meeting family psychosocial needs
29 (Component 1); the process of implementing FDCC (Component 2); and the cost-effectiveness of
30 FDCC (Component 3).
31
32
33
34

35 36 **METHODS AND ANALYSIS**

37 38 **Study Setting**

39
40 FDCC is a multisite study, conducted across three metropolitan LHDs in Greater Sydney, NSW –
41 namely, SESLHD, SWSLHD, and NSLHD. Participants will be recruited from public and
42 universally available antenatal services at participating public hospitals within the LHDs and receive
43 services from CFHN services within each LHD.
44
45
46

47 48 **Recruitment and Consent**

49
50 The study will recruit 240 women between November 2021 and April 2022. Eighty participants will
51 be enrolled within SESLHD, NSLHD, and SWSLHD, with 40 allocated to the intervention arm
52
53

54
55
56
57
58
59
60
6

(FDCC Hub) and 40 to the control arm (routine care). Potential participants are women attending antenatal clinics at the participating public hospitals within each study site and fulfilling the eligibility criteria (Table 1).

Table 1: Inclusion and Exclusion Criteria

Inclusion criteria	Exclusion criteria
<p>Eligible women will be expectant mothers who are:</p> <ul style="list-style-type: none"> • Attending antenatal clinics linked to the three study sites • Residing in geographical catchment for the respective antenatal clinic • Expectant mother > 20 weeks gestation • 16 years of age or older at enrolment • Newly arrived migrant (< 10 years in Australia) or self-identified refugee (< 10 years in Australia), from a non-English speaking background • Provide a signed and dated informed consent form 	<ul style="list-style-type: none"> • Does not comprehend the recruitment invitation (not proficient in English and/or declines the offer of an interpreter in their home language) • Have no mechanism for contact (telephone or email) • Already an active client in other targeted support services • Less than 16 years of age at enrolment • Migrant > 10 years in Australia or self-identified refugee > 10 years in Australia, • From an English speaking background • Not residing in geographical area of study

Using three processes, midwives and CCWs (where available) will identify eligible women attending antenatal services at the intervention sites during regular consultations. The processes include: midwives and CCW introduce the project to women attending a group model of antenatal care; midwives will promote the study during individual hospital antenatal visits and provide potential participants a flyer; and midwives will identify potential participants who meet the eligibility criteria and provide study details during regular antenatal visits. If potential participants provide verbal consent, they will be introduced to the project officer. The project officer will explain the study and provide a participant information sheet and consent form (PISCF) using translated documents and/or interpreter services, if required. They will confirm eligibility at face-to-face clinic visits or via telephone consultation. If the woman is not interested in the study, there will be no further contact regarding the study.

Participants will provide informed consent via completing paper-based consent forms, via email or verbally via phone or via online electronic signature option using the RedCap database. Participants consenting to the study can opt out of the data linkage component.

7

1
2
3 For component 2, once the FDCC trial is underway, the project implementation scientist will contact
4 participating CFHNs, NGO staff, and Hub administrative staff via telephone and/or email to invite
5 them to an interview or focus group. Prior to the interviews and focus groups, the implementation
6 researcher will describe the study to participants and its rationale, providing a PISCF, and obtain
7 informed consent. Hub staff and service leaders, including LHD partners and policymakers, will be
8 invited to complete a 32-item online survey at the completion of *Component 1*. The online survey
9 will include a detailed description of the study, rationale, and an opportunity to indicate informed
10 consent before survey completion. Hub staff and managers who do not complete the survey will
11 receive a reminder thrice via email.
12
13
14
15
16
17
18

19 **Study Procedures**

20
21 This protocol has used the SPIRIT reporting guidelines.⁴⁶ Following the identification of potential
22 participants, project officers will confirm participant eligibility as part of the consent process. This is
23 a non-randomised study whereby eligible participants will be allocated to a study arm (FDCC
24 intervention or control group) based on their residential postcode at the time of enrolment (see
25 below). Participation will be 12 months, including: intervention allocation; intervention delivery (12
26 months); and data collection (baseline, 6 months post-partum, 12 month post-partum). In addition to
27 English, the study materials will be translated in the six most common community languages
28 (Arabic, Bengali, Simplified Chinese, Korean, Hindi, and Vietnamese).
29
30
31
32
33
34

35 *Allocation, Concealment, and Implementation*

36
37 Women attending antenatal services from the participating hospitals who live in a defined
38 geographic area (postcode) served by an established CFH Hub in their LHD will be allocated to the
39 FDCC intervention group. Women attending antenatal services from the participating hospitals but
40 do not live in the defined geographic area above will be in the control group.
41
42
43
44

45 *Blinding*

46
47 Given the nature of the study, blinding to group allocation is impractical. However, as the
48 intervention is dependent on participant postcode of residence, there is expected to be minimal
49 treatment contamination between the intervention and control groups. To assess for intervention
50 contamination, women in all groups will be asked at the 12 months postpartum assessment regarding
51
52
53
54
55
56
57
58
59
60

1
2
3 the use of any Hub and CFHN service. While the site project officers collecting survey data at each
4 site will not be blinded to allocation, the researcher analysing data will be blinded to group
5 allocation.
6
7

8 9 *Intervention*

10
11 After recruitment, the Hub navigator or key worker (i.e. an individual based at the hub responsible
12 for linking participants with services, usually the CFHN) will contact participants to introduce Hub
13 services and support engagement with identified services, if needed. This will be followed by another
14 contact between birth and 8 weeks postpartum. Following mothers' and infants' discharge from
15 birthing services, women will access CFH services via the Hub, as well as psychosocial support
16 services suited to maternal needs and preferences. Per routine care, all women and their babies will
17 be offered an appointment (approximately 1 hour) with a CFHN at 1 to 4 weeks postpartum, 6 to 8
18 weeks postpartum, 6 months postpartum, and 12 months postpartum.
19
20
21
22
23
24

25 Hub services will be face-to-face, online, and one-to-one. Some services, such as playgroup or
26 mothers' groups, might be in a group setting. Mothers and their babies will have access to the Hub
27 for 12 months. Further contacts with the Hub navigator or keyworker as participants require.
28
29

30
31 The integrated FDCC Hubs are a physical building and a way of working, facilitating service
32 collaboration, integration, and a community-led approach to local needs. Hubs most commonly
33 operate from a host building from which partner community-based or public services are delivered.
34 In our Hub model, CFH services are co-located with NGOs. Families are linked with psychosocial
35 support services, including playgroups, early childhood learning opportunities, and family support.
36 Within the Hub services, existing CFH and NGO services support families to navigate systems and
37 engage with other health services. These include general practitioners, early childhood, education,
38 and psychosocial support to address their needs.
39
40
41
42
43
44

45 *Control Arm: Routine Care*

46
47 Pregnant women attending the participating hospitals who meet eligibility criteria but do not live in
48 the geographic area will be allocated to a control cohort and receive routine care (e.g., receive
49 information on CFHN services at discharge and follow-up as per current pathways).
50
51
52
53

54 9
55
56
57
58
59
60

Implementation Evaluation

Our mixed-methods implementation evaluation will assess the barriers and facilitators to implementing the FDCC Hubs at the three sites, as guided by the consolidated framework for implementation research (CFIR).⁴⁷ The CFIR is a comprehensive framework designed to ‘offer an overarching typology to promote implementation theory development and verification about what works where and why across multiple contexts’.⁴⁷ The CFIR is widely used in diverse healthcare contexts, including primary care.⁴⁸ The CFIR identifies five major domains and guides the consideration and assessment of factors that can impact intervention implementation and effectiveness. Additionally, the researchers will evaluate specific implementation outcomes of acceptability, appropriateness, fidelity to the implementation strategy, coverage, sustainability, and cost (Table 2) as guided by the taxonomy proposed by Proctor and colleagues.⁴⁹

Table 2: Proctor and colleagues (2011) implementation outcomes mapped to FDCC evaluation

	Questions addressed by each implementation factor
Acceptability	Do Hub staff and families view the Hub model as acceptable?
Adoption	Do Hub staff intend to apply the Hub model as described in the study protocol?
Appropriateness	Do Hub staff perceive the Hub model as relevant & useful for their services?
Fidelity	Is the Hub model applied as intended?
Coverage	How many eligible families are reached through the Hub model and keyworker?
Cost	How much does it cost to implement Hubs?
Sustainability	What are the factors that will allow the Hubs to be sustained/scaled-up further?

Logic Model

We developed a logic model to inform the FDCC implementation evaluation (**Error! Reference source not found.**). We used a modified version of existing logic model frameworks^{50 51} to include the inner context (i.e., individual factors, organisational settings) and the outer context of each site (i.e., area demographics, policy climate, relevant geographically adjacent clinical services). These contextual factors were incorporated within the logic modelling to enable implementation researchers to better describe the determinants of successful implementation in clinical practice.⁵²

[INSERT FIGURE 1]

Additionally, we included a detailed description of the intervention to identify feasibility elements to measure during the study. These include features of the physical location of services, how services are integrated, the availability of culturally sensitive support materials and services, and the

10

1
2
3 navigator or keyworker. To supplement the practical elements of the intervention, we described the
4 underlying theoretical principles of the model. These include the collective impact framework⁵³ and
5 the elements of the behaviour change wheel that we perceived the model to adhere.⁵⁴ Collective
6 impact is designed to inform change on complex social issues, and draws on five conditions:
7 common agenda; continuous communication; mutually reinforcing activities; backbone support; and
8 shared measurement.⁵⁵ Collective impact and the behavioural change wheel mechanisms of change
9 within the logic model will inform the qualitative interview schedule. Finally, we drew connections
10 from these underlying theories of change to the specific intermediate and long-term outcomes that
11 we hypothesised the model will produce. Principally, we hypothesise that the intervention
12 components will work on the core principles of environmental restructure, enablement, modelling,
13 and training within the Hub sites, underpinned by the collective impact principles to support migrant
14 and refugee parents to engage with health and social support services. This engagement will provide
15 better outcomes for children and families. It will also create opportunities for shared knowledge
16 between health and non-health services, as part of an acceptable and cost-effective model delivery.
17 Table 3 provides an overview of the planned outcomes and measurement for the implementation
18 evaluation.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Table 3: Overview of the Implementation Evaluation Outcomes

Implementation Evaluation Outcomes			
Outcome measure	Data Source	Methods	Data Collection
Description of local context and Hub	SEIFA data, search of grey literature, informal contact with Hub service leaders	SEIFA data, search of grey literature, informal contact with Hub service leaders	Trial commencement
Fidelity of Hub Model	Hub intervention log	A bespoke log completed by site project officers	Ongoing during the trial

Acceptability of intervention measure (AIM), intervention appropriateness measure (IAM), and feasibility of intervention measure (FIM) ⁵⁶	Research survey administered by project officer	AIM, IAM, and FIM measures completed by Hub staff, service leaders, participants in the intervention group	Trial end (included in the 12-month postpartum parent survey for parents and separate staff survey)
Barriers and facilitators to running the FDCC Hubs	Interviews with Hub staff, service leaders, participants in the intervention group	Qualitative interviews and focus groups, guided by the CFIR	Pre-trial (with Hub staff and service leaders). Ongoing during and end of the trial for all participants
The NoMAD tool ⁵⁷ to assess Hub staff buy in to the model	Research survey administered by project officer	NoMAD tool completed by Hub staff	Trial end

Economic Evaluation

The economic evaluation will adopt a healthcare perspective beginning with a cost consequence analysis to describe the costs and all main study outcome measures (tables 4 and 5) and then generate a cost-utility analysis. The costs of Hub implementation will include: the establishment and operation of Hubs; and the flow-on cost from service use from Hub referrals. Hubs are likely to be implemented in different ways relative to local context and, as such, costs might differ. Two bespoke costing templates will be shared with Hub managers upon trial commencement to be completed at 6 and 12 months, with researcher support to ensure accuracy. The templates will allow for standardisation and between-site comparison.

Establishment and Operational Costs

A micro-costing approach will be adopted to account for funded and in-kind expenditures.^{58 59} A simple template will have major generic expenditure categories, including upfront capital costs (e.g., vehicles, buildings), governance arrangements to manage the Hubs (e.g., staff meeting time), material costs (e.g., brochures), and in-kind support from staff, including partner agencies. There

12

might be expenditures against these categories. At this stage, there is no plan for capital expenditures. This is included for completeness. Operational costs pertain to daily Hub operation, including new staff hired (e.g., salary, on-costs), in-kind costs (e.g., time costs from non-salaried staff), venue costs (e.g., utilities, even if in-kind), and material costs (e.g., brochures).

Referral Costs

Prior to Hub commencement, Hub personnel will be asked for a list of service partners to create a template where clients will be asked the services accessed and frequency; clients will be surveyed using this. Other sites will follow suit. Full client recall is not anticipated. However, it is important that the study clarifies the impact on referral services, if possible. A top-down costing estimate will then be made.^{58 59} Each partner service will then be contacted to generate an estimate of the average client service cost. Providers typically adopt an activity-based costing approach in accounting and funding proposals. No specific client data will be accessed. Rather, the researchers will guide service providers to generate average costs, which typically only involves dividing total funding for service(s) by total occasions of service. Researchers will only be privy to the overall average costs. Where costs are unavailable, an approximation will be made if public and research data are available. Otherwise, a list of service counts only will be made and remain un-costed. Table 4 provides an overview of the planned outcomes and measurement for the implementation evaluation.

Table 4: Overview of the Economic Evaluation Outcomes

<i>Economic Evaluation Outcomes</i>			
Outcome measure	Data Source	Methods	Data Collection
Mother quality of life (EQ-5D quality of life)	Research survey administered by project officer	Research survey administered by project officer. EQ-5D quality of life questionnaire.	Baseline (antenatal time of enrolment) 6 months post-partum 12 months post-partum
Cost of implementing Hubs and referral services	Bespoke surveys	Bespoke surveys completed by Hub Staff and Participants in the intervention group	6 and 12 months 6 and 12 months

Primary and Secondary Outcome Measures

13

Outcomes will be measured from enrolment (baseline) until and including 12 months post-partum (Table 5). Outcomes will be gathered via: the extraction of routinely collected clinical data from electronic medical records at each site or LHD; surveys administered by a researcher to mothers; and data linkage of participants with administrative datasets (NSW perinatal data collection, NSW emergency department data collection). The primary outcome measure is the proportion of mothers and their respective infant who attend CFHN services for early childhood health checks at 1 to 4 weeks postpartum, 6-8 weeks postpartum, 6 months postpartum, and 12 months postpartum. For primary and secondary variables, see Table 5.

Table 5: Overview of the FDCC Study Outcome Variables

FDCC trial			
Outcome measure	Data Source	Methods	Data Collection
Proportion of mothers, children and families who attend CFHN at FDCC Hub for checks (<i>Primary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD.	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Proportion of mothers, children and families who are up to date with age appropriate health checks, either via CFHN services or GP (<i>Primary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical record at LHD.	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
Proportion of women identified as at risk of experiencing depression on the Edinburgh Depression Scale (EPDS) ⁶⁰ (<i>Secondary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical. <ul style="list-style-type: none"> • Edinburgh Depression Scale (EPDS) total score Response to item 10 of EDS	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum

1 2 3 4 5 6 7 8 9	Proportion of women identified as having more than one unmet social need on the We Care questionnaire ⁶¹ (<i>Secondary Outcome</i>)	Research survey administered by project officer	Research survey administered by project officer. We Care questionnaire.	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 6 months post-partum • 12 months post-partum
10 11 12 13 14 15 16 17 18 19 20 21	Proportion of women identified as experiencing psychosocial vulnerability on NSW Health psychosocial screening tools (Safe Start Psychosocial assessment including Domestic Violence screen) ⁶² (<i>Secondary Outcome</i>)	Electronic medical record at LHD.	Extraction of routine clinical data from electronic medical. Presence/absence of psychosocial risk factors on Safe Start Psychosocial assessment including the Domestic Violence screen.	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 1-4 weeks post-partum or by 6-8 weeks post-partum • 6 months post-partum
22 23 24 25 26 27 28	Proportion of mothers reporting poor quality of life on EQ-5D quality of life questionnaire (<i>Secondary Outcome</i>)	Research survey administered by project officer	Research survey administered by project officer. EQ-5D quality of life questionnaire.	<ul style="list-style-type: none"> • Baseline (antenatal time of enrolment) • 6 months post-partum • 12 months post-partum
29 30 31 32 33 34 35 36 37 38	Proportion of children monitored for growth parameters and their growth parameters (weight, height, head circumference) (<i>Secondary Outcome</i>)	Electronic medical record at LHD	Extraction of routine clinical data from electronic medical. <ul style="list-style-type: none"> • height (cm) • weight (kg) head circumference (cm)	<ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum • 12 months post-partum
39 40 41 42 43 44 45 46 47 48 49 50 51 52 53				

<p>Proportion of women exclusively breastfeeding /predominately breastfeeding/partially breastfeeding/ artificially feeding (<i>Secondary Outcome</i>)</p>	<p>Electronic medical record at LHD. Data linkage with NSW Perinatal Data Collection.</p>	<p>Extraction of routine clinical data from electronic medical.</p> <ul style="list-style-type: none"> • Exclusively breastfed • Predominately breastfed • Partial breastfed • Artificial feeding 	<p>Electronic medical record at LHD:</p> <ul style="list-style-type: none"> • 1-4 weeks post-partum • 6-8 weeks post-partum • 6 months post-partum <p>Data linkage with NSW Perinatal Data Collection</p> <ul style="list-style-type: none"> • Breast feeding initiated at discharge postnatally.
<p>Proportion of children identified by CFHN as at developmental risk on the Learn the Signs Act Early (LtSAE) and Ages and Stages Questionnaire Screening tools (<i>Secondary Outcome</i>)</p>	<p>Electronic medical record at LHD</p>	<p>Extraction of routine clinical data from electronic medical record at LHD.</p> <ul style="list-style-type: none"> • LtSAE screening completed, and the concerns/no concerns identified on LtSAE screening domains. <p>Ages and Stages Questionnaire (ASQ & ASQ-SE) secondary screener given to families by CFHN as clinically required .</p>	<ul style="list-style-type: none"> • 6-8 weeks post-partum (LtSAE) • 6 months post-partum (LtSAE and ASQ) <p>12 months post-partum (LtSAE and ASQ and ASQ-SE)</p>
<p>Mother and infant attendance at emergency departments from recruitment at 6-month postpartum and 12-month postpartum. (<i>Secondary Outcome</i>)</p>	<p>Data linkage with NSW-wide Emergency Department Data Collection (EDDC)</p>	<p>NSW-wide EDDC data Linkage</p>	<p>At 6-month postpartum and 12-month postpartum.</p>

Data Analysis Plan

Sample Size Estimation

Based on pilot data, we anticipate the percentage of children to have their CFH check done by a CFHN will be 60% in the intervention group and 30% in the control group. Therefore, 72 children will be needed for each arm to provide 80% of power to detect the magnitude of such an increase with a p value <0.05 . Allowing for a 40% attrition rate (i.e., loss-to-follow-up) as this is a vulnerable community¹⁵, we aim to recruit 120 children in each arm or 240 children in total across the three sites.

Statistical Analysis

Statistical analysis will include descriptive analysis of participating mother and child outcomes at each assessment. We will compare outcomes between the intervention and control groups using the Fisher's test for binary outcomes, Chi-square method for categorical outcomes, non-parametric method (e.g., Wilcoxon rank-sum test) and parametric methods (e.g., t -test) for continuous and ordinal variables. As outcomes will be measured repeatedly, multilevel regression analysis will be undertaken to examine intervention impact on outcomes, controlling for the plausible confounders at the individual (e.g., mother's sociodemographic characteristics, geographic area of residence) and community levels at baseline (e.g., neighbourhood socioeconomic factors). Generalised estimating equations method will be used in the regression analysis, considering the potential clustering effect by site. Only deidentified data will be analysed. No data safety monitoring committee is needed for this study due to the known minimal risks. No interim analyses or stopping rules will be applied.

Implementation Evaluation Analysis

Implementation effectiveness will be evaluated using the validated scoring system of -2 to $+2$ with score descriptions as follows: -2 indicates the construct has negatively influenced the practice and examples of negative manifestations are indicated; -1 indicates the construct has negatively influenced the practice and general statements of negative manifestations are made; 0 indicates the construct neutrally influenced the practice; $+1$ indicates the construct positively influenced the practice and general statements of positive manifestations are made; and $+2$ indicates the construct positively influenced the practice and explicit examples of positive manifestations are described.⁶³

17

1
2
3 Using these scores, construct scores can range from a low of -80 to a high of +80, demonstrating the
4 key barriers and facilitators to uptake and sustain the FDCC hubs. This method of quantifying
5 implementation effectiveness will be supplemented with an inductive analysis of qualitative data to
6 ensure openness to emerging themes not readily captured by the CFIR and Proctor and colleague's
7 outcome measures.⁴⁹
8
9

10 11 12 *Economic Analysis* 13

14 First, a cost consequence analysis will collate and list the main costs and outcomes from the trial
15 (table 4 and 5) to provide transparency regarding the overall impacts of Hubs. Second, a cost-utility
16 will then report the incremental (net) cost per change in quality adjusted life years (QALYs) (with
17 health utilities derived from the EQ5D)⁶⁴ simulated using a decision tree, and where the threshold
18 willingness to pay is varied between \$42,000-\$67,000.⁶⁵ Third, a probability sensitivity analysis
19 (PSA) will be undertaken and, where there is statistical uncertainty regarding cost effectiveness, a
20 value of information analysis (VOI) will assess statistical uncertainty and value for further research,
21 including for example the value of longer follow-up to assess medium-to-long term impacts.⁶⁶
22 Finally, a budget impact analysis (BIA) will be undertaken where there are positive and attributable
23 impacts regarding primary and/or secondary outcomes (captured in the CCA). This will estimate the
24 overall financial cost if Hubs were scaled-up across NSW to inform policy affordability
25 considerations. The latter will involve estimating the potential Hubs would be made and an average
26 cost (of the three Hubs) applied, with high and low estimates in a sensitivity analysis.
27
28
29
30
31
32
33
34
35
36

37 **Data Management** 38

39 All participants will be allocated a randomly generated unique identifier code to be used throughout
40 the study. Project officers will have identified information of the participants enrolled at their site,
41 stored in password protected files. The project officer within each LHD will work with data
42 managers to extract routinely collected clinical data from electronic medical records for all
43 participants, per Table 3. Data will be stored within a protected site-based server. Only deidentified
44 data will be transferred from each LHD to the researchers (SW, KO, NH) for data analysis, using
45 encrypted transfer.
46
47
48
49
50
51

52 Project officers with support from CCWs and/or interpreters will collect surveys at baseline, 6
53
54
55
56
57
58
59
60

1
2
3 months postpartum, and 12 months postpartum. The survey can be completed in hardcopy (face-to-
4 face or telephone) or online by participants using a secure link to REDCap®. Subsequently, project
5 officers who can access the identifying information within each LHD will enter survey data into the
6 REDCap® database. REDCap® is hosted on the University of NSW (UNSW) infrastructure.

7
8
9
10 Permissions granted to each user within each REDCap® project is controlled by and is the
11 responsibility of the project team. Hardcopy materials will be stored in locked cabinets for the
12 required period, either indefinitely if the participant consents to providing their data for data pooling
13 or for 15 years after the completion of the study. After these periods, hardcopy materials will be
14 destroyed and password-protected electronic archives will be deleted.

15
16
17
18
19 The identifying information collected within each LHD will be compiled into a single password-
20 protected file and sent to The Centre for Health Record Linkage (CHeReL) for data linkage. The
21 minimum identifying information for mothers and infants will be used to extract participant records
22 from the administrative data. Upon completion of data extraction, CHeReL will transfer to UNSW
23 administrative data of the participants who consented to data linkage. The administrative records will
24 be deidentified by CHeReL, which will create the person project number (PPN) for each participant.
25 The PPN will be linked to the participant's unique project identification number to link the
26 administrative records with the electronic medical record (eMR) and survey records that belong to
27 the same participant.

28 29 30 31 32 33 34 35 **Patient and Public Involvement**

36
37 The research questions were developed based on qualitative research undertaken with Hub
38 participants and community members and service providers in the pilot study.^{41 67} The FDCC team
39 have a consumer representative and consultation was undertaken with local Hub partner services.
40 The researchers also consulted multicultural health services, including cultural support workers, to
41 ensure research materials are culturally nuanced. Patients or participants have not directly been
42 involved in the current study design.

43 44 45 46 47 48 49 **ETHICS AND DISSEMINATION**

50
51 Ethical approval was granted by the South Eastern Sydney LHD (SESLHD) (2020/ETH03295). This
52 trial was registered with the Australian New Zealand Clinical Trials (ACTRN12621001088831).

53
54
55
56
57
58
59
60

Confidentiality

The researchers acknowledge that ensuring confidentiality is essential. The researchers will exercise due diligence to anonymise participants' responses for reporting, publication, and presentation purposes. Only deidentified data will be transferred from each LHD to the UNSW researchers for data analysis. The deidentified data from each LHD to the UNSW team will be securely transferred through a NSW Health-approved e-health platform.

Managing Potential Harms

If issues are disclosed outside of the study parameters, mandatory NSW Health policy directives will apply (e.g., family and domestic violence, child protection matters). These will be managed as per current policies and practices within LHDs. The child protection and domestic violence counselling teams are readily accessible to provide advice and support if issues are identified. As the researchers are all mandatory reporters, they will inform participants that they are not able to maintain confidentiality when it relates to the safety of the participant, the child/ren, the family, and the wider community. These obligations are detailed in the PISCF (appendix 1).

Dissemination

Data obtained for the study will be published in reports, peer reviewed journals and presented at appropriate conferences. The de-identified data will be available to all investigators. Access by individuals' other than the named investigators will only be permitted after consideration and agreement by all the remaining investigators. An essential element of knowledge translation are the study partners and advisors who will share findings and consider if and how to progress to trialling or implementing the program at scale. We intend to produce at least two papers (e.g. protocol, main findings) for peer-review publication, written by core research and implementation team.

Study governance

The FDCC Team will support planning, implementation and governance of the project and ensure that WH&S requirements and policies are considered and actioned. There are currently no procedures for auditing trial conduct. All protocol modifications will be discussed within all levels of governance and communicated to the SESLHD HREC. Figure 2 outlines our governance structure.

20

1
2
3 [INSERT FIGURE 2]
4
5

6 **Author contributions**

7
8 The original trial design was conceived by SW, TR, AW, RL, VE and HR. The implementation
9 evaluation design was conceived by MH and RL. The economic evaluation design was conceived by
10 KL. The statistical analysis methods were initially designed by NH. MH developed the initial draft of
11 the protocol, which was refined by SW, TR, AW, RL, VE, HR, KO, NH, KL, NS, AH, EM, SR,
12 AMD, and AD. All authors approved, the final manuscript.
13
14
15
16

17 **Funding statement**

18 This project was funded by the NSW Health Translational Research Grants Scheme. The views
19 expressed are those of the authors and not necessarily those of the partner organisations. Sue
20 Woolfenden is funded through the National Health and Medical Research Council. Raghu Lingam is
21 funded through the Financial Markets Foundation for Children. The project is supported in-kind by
22 the Early Life Determinants of Health Clinical Academic Group, Maridulu Budyari Gumal
23 (SPHERE).
24
25
26
27
28
29

30 **Competing interests**

31 The views expressed are those of the author(s) and not necessarily those of the funding partners.
32 NSW Health has no direct role in study design; data collection, analysis, and interpretation, or
33 writing of final reports, presentations, or publications.
34
35
36
37
38
39

40 **Acknowledgements**

41 This protocol has been authored on behalf of the FDCC Collaborative Group. The authors would like
42 to acknowledge the members of the group not listed as authors: Melissa Green, John Eastwood,
43 Karen Sorensen, Kim Lyle, Catherine Jones, Vicki Blight, Amit Arora, Michelle de Vroome,
44 Andrew Hayen, Nick Hopwood, Virginia Schmied, Rebekah Grace, Jane Kohlhoff, Fiona Brooks,
45 Cathy Kaplun, Kathleen Baird, Myna Hua, Lisa Woodland, Ben Harris-Roxas, Brendan Goodger,
46 Tracey Szanto, Karen Zwi, and Grainne O'Loughlin.
47
48
49
50
51
52
53

54 21
55
56
57
58
59
60

REFERENCES

1. AEDC. Australian Early Development Census. <https://www.aedc.gov.au/data/data-explorer?id=135216>. 2020
2. COAG. COAG Health Council 2019 The Australian National Breastfeeding Strategy: 2019 and Beyond was prepared under the auspices of the COAG Health Council. 2019
3. Moore T, Arefadib N, Deery A, et al. The first thousand days: an evidence paper. *Melbourne: Murdoch Children's Research Institute* 2017
4. Goldfeld S, D'Abaco E, Bryson H, et al. Surveying social adversity in pregnancy: The antenatal risk burden experienced by Australian women. *Journal of paediatrics and child health* 2018;54(7):754-60.
5. NSW Ministry of Health. The First 2000 Days Framework. 2019
6. Goldfeld S, O'Connor M, Chong S, et al. The impact of multidimensional disadvantage over childhood on developmental outcomes in Australia. *International Journal of Epidemiology* doi:<https://doi.org/10.1093/ije/dyy087>
7. Woolfenden S, Asher I, Bauert P, et al. Summary of position statement on inequities in child health. 2018;54(8):832-33.
8. Rogers HJ, Hogan L, Coates D, et al. Responding to the health needs of women from migrant and refugee backgrounds—Models of maternity and postpartum care in high-income countries: A systematic scoping review. *Health & Social Care in the Community* 2020
9. Hiscock H, Danchin MH, Efron D, et al. Trends in paediatric practice in Australia: 2008 and 2013 national audits from the Australian Paediatric Research Network. *Journal of paediatrics and child health* 2017;53(1):55-61.
10. Palfrey JS, Tonniges TF, Green M, et al. Introduction: addressing the millennial morbidity—the context of community pediatrics. *Pediatrics* 2005;115(Supplement 3):1121-23.
11. Woolfenden S, Galea C, Smithers-Sheedy H, et al. Impact of social disadvantage on cerebral palsy severity. *Developmental Medicine & Child Neurology* 2019;61(5):586-92.
12. Brinkman S, Gregory T, Harris J, et al. Associations between the early development instrument at age 5, and reading and numeracy skills at ages 8, 10 and 12: a prospective linked data study. *Child Indicators Research* 2013;6(4):695-708.
13. Merrick MT, Ford DC, Ports KA, et al. Vital signs: Estimated proportion of adult health problems attributable to adverse childhood experiences and implications for prevention—25 States, 2015–2017. *Morbidity and Mortality Weekly Report* 2019;68(44):999.
14. Kezelman C, Hossack N, Stavropoulos P, et al. The cost of unresolved childhood trauma and abuse in adults in Australia, Adults Surviving Child Abuse and Pegasus Economics, Sydney. 2015
15. Woolfenden S, Eapen V, Jalaludin B, et al. Prevalence and factors associated with parental concerns about development detected by the Parents' Evaluation of Developmental Status (PEDS) at 6-month, 12-month and 18-month well-child checks in a birth cohort. *BMJ open* 2016;6(9):e012144.
16. Ayer C, Eapen V, Overs B, et al. Risk factors for non-participation in a universal developmental surveillance program in a population in Australia. *Australian Health Review*
17. Eapen V, Walter A, Guan J, et al. Maternal help-seeking for child developmental concerns: Associations with socio-demographic factors. *J Paediatr Child Health* 2017;53(10):963-69. doi: 10.1111/jpc.13607 [published Online First: 2017/07/01]

22

18. Zwi K, Rungan S, Woolfenden S, et al. Refugee children and their health, development and well-being over the first year of settlement: A longitudinal study. *Journal of paediatrics and child health* 2017;53(9):841-49.
19. NSW Health. NSW Child Health Survey 2009-2010 Summary report. 2010
20. McLean K, Goldfeld S, Molloy C, et al. Screening and surveillance in early childhood health: rapid review of evidence for effectiveness and efficiency of models. *Ultimo, NSW, Australia: The Sax Institute* 2014
21. Garg P, Ha MT, Eastwood J, et al. Explaining culturally and linguistically diverse (CALD) parents' access of healthcare services for developmental surveillance and anticipatory guidance: qualitative findings from the 'Watch Me Grow' study. *BMC health services research* 2017;17(1):228.
22. Almeida LM, Caldas J, Ayres-de-Campos D, et al. Maternal healthcare in migrants: a systematic review. *Matern Child Health J* 2013;17(8):1346-54. doi: <https://dx.doi.org/10.1007/s10995-012-1149-x> [published Online First: 2013/01/22]
23. Fellmeth G, Fazel M, Plugge E. Migration and perinatal mental health in women from low- and middle-income countries: a systematic review and meta-analysis. *BJOG* 2017;124(5):742-52. doi: <https://doi.org/10.1111/1471-0528.14184> [published Online First: 2016/06/21]
24. World Health Organization (WHO). Promoting the health of refugees and migrants: Framework of priorities and guiding principles to promote the health of refugees and migrants. Geneva: WHO Secretariat, 2017:1-4.
25. Higginbottom G, Morgan M, Alexandre M, et al. Immigrant women's experiences of maternity-care services in Canada: a systematic review using a narrative synthesis. *Syst Rev* 2015;4(13):13. doi: <https://doi.org/10.1186/2046-4053-4-13> [published Online First: 2015/07/19]
26. Correa-Velez I, Ryan J. Developing a best practice model of refugee maternity care. *Women Birth* 2012;25(1):13-22. doi: <https://dx.doi.org/10.1016/j.wombi.2011.01.002> [published Online First: 2011/02/15]
27. Henderson S, Kendall E. Culturally and linguistically diverse peoples' knowledge of accessibility and utilisation of health services: exploring the need for improvement in health service delivery. *Aust J Prim Health* 2011;17(2):195-201. doi: <https://doi.org/10.1071/PY10065> [published Online First: 2011/06/08]
28. Heslehurst N, Brown H, Pemu A, et al. Perinatal health outcomes and care among asylum seekers and refugees: a systematic review of systematic reviews. *BMC Medicine* 2018;16(1) doi: <https://doi.org/10.1186/s12916-018-1064-0> [published Online First: 2018/06/13]
29. Boyle JA, Willey S, Abbasova G. Supporting better outcomes for migrant and refugee women. *O&G Magazine* 2018; 20(1). <https://www.ogmagazine.org.au/20/1-20/better-outcomes-migrant-refugee-women/>.
30. Small R, Roth C, Raval M, et al. Immigrant and non-immigrant women's experiences of maternity care: a systematic and comparative review of studies in five countries. *BMC Pregnancy Childbirth* 2014;14(152):1-17. doi: 10.1186/1471-2393-14-152 [published Online First: 2014/04/30]
31. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expectations* 2015;18(6):3286-301. doi:

23

- 10.1111/hex.12318
32. Woolfenden S, Posada N, Krchnakova R, et al. Equitable access to developmental surveillance and early intervention - understanding the barriers for children from culturally and linguistically diverse (CALD) backgrounds. *Health Expect* doi: 101111/hex12318 2014
 33. Woolfenden S, Eapen V, Williams K, et al. A systematic review of the prevalence of parental concerns measured by the Parents' Evaluation of Developmental Status (PEDS) indicating developmental risk. *BMC Pediatr* 2014;14
 34. Woolfenden S, Galea C, Badland H, et al. Use of health services by preschool-aged children who are developmentally vulnerable and socioeconomically disadvantaged: testing the inverse care law. *J Epidemiol Community Health* 2020;74(6):495-501.
 35. Chando S, Craig JC, Burgess L, et al. Developmental risk among Aboriginal children living in urban areas in Australia: the Study of Environment on Aboriginal Resilience and Child Health (SEARCH). *BMC pediatrics* 2020;20(1):1-13.
 36. Alrashdi M, Hameed A, Cervantes Mendez MJ, et al. Education intervention with respect to the oral health knowledge, attitude, and behaviors of refugee families: A randomized clinical trial of effectiveness. *Journal of Public Health Dentistry* 2021;81(2):90-99. doi: <https://doi.org/10.1111/jphd.12415>
 37. Henry R. Review of health services for children, young people and families within the NSW Health system, 2019.
 38. National Academies of Sciences E, Medicine. Integrating Social Care Into the Delivery of Health Care: Moving Upstream to Improve the Nation's Health: Washington, DC: National Academies Press, 2019.
 39. Moore T. Using place-based approaches to strengthen child wellbeing. *Developing Practice: The Child, Youth and Family Work Journal* 2014(40):40.
 40. Glover J, Samir N, Kaplun C, et al. The effectiveness of place-based interventions in improving development, health and wellbeing outcomes in children aged 0–6 years living in disadvantaged neighbourhoods in high-income countries – A systematic review. *Wellbeing, Space and Society* 2021;2:100064. doi: <https://doi.org/10.1016/j.wss.2021.100064>
 41. Edwards K, Rimes T, Smith R, et al. Improving Access to Early Childhood Developmental Surveillance for Children from Culturally and Linguistically Diverse (CALD) Background. *Int J Integr Care* 2020;Apr;20(2)
 42. Edwards K, Fernandez R, Rimes T, et al. “Happy, Healthy, Ready – working with early childhood non-government organisations for developmental surveillance for vulnerable children”. *Australian Journal of Advanced Nursing* 2020; 37(4)
 43. Alrashdi M, Cervantes Mendez MJ, Farokhi MR. A Randomized Clinical Trial Preventive Outreach Targeting Dental Caries and Oral-Health-Related Quality of Life for Refugee Children. *International Journal of Environmental Research and Public Health* 2021;18(4):1686.
 44. Rogers HJ, Hogan L, Coates D, et al. Cross Cultural Workers for women and families from migrant and refugee backgrounds: a mixed-methods study of service providers perceptions. *BMC Women's Health* 2021;21(1):222. doi: 10.1186/s12905-021-01368-4
 45. Rogers HJ, Hogan L, Coates D, et al.

A Bridge to Health: The Cross Cultural Workers in Maternity and Child and Family Health Service

24

- 1
2
3 for women and families from migrant and refugee backgrounds: A mixed-methods study of
4 service providers perceptions in Sydney, Australia (Manuscript not yet published). 2020
5
6 46. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
7 for protocols of clinical trials. *Bmj* 2013;346
8
9 47. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research
10 findings into practice: a consolidated framework for advancing implementation science.
11 *Implement Science* 2009;4(1):50.
12
13 48. Kirk MA, Kelley C, Yankey N, et al. A systematic review of the use of the consolidated framework
14 for implementation research. *Implementation Science* 2016;11(72):1-13.
15
16 49. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
17 distinctions, measurement challenges, and research agenda. *Administration and Policy in*
18 *Mental Health and Mental Health Services Research* 2011;38(2):65-76.
19
20 50. Lawton B, Brandon PR, Cicchinelli L, et al. Logic Models: A Tool for Designing and Monitoring
21 Program Evaluations. REL 2014-007. *Regional Educational Laboratory Pacific* 2014
22
23 51. U.S. Department of Health and Human Services Centres for Disease Control and Prevention.
24 Introduction to program evaluation for public health programs: A self-study guide. Atlanta,
25 GA: Centers for Disease Control and Prevention, 2011.
26
27 52. Li S-A, Jeffs L, Barwick M, et al. Organizational contextual features that influence the
28 implementation of evidence-based practices across healthcare settings: a systematic integrative
29 review. *Systematic Reviews* 2018;7(1):72. doi: 10.1186/s13643-018-0734-5
30
31 53. Kania J, Kramer M. Collective impact: Leland Stanford Jr. University 2011.
32
33 54. Michie S, Atkins L, West R. The behaviour change wheel. *A guide to designing interventions 1st*
34 *ed Great Britain: Silverback Publishing* 2014:1003-10.
35
36 55. Smart JR. Collective impact: Evidence and implications for practice: Australian Institute of Family
37 Studies Melbourne 2017.
38
39 56. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed
40 implementation outcome measures. *Implementation Science* 2017;12(1):108.
41
42 57. Finch TL, Rapley T, Girling M, et al. Improving the normalization of complex interventions:
43 measure development based on normalization process theory (NoMAD): study protocol.
44 *Implementation Science* 2013;8(1):43. doi: 10.1186/1748-5908-8-43
45
46 58. Chapko MK, Liu CF, Perkins M, et al. Equivalence of two healthcare costing methods: bottom-up
47 and top-down. *Health economics* 2009;18(10):1188-201.
48
49 59. O'Brien B, Drummond MF, Sculpher MJ, et al. Methods for the economic evaluation of health care
50 programmes: Oxford university press 2015.
51
52 60. Cox JL, Holden JM, Sagovsky R. Detection of Postnatal Depression: Development of the 10-item
53 Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 1987;150(6):782-86. doi:
54 10.1192/bjp.150.6.782 [published Online First: 2018/01/02]
55
56 61. Garg A, Toy S, Tripodis Y, et al. Addressing Social Determinants of Health at Well Child Care
57 Visits: A Cluster RCT. *Pediatrics* 2015;135(2):e296-e304. doi: 10.1542/peds.2014-2888
58
59 62. NSW Department of Health. NSW Health/Families NSW Supporting Families Early Package –
60 SAFE START Strategic Policy, 2009.
63. Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the
consolidated framework for implementation research (CFIR). *Implementation Science*
2013;8(51):1-32.

25

- 1
2
3 64. Viney R, Norman R, King MT, et al. Time trade-off derived EQ-5D weights for Australia. *Value*
4 *Health* 2011;14(6):928-36. doi: 10.1016/j.jval.2011.04.009 [published Online First:
5 2011/09/15]
6
7 65. Huang L, Frijters P, Dalziel K, et al. Life satisfaction, QALYs, and the monetary value of health.
8 *Social Science & Medicine* 2018;211:131-36. doi:
9 <https://doi.org/10.1016/j.socscimed.2018.06.009>
10
11 66. Briggs AH, Weinstein MC, Fenwick EAL, et al. Model Parameter Estimation and Uncertainty
12 Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force
13 Working Group–6. *Medical Decision Making* 2012;32(5):722-32. doi:
14 10.1177/0272989X12458348
15
16 67. Edwards B, Mullan K, Katz I, et al. The Stronger Families in Australia (SFIA) Study: Phase 2 The
17 Stronger Families in Australia (SFIA) Study: Phase 2. 2014

18 FIGURE 1: FDCC IMPLEMENTATION EVALUATION LOGIC MODEL

19
20
21 FIGURE 2: FDCC GOVERNANCE STRUCTURE
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONTEXT

INTERVENTIONS

THEORETICAL FRAMEWORK

INTERMEDIATE OUTCOMES

LONG-TERM OUTCOMES

OUTER CONTEXT

INNER CONTEXT

Local area factors/LHD

- Patient load
- Area socio-economic status
- Community health relationship with hospital
- Make up of community based agencies, public and private health services in area (Area mapping)

Policy and governance context

- Existing CAFH policy affecting practice
- First 2000 days
- NGO partners core business, funding bodies, governance board

NGO factors

- Partner buy in
- Diversity of partner services
- Alignment of partner services (Reciprocity between health & NGOs) Location
- Collaboration features (i.e. frequency of contact, regular meetings, services integrating in real time)
- Billing and funding

Early childhood health staff factors

- Organisational context Support of Hub intervention within practice
- Structure and delivery of hub model (times location, structure)
- Altered work flows
- Care navigation (dedicated role, clear pathways)
- Number of CFHN in Hub
- Involvement of allied health
- GP relationships (Bilingual, referrals, knowledge of CFH, Medicare eligible)

Physical location

- Services in the same building
- Soft entry through existing non-health, non-threatening service (i.e. playgroup)
- Accessible to migrant and refugee communities

Integration of services

- Referral pathways between services (supported/warm referral or proactive introduction)
- Communication between services
- Shared resources/training/measurement
- Common agenda

Cultural sensitivity

- Culturally sensitive practices
- Training and resources

Key worker/ Navigator

Point of contact between maternity and hub

Collective Impact

Collective impact is designed to create change on complex social issues, and draws on five conditions: common agenda, continuous communication, mutually reinforcing activities, backbone support and shared measurement.

MECHANISMS OF CHANGE

Behaviour change wheel constructs

- **Enablement** – Hub in a location that suits families, helping navigation to relevant services
- **Modelling** – Modelling health/NGO practices
- **Training** – Ensure staff have been trained in culturally sensitive practices. Shared language/ understanding of the model
- **Environment restructure** – Hub creating integrated care environment

Service and community

- Increased knowledge and capacity of local services to provide culturally sensitive care and address health and social needs.

Child and Family

- 60% of mothers/families attending CFH service at Hubs
- Increased Breastfeeding rates
- Early identification of psychosocial concerns
- Social needs met by improved service access
- Child at healthy weight


System

- Earlier intervention for health and social need, reduced hospital visits (ED presentations)
- Cost-effective model of care for NSW Health
- Evidence that access is feasible, appropriate and acceptable
- Replicable, acceptable, appropriate and sustainable models of care - First 2000 Days Framework.

Child and Family

- Mothers/families will have optimal mental health and children will be school ready

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



APPENDICES

Appendix 1: Participant Information Sheet and Consent Form

Primary and Community Health Directorate

PARTICIPANT INFORMATION SHEET AND CONSENT FORM Participant

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

Invitation

You are invited to take part in the Family Care Connect project. Family Care Connect involves child and family Hubs, where health and other agencies work together and you are supported to navigate these services. Our research is seeing whether these Hubs support the health and development of children, mothers and families from migrant and refugee communities.

Who is doing the research?

Tania Rimes

Children and Communities Program Coordinator

Primary and Community Health Directorate | South Eastern Sydney Local Health District (SESLHD).

Associate Professor Sue Woolfenden (Research lead)

NHMRC Senior Research Fellow, Population Child Health Group | The University of New South Wales (UNSW). Senior Staff Specialist, Community Child Health | Sydney Children's Hospitals Network.

Before you decide if you want to take part in this research, we would like to explain what we are doing and why we are doing it. . Please take the time to read the following information carefully. You can talk about it with a relative or a friend if you wish before deciding.

What is the purpose of this research?

We want to see if child and family Hubs help women and families from migrant and refugee communities move from pregnancy to Child and Family Health services. Also, we want to see if these Hubs support children's health and development in the first 12 months of life.

We will also look at how easy and cost-effective the Hub is for you and other women and families.

Why have I been invited to participate in this research?

You are eligible to participate in this research because you:

- are having your baby or recently given birth to your baby at [INSERT HOSPITAL SITES]
- live in the postcode of [INSERT POSTCODE/S]

- are at least 20 weeks pregnant, OR have recently given birth to your baby and have not been discharged home from postnatal ward
- are a newly arrived migrant (within the last 10 years) from a non-English speaking background; or a refugee (living in Australia for less than 10 years) from a non-English speaking background
- are 16 years of age or older.

If I say yes, what will it involve?

If you decide to take part in the research and live in [INSERT SITE AREA] you will be in the **'FDCC Group'**. You will receive information about the child and family services in your area you can access after the birth of your baby. This information is given to all women, regardless of whether or not they participate in the study.

If you take part in the **"FDCC Group"**, you will also be contacted by a worker from the local child and family Hub who will give you more information on the services offered and assist you with accessing these services if you choose.

If you agree to take part, we will ask you to sign the Participant Information and Consent form below; OR sign the online consent found here [INSERT ONLINE CONSENT URL]; OR provide verbal consent over the telephone to the contact person for the research.

After you provide consent to take part in this research, we will ask you to:

- Complete a survey about you, your family, your support needs, and your wellbeing. This will take about 30 minutes. You can choose to do it online, by paper, over the phone, or in-person. **We can provide an interpreter to assist.**
- Complete another survey when your baby is 6 months and 12 months old. This will ask questions about you, what your needs are, and what services you have used. **We can provide an interpreter to assist.**
- We will also collect data from your local and state-wide hospital/s about you and your baby. This reduces the number of questions we need to ask you.

The data we collect from local hospitals includes:

- Information about you and your child such as country of birth, date of birth, gender, language spoken at home
- Information from routine questions asked to all women when they come to hospital about their health and wellbeing and their child's
- Information about the services you or your child has seen, for example the child and family health nurse.

The data we collect from state-wide hospitals includes:

- Information that is collected on all new mothers and babies in NSW
- Emergency Department presentations for you and your baby

If you don't want us to collect data about you and your baby from state-wide hospitals, then we won't. Please let us know by checking the box.

I DO NOT want my state-wide hospital data included as part of this research

1
2
3
4 **If you only provide verbal consent, we will not collect data about you and your baby**
5 **from state-wide hospitals.**

6 As part of this research, we may also invite you to be interviewed. We will contact you at
7 another time to discuss this process before the research is complete.
8
9

10 Any information we collect that can identify you or your child will remain confidential.
11

12 The total time you are involved with this project will be for 12 to 18 months, but you can
13 choose to withdraw at any time.
14

15
16 **What if I don't want to take part in this research, or if I want to withdraw later?**

17 It is completely up to you whether or not you decide to take part. Saying yes or no will not
18 affect your relationship with the care you receive, the services you access, or your visa
19 status now or in the future.
20

21 If you wish to leave the research once it has started, you can do so verbally or in writing at
22 any time without giving a reason. However, it may not be possible to withdraw your data
23 from the research results once we have collected it and removed your identifying details.
24 This is due to be done from March 2023.
25
26

27 **How is this research being paid for?**

28 The research is being paid for by NSW Health as part of the Translational Research Grant
29 Scheme. More information about this scheme can be found here:

30 <https://www.medicalresearch.nsw.gov.au/translational-research-grants-scheme/>
31
32

33 **Are there risks to me in taking part in this research?**

34 There is very little risk to you, however if you become upset or distressed because of taking
35 part in the research, the research team will arrange for counselling or other help. Any
36 counselling or help will be provided by qualified staff who are not members of the research
37 team. This will be provided free of charge.
38
39

40 Another risk in taking part in this research is the risk to your privacy as part of collecting
41 data about you, your child, and your family. While this is a risk, we will take all the steps to
42 ensure your information remains private and confidential. We do not collect you or your
43 baby's name, or anything else that could identify you or your family. Instead, your name will
44 be replaced with a number. Only people involved with this research will be able to tell that
45 the information is about you.
46
47

48 **What happens if I suffer injury or complications as a result of the research?**

49 It is very unlikely that you will suffer any injury as we are only asking you to complete
50 questionnaires. However, if you require treatment or suffer loss as a result of the
51 wrongdoing of any of the parties involved in the research, you can seek compensation. The
52 cost of your treatment must be paid by the compensation you receive.
53
54

55 **Will I benefit from the research?**

56 This research aims to determine how best to provide child health services for families and
57 to improve how parents in the future access child and family health services, however it
58 may or may not directly benefit you or your baby.
59
60

Will taking part in this research cost me anything, and will I be paid?

Taking part in this research will not cost you anything, nor will you be paid.

How will my confidentiality be protected?

Any information that is collected about you as part of this research will remain private and confidential and will be discussed only with your permission, except as required by law. This means the research team are Mandatory Reporters and may need to speak with NSW Department of Communities and Justice if they are told or are concerned that a child is being hurt or is at risk of being hurt e.g. if there is abuse or violence in the home.

If such a situation happens, we would discuss this with you in private and arrange for you to speak with another professional if required.

Only the researchers named above will have access to your details. All information will be stored on a secure drive within [INSERT LHD SITES] and UNSW. We will keep the information for 5 years after the research ends. After this time, it will be destroyed.

In line with Australian, New South Wales, and other relevant laws, you have the right to access and correct the information we collect and store about you. Please contact us if you would like to access the information.

What happens with the results?

If you give us your permission by providing your consent in written form, online, or verbally, we plan to publish the results in a report and in peer reviewed journals. We may also present results at professional forums and conferences to inform better ways of working and providing services.

We will also give a report on the research to the South Eastern Sydney Local Health District Human Research Ethics Committee.

In any report, publication, or presentation, information will be provided in such a way that you or your family cannot be identified.

What should I do if I want to discuss this research further before I decide?

When you have read this information, the researcher interviewer/project officer will discuss it with you and answer any queries you may have. If you would like to know more at any stage, please do not hesitate to contact Tania Rimes, Principal Investigator on (02) 9382 8696 or email her at tania.rimes@health.nsw.gov.au. If you need an interpreter, you can contact Tania through the Translating and Interpreting Service (TIS) on 131 450.

Who should I contact if I have concerns about the conduct of this research?

This research has been approved by the South Eastern Sydney Local Health District Human Research Ethics Committee. Any person with concerns or complaints about the conduct of this research should contact the Research Support Office which is nominated to receive complaints from research participants. You should contact them on 02 9382 3587, or email SESLHD-RSO@health.nsw.gov.au and quote HREC reference number: 2020/ETH03295.

The conduct of this research is at the [INSERT SITE NAMES]. Any person with concerns or complaints about the conduct of this research may also contact the [*details of the Research Governance Officer of the health district will be provided following SSA application*]

1
2
3
4 **Thank you for taking the time to consider this research.**
5 **If you wish to take part in it, please sign the attached consent form.**
6 **This information sheet is for you to keep.**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Primary and Community Health Directorate

CONSENT FORM

Family Care Connect – a holistic first 2000 days model of care for women and families from migrant and refugee communities.

1. I,.....
of.....
agree to take part in the research described in the participant information statement set out above and to have my data linked as outlined in the information sheet.
2. I have read the participant information statement, which explains why I have been asked to take part, the aims of the research and the possible risks of the research, and the statement has been explained to me to my satisfaction.
3. Before signing this consent form, I have been able to ask any questions relating to any possible physical and mental harm I might suffer as a result of taking part and I have received satisfactory answers.
4. I understand that I can withdraw from the research at any time without affecting my relationship with South Eastern Sydney Local Health District or service at the child and family hub.
5. I agree that research information collected from the results of the research may be published and presented, provided that I cannot be identified.
6. I understand that if I have any questions relating to my participation in this research, I may contact Tania Rimes on telephone (02) 9382 8696, who will be happy to answer them. I can call 131450 (TIS) for language support.
7. I have been given a copy of this Consent Form and the Participant Information Statement.

Complaints may be directed to the Research Support Office, South Eastern Sydney Local Health District, Prince of Wales Hospital, Randwick NSW 2031 Australia (phone 02-9382 3587, fax 02-9382 2813, email SESLHD-RSO@health.nsw.gov.au).

Signature of participant

Please PRINT name

Date

Signature of witness

Please PRINT name

Date

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Signature of investigator

Please PRINT name

Date

Investigator/officer taking consent to complete:

Check box if participant DOES NOT want their state-wide hospital data included as part of this research

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a Trial identifier and registry name. If not yet	17

1		registered, name of intended registry	
2			
3			
4	Trial registration:	#2b All items from the World Health Organization Trial	
5			
6	data set	Registration Data Set	
7			
8			
9	Protocol version	#3 Date and version identifier	2
10			
11			
12	Funding	#4 Sources and types of financial, material, and other	19
13			
14		support	
15			
16			
17	Roles and	#5a Names, affiliations, and roles of protocol	19
18			
19	responsibilities:	contributors	
20			
21	contributorship		
22			
23			
24			
25	Roles and	#5b Name and contact information for the trial sponsor	19
26			
27	responsibilities:		
28			
29	sponsor contact		
30			
31	information		
32			
33			
34			
35	Roles and	#5c Role of study sponsor and funders, if any, in study	19
36			
37	responsibilities:	design; collection, management, analysis, and	
38			
39	sponsor and funder	interpretation of data; writing of the report; and the	
40			
41		decision to submit the report for publication,	
42			
43		including whether they will have ultimate authority	
44			
45		over any of these activities	
46			
47			
48			
49	Roles and	#5d Composition, roles, and responsibilities of the	19
50			
51	responsibilities:	coordinating centre, steering committee, endpoint	
52			
53	committees	adjudication committee, data management team,	
54			
55		and other individuals or groups overseeing the	
56			
57			
58			
59			
60			

trial, if applicable (see Item 21a for data
monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4
Objectives	#7	Specific objectives or hypotheses	5-6
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	7
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries	6

1		where data will be collected. Reference to where	
2			
3		list of study sites can be obtained	
4			
5			
6	Eligibility criteria	#10 Inclusion and exclusion criteria for participants. If	6
7			
8		applicable, eligibility criteria for study centres and	
9			
10		individuals who will perform the interventions (eg,	
11			
12		surgeons, psychotherapists)	
13			
14			
15			
16	Interventions:	#11a Interventions for each group with sufficient detail	5,8
17			
18	description	to allow replication, including how and when they	
19			
20		will be administered	
21			
22			
23	Interventions:	#11b Criteria for discontinuing or modifying allocated	n/a
24			
25	modifications	interventions for a given trial participant (eg, drug	
26			There are no plans
27			to discontinue or
28		dose change in response to harms, participant	modify the
29			interventions.
30		request, or improving / worsening disease)	
31			
32			
33			
34			
35			
36	Interventions:	#11c Strategies to improve adherence to intervention	7
37			
38	adherence	protocols, and any procedures for monitoring	
39			
40		adherence (eg, drug tablet return; laboratory	
41			
42		tests)	
43			
44			
45			
46	Interventions:	#11d Relevant concomitant care and interventions that	n/a
47			
48	concomitant care	are permitted or prohibited during the trial	
49			
50			
51	Outcomes	#12 Primary, secondary, and other outcomes,	12-15
52			
53		including the specific measurement variable (eg,	
54			
55		systolic blood pressure), analysis metric (eg,	
56			
57			
58			
59			
60			

change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6-7

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce	7
---------------------------------	----------------------	---	---

1 predictability of a random sequence, details of any
 2
 3 planned restriction (eg, blocking) should be
 4
 5 provided in a separate document that is
 6
 7 unavailable to those who enrol participants or
 8
 9 assign interventions
 10

11			
12			
13	Allocation	#16b Mechanism of implementing the allocation	7
14			
15	concealment	sequence (eg, central telephone; sequentially	
16			
17	mechanism	numbered, opaque, sealed envelopes), describing	
18			
19		any steps to conceal the sequence until	
20			
21		interventions are assigned	
22			
23			
24			
25	Allocation:	#16c Who will generate the allocation sequence, who	7
26			
27	implementation	will enrol participants, and who will assign	
28			
29		participants to interventions	
30			
31			
32	Blinding (masking)	#17a Who will be blinded after assignment to	8
33			
34		interventions (eg, trial participants, care providers,	
35			
36		outcome assessors, data analysts), and how	
37			
38			
39			
40	Blinding (masking):	#17b If blinded, circumstances under which unblinding	8
41			
42	emergency	is permissible, and procedure for revealing a	
43			
44	unblinding	participant's allocated intervention during the trial	
45			
46			
47			
48	Methods: Data		
49			
50	collection,		
51			
52	management, and		
53			
54	analysis		
55			
56			
57			
58	Data collection plan	#18a Plans for assessment and collection of outcome,	12-15
59			
60			

1 baseline, and other trial data, including any
 2 related processes to promote data quality (eg,
 3 duplicate measurements, training of assessors)
 4 and a description of study instruments (eg,
 5 questionnaires, laboratory tests) along with their
 6 reliability and validity, if known. Reference to
 7 where data collection forms can be found, if not in
 8 the protocol
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18

19	Data collection plan: #18b	Plans to promote participant retention and	14
20	retention	complete follow-up, including list of any outcome	
21		data to be collected for participants who	
22		discontinue or deviate from intervention protocols	
23			
24			
25			
26			
27			
28			
29	Data management #19	Plans for data entry, coding, security, and storage,	15-16
30		including any related processes to promote data	
31		quality (eg, double data entry; range checks for	
32		data values). Reference to where details of data	
33		management procedures can be found, if not in	
34		the protocol	
35			
36			
37			
38			
39			
40			
41			
42			
43			
44	Statistics: outcomes #20a	Statistical methods for analysing primary and	16
45		secondary outcomes. Reference to where other	
46		details of the statistical analysis plan can be	
47		found, if not in the protocol	
48			
49			
50			
51			
52			
53			
54	Statistics: additional #20b	Methods for any additional analyses (eg,	16
55	analyses	subgroup and adjusted analyses)	
56			
57			
58			
59			
60			

1	Statistics: analysis	#20c	Definition of analysis population relating to	16
2				
3	population and		protocol non-adherence (eg, as randomised	
4				
5	missing data		analysis), and any statistical methods to handle	
6				
7			missing data (eg, multiple imputation)	
8				
9				
10				
11	Methods: Monitoring			
12				
13				
14	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	16
15				
16	formal committee		summary of its role and reporting structure;	
17				
18			statement of whether it is independent from the	
19				
20			sponsor and competing interests; and reference to	
21				
22			where further details about its charter can be	
23				
24			found, if not in the protocol. Alternatively, an	
25				
26			explanation of why a DMC is not needed	
27				
28				
29				
30				
31	Data monitoring:	#21b	Description of any interim analyses and stopping	16
32				
33	interim analysis		guidelines, including who will have access to	
34				
35			these interim results and make the final decision	
36				
37			to terminate the trial	
38				
39				
40				
41	Harms	#22	Plans for collecting, assessing, reporting, and	16-17
42				
43			managing solicited and spontaneously reported	
44				
45			adverse events and other unintended effects of	
46				
47			trial interventions or trial conduct	
48				
49				
50				
51	Auditing	#23	Frequency and procedures for auditing trial	19
52				
53			conduct, if any, and whether the process will be	
54				
55			independent from investigators and the sponsor	
56				
57				
58				
59				
60				

1 **Ethics and**

2
3 **dissemination**

4			
5			
6			
7	Research ethics	#24	Plans for seeking research ethics committee /
8			
9	approval		institutional review board (REC / IRB) approval
10			
11			
12	Protocol	#25	Plans for communicating important protocol
13			
14	amendments		modifications (eg, changes to eligibility criteria,
15			outcomes, analyses) to relevant parties (eg,
16			investigators, REC / IRBs, trial participants, trial
17			registries, journals, regulators)
18			
19			
20			
21			
22			
23			
24	Consent or assent	#26a	Who will obtain informed consent or assent from
25			
26			potential trial participants or authorised
27			surrogates, and how (see Item 32)
28			
29			
30			
31			
32	Consent or assent:	#26b	Additional consent provisions for collection and
33			
34	ancillary studies		use of participant data and biological specimens
35			
36			in ancillary studies, if applicable
37			
38			
39			
40			
41			
42			
43	Confidentiality	#27	How personal information about potential and
44			
45			enrolled participants will be collected, shared, and
46			
47			maintained in order to protect confidentiality
48			
49			before, during, and after the trial
50			
51			
52	Declaration of	#28	Financial and other competing interests for
53			
54	interests		principal investigators for the overall trial and each
55			
56			study site
57			
58			
59			
60			

1	Data access	#29	Statement of who will have access to the final trial	16
2			dataset, and disclosure of contractual agreements	
3			that limit such access for investigators	
4				
5				
6				
7				
8	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	n/a
9	trial care		and for compensation to those who suffer harm	This is a low-risk
10			from trial participation	trial with minimal
11				foreseen harms to
12				participants.
13				
14				
15				
16				
17				
18				
19				
20				
21				
22	Dissemination	#31a	Plans for investigators and sponsor to	17
23	policy: trial results		communicate trial results to participants,	
24			healthcare professionals, the public, and other	
25			relevant groups (eg, via publication, reporting in	
26			results databases, or other data sharing	
27			arrangements), including any publication	
28			restrictions	
29				
30				
31				
32				
33				
34				
35				
36				
37				
38	Dissemination	#31b	Authorship eligibility guidelines and any intended	17
39	policy: authorship		use of professional writers	
40				
41				
42				
43				
44	Dissemination	#31c	Plans, if any, for granting public access to the full	17
45	policy: reproducible		protocol, participant-level dataset, and statistical	
46			code	
47				
48				
49				
50				
51	Appendices			
52				
53				
54	Informed consent	#32	Model consent form and other related	Supp. file
55	materials		documentation given to participants and	
56				
57				
58				
59				
60				

1 authorised surrogates

2
3
4 Biological [#33](#) Plans for collection, laboratory evaluation, and n/a
5
6 specimens storage of biological specimens for genetic or No biological
7
8 molecular analysis in the current trial and for specimens will be
9
10 future use in ancillary studies, if applicable collected as part of
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a No biological specimens will be collected as part of this trial.
----------------------	---------------------	--	---

None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)